S&P 500 Financials Sector SEC Filings — March 05, 2026

05-03-2026

Full House Resorts reported fourth quarter 2025 revenues of $75.4 million, up 3.4% YoY (5.6% excluding Stockman’s sale), driven by 11.0% growth at American Place Casino and ramp-up at Chamonix/Bronco Billy’s, while full-year revenues rose 3.5% to $302.4 million (5.2% excluding Stockman’s). However, Adjusted EBITDA was nearly flat full-year at $48.1 million versus $48.6 million in 2024, with Q4 up slightly to $10.7 million, and net losses persisted at $(12.4) million for Q4 and $(40.2) million for the year amid ongoing depreciation and development costs. West segment revenues declined 3.1% in Q4 to $15.6 million and remained negative EBITDA at $(2.0) million despite improvement, while Contracted Sports Wagering revenues fell to $1.7 million.

• ·Depreciation and amortization: $42.6M in FY 2025 vs $42.1M in FY 2024
• ·Revolving credit facility extended to August 15, 2027
• ·Break ground on permanent American Place anticipated March/April 2026, opening in 18-24 months
• ·Waukegan City Council approved revised site plans in September 2025
• ·Competitor lawsuit resolved January 2025

05-03-2026

On February 27, 2026, ZyVersa Therapeutics, Inc. entered into a Securities Purchase Agreement with accredited investors, issuing convertible promissory notes with an aggregate principal of $1M at 10% interest, maturing in 12 months, and Series A-4 Common Stock Purchase Warrants. The notes are convertible into common stock at 80% of a qualified offering price or recent VWAP (with a $0.02 floor), while warrants are exercisable after six months at 110% of a reference price and cover shares equal to 50% of each purchaser's subscription amount. Net proceeds will fund working capital, with obligations guaranteed by subsidiary ZyVersa Therapeutics Operating, Inc.

• ·Notes convertible following the earlier of six months after issuance or an Event of Default, subject to $0.02 per share floor price.
• ·Warrants expire on five-year anniversary of issuance and include anti-dilution adjustments for stock dividends, splits, and fundamental transactions.
• ·Company covenants include filing resale registration statements within six months for note conversions and within 30 days of warrant Initial Exercise Date, plus restrictions on redemptions, dividends, and variable rate transactions.

05-03-2026

On February 27, 2026, the Compensation Committee of Digi International Inc. approved one-time performance stock unit awards under the 2021 Omnibus Incentive Plan to two executives: James J. Loch (EVP, CFO, Treasurer) eligible to vest into 14,668 shares based on business/software integration goals by September 30, 2026, 2027, and 2028; and David H. Sampsell (EVP, Corporate Development, General Counsel, Corporate Secretary) eligible for 12,223 shares upon successor onboarding by December 31, 2028. Vesting requires continued service and committee certification of performance goals. No share values or broader financial impacts are disclosed.

• ·Loch's first tranche (4,890 shares) vests November 1, 2026 if business and software integration goals achieved by September 30, 2026.
• ·Loch's second and third tranches (4,889 shares each) vest November 1, 2027 and 2028 upon program migrations to designated software platform by respective September 30 deadlines.
• ·Sampsell's award vests December 31, 2028 with assistance in identifying and onboarding successors for general counsel and corporate development roles.

05-03-2026

CarParts.com, Inc. filed an 8-K on March 5, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, margins, period-over-period changes, or other financial metrics were disclosed in the provided filing information. No positive, negative, or flat performance indicators were detailed.

05-03-2026

Ranger Energy Services reported full year 2025 revenue of $546.9 million and Adjusted EBITDA of $73.2 million (13.4% margin), down from $78.9 million (13.8%) in 2024, while Q4 2025 revenue increased 10% QoQ to $142.2 million from $128.9 million but declined 1% YoY from $143.1 million, with Q4 Adjusted EBITDA up 21% QoQ to $20.3 million (14.3% margin) yet down 7% YoY from $21.9 million. High Specification Rigs drove growth with Q4 revenue up 14% QoQ and 6% YoY, bolstered by the AWS acquisition, and Processing Solutions revenue rose 22% QoQ; however, Wireline Services revenue plunged 28% QoQ and 45% YoY amid pricing pressures. Free Cash Flow totaled $42.9 million for the year (down from $50.4 million in 2024), supporting share repurchases and dividends exceeding 40% of FCF.

• ·Share repurchases: 994,400 shares at avg $12.26/share in 2025; cumulative 4,320,200 shares at avg $10.80/share since 2023.
• ·Quarterly dividend: $0.06 per share, payable April 6, 2026 (record date March 20, 2026).
• ·Total liquidity Dec 31, 2025: $67.7M (down from $112.1M at Dec 31, 2024).
• ·AWS acquisition funded with ~$22M borrowing, ended year in net cash position.
• ·Contract for 15 additional ECHO rigs: deliveries start Q3 2026, full by end 2027.
• ·Full year 2025 cash from operations: $69.0M (down from $84.5M in 2024).

05-03-2026

Burlington Stores reported strong Q4 FY25 results with total sales up 11% YoY to $3.6B and comparable store sales +4% (two-year stack +10%), driving net income to $310M (+19%) and adjusted EPS up 21% to $4.99, with adjusted EBIT margin expanding 100bps to support 21% EPS growth. For full FY25, total sales grew 9% to $11.5B with comparable store sales +2% (on top of prior +4%), net income up 21% to $610M, and adjusted EPS +22% to $10.17 despite tariffs, aided by successful mitigation actions and 80bps adjusted EBIT margin expansion. However, comparable store inventories increased 12% YoY, reserve inventory share declined to 40% from 46%, and FY26 comparable store sales guidance is modest at 1-3%.

• ·Q4 FY25 gross margin 43.7% (+80bps YoY); adjusted SG&A 22.2% (-40bps YoY).
• ·FY26 guidance: total sales +8-10%; adjusted EBIT margin +0-20bps; adjusted EPS $10.95-$11.45.
• ·Q1 FY26 guidance: total sales +9-11%; comp sales +2-4%; adjusted EPS $1.60-$1.75.
• ·Operated in 46 states, Washington D.C., and Puerto Rico.
• ·Conference call March 5, 2026 at 8:30 a.m. ET.

05-03-2026

Kroger reported fourth quarter FY2025 identical sales without fuel up 2.4% (matching prior year) and full-year up 2.9% (from 1.5%), with adjusted FIFO operating profit of $1.206B (up slightly from $1.174B) and $4.9B (up from $4.7B), and adjusted EPS of $1.28 (up from $1.14) and $4.85 (up from $4.47). However, total sales grew only 1% to $34.7B in Q4 and were flat at $147.6B for the year, GAAP operating profit fell to $1.9B from $3.8B due to $2.5B impairment charges on automated fulfillment network, FIFO gross margin was flat in Q4, and OG&A rate increased 21 basis points in Q4 and 29 basis points for the year. The company completed a $7.5B share repurchase, approved $2B more, appointed Greg Foran as CEO, and guided identical sales without fuel growth of 1.0%-2.0% for FY2026 with adjusted FIFO operating profit of $5.0-$5.2B.

• ·Q4 LIFO charge $11M vs $30M prior year
• ·FY2025 LIFO charge $157M vs $95M prior year
• ·FY2026 guidance: Free Cash Flow $2.7-$2.9B, Cap Ex $3.8-$4.0B, Tax Rate 23%
• ·Identical sales guidance includes 130 basis points unfavorable from Inflation Reduction Act
• ·Q4 ended January 31, 2026

05-03-2026

USA Rare Earth, Inc. (USAR) announced a definitive agreement to acquire all outstanding shares of Texas Mineral Resources Corp. (TMRC) for 3,823,328 shares of USAR common stock, implying a $73M deal value, securing USAR's 100% ownership and operational control of the Round Top Heavy Rare Earth and Critical Minerals Project by acquiring TMRC's 18.6% interest along with key land leases. This supports USAR's Accelerated Mining Plan, targeting commercial production in 2028 and 40,000 metric tons per day extraction by 2030. The transaction, approved by both boards, awaits TMRC stockholder approval and is expected to close by Q3 2026, amid forward-looking risks including going concern doubts for both companies.

• ·In January 2026, USAR selected Fluor Corp. and WSP Global Inc. as EPCM partners for Definitive Feasibility Study and mining infrastructure.
• ·TMRC directors and executive officers entered voting support agreements in favor of the transaction.
• ·Round Top operated under long-term lease with Texas General Land Office, supporting Texas Permanent School Fund.

05-03-2026

QuasarEdge Acquisition Corp (QRED), a Cayman Islands-based blank check SPAC with sponsor and management ties to China, filed an S-1 to offer 10 million units at $10 each, raising $100M gross proceeds ($99.5M net before expenses) to be held in trust for an initial business combination. However, the filing highlights substantial risks from potential PRC regulatory uncertainties, which could materially impact operations or security values, and significant dilution to public shareholders ranging from $2.70 to $8.19 per share across redemption scenarios (25% to 100%). The units include ordinary shares (QRED) and rights (QREDR) expected to list on NYSE.

• ·Dilution scenarios as of January 31, 2026: pro forma net tangible book value per share ranges from $5.64 (25% redemptions, over-allotment) to $0.14 (maximum redemptions).
• ·Auditor Simon & Edward, LLP is PCAOB-registered and U.S.-headquartered, mitigating current HFCAA risks but with potential future exposure.
• ·Company qualifies as emerging growth company with reduced reporting requirements.
• ·Over-allotment option could increase units/shares to 11.5M and underwriting to $575K.

05-03-2026

On March 3, 2026, the Board of Directors of Acadia Pharmaceuticals Inc. appointed Jonathan M. Poole as a Class II director to fill a vacancy and as a member of the Audit Committee, effective immediately, with his term expiring at the 2027 Annual Meeting of Stockholders. Pursuant to the Non-Employee Director Compensation Policy, Mr. Poole will receive prorated annual cash retainers of $50,000 for Board service and $12,500 for Audit Committee service. He also received an initial equity grant under the 2024 Equity Incentive Plan with $200,000 target fair value and a prorated annual grant of $95,300 target fair value, with future annual grants set at $400,000 target fair value.

• ·Equity grants divided equally between nonstatutory stock options and restricted stock units; initial grant vests over three years, prorated grants vest over one year or at next annual meeting.
• ·No arrangements or understandings pursuant to which Mr. Poole was selected as director.
• ·No related person transactions required to be disclosed under Item 404(a) of Regulation S-K.

05-03-2026

HMH Holding Inc filed an S-1/A registration statement on March 4, 2026, disclosing prior material weaknesses in internal controls over financial reporting identified for 2022-2023 and a new one in 2025 related to revenue cutoff in certain subsidiaries, all of which were fully remediated by December 31, 2025 through hiring additional personnel and enhanced procedures. The company reports no outstanding debt under its Revolver as of December 31, 2025 (down from $14.4M in 2024), but highlights ongoing risks from inflation, foreign currency exposure (63.3% of 2025 revenues in foreign currencies, slightly down from 63.9% in 2024), and commodity price fluctuations tied to oil and gas drilling activity. Industry data indicates expected global hydrocarbon production growth from 172 MM Boe/day in 2025 to 188 MM Boe/day in 2030 (+9%), though with potential future supply shortfalls.

• ·Hired five additional qualified personnel in 2024 for GAAP/SEC expertise and controls.
• ·Global upstream capex declined 33% YoY to $470B in 2020.
• ·Hydrocarbon liquids demand decreased 10% from 2019 to 2020.
• ·Rystad estimates supply shortfall of 0.6 MM Bbls/day average 2021-2024, surplus of 1.1 MM Bbls/day in 2025.
• ·Global production expected to rise 9% to 188 MM Boe/day by 2030 from 172 MM Boe/day in 2025; offshore +13%.
• ·Shale/tight oil spending share rose from 12% in 2010 to 23% in 2025.
• ·14,000 additional offshore wells required 2025-2028.

05-03-2026

flyExclusive reported record Q4 2025 consolidated revenue of $104M, up 15% YoY, with double-digit growth across Jet Club, MRO (+48% YoY, +65% flight revenue), and Fractional (+56% YoY, +21% flight revenue), alongside positive Adjusted EBITDA of $6.6M and 13% flight hours growth despite 14% fewer aircraft. Full year 2025 revenue grew 15% YoY to achieve $48.8M Adjusted EBITDA, with gross profit up 52%, $84M paydown in long-term notes payable, and cash up 2% YoY. However, Q4 retail Jet Club sales declined 39% and YTD fractional retail sales fell 8%, while two non-performing aircraft remained at year-end.

• ·5th largest private operator in the U.S. per Argus since 2019
• ·Operating loss from non-performing aircraft reduced to >$400K per month from over $3M monthly at start of 2024; full elimination targeted by 2026
• ·Sequential quarterly Adjusted EBITDA improvement averaging +$3.7M per quarter
• ·Q4 2025 retail members +8% YoY; full year 2025 retail members +9% YoY
• ·12% YoY reduction in Q4 SG&A expense; 10% reduction full year 2025
• ·Core fleet aircraft utilization +23% YoY Q4 / +8% full year vs. contractually committed demand hours

05-03-2026

Silence Therapeutics reported FY2025 financial results with collaboration revenue plummeting 99% YoY to $0.6M from $43.3M, driven by the conclusion of the Hansoh collaboration and reduced AstraZeneca revenue, while net loss widened to $88.6M ($0.63/share) from $45.3M ($0.33/share). R&D expenses remained essentially flat at $67.8M, but G&A decreased 17% to $22.3M amid cost savings; cash and short-term investments stood at $85.1M as of Dec 31, 2025, down from $147.3M prior year. Pipeline advances include divesiran Phase 2 SANRECO topline on track for Q3 2026 (accelerated from 2H'26), zerlasiran Phase 3-ready, though AstraZeneca ceased SLN312 development post-Phase 1.

• ·AstraZeneca notified Silence on March 4, 2026, of decision not to pursue SLN312 beyond Phase 1; Silence regains global rights.
• ·Iain Ross appointed Interim Principal Executive Officer on Dec 15, 2025, following former CEO departure; CEO search underway.
• ·James Ede Golightly reappointed to Board and Rhonda Hellums appointed as Executive Director in Dec 2025.
• ·Anticipated milestones: SLN365/SLN098 preclinical data in Q2 2026; SLN312 Phase 1 data presentations in 2026.

05-03-2026

Tenaya Therapeutics, Inc. entered into a Collaboration Agreement with Alnylam Pharmaceuticals, Inc. on March 4, 2026, to discover and validate up to 15 novel gene targets for cardiovascular disease treatments over a 24-month period. Alnylam will provide an upfront payment of up to $10 million (subject to potential $0.5 million reductions for non-advancing targets) and reimburse Tenaya's research costs, with Tenaya eligible for up to $1.13 billion in milestones. Post-validation, Alnylam gains exclusive rights to develop and commercialize products, while Tenaya is restricted from independent work on collaboration targets during the term.

• ·Agreement filed as exhibit to Q1 2026 10-Q.
• ·Alnylam has 24-month post-validation evaluation period; failure to start non-human primate study reverts Company-nominated targets to Tenaya.
• ·Each party bears own costs except Alnylam's reimbursement of Tenaya's FTE and out-of-pocket expenses per research budget.
• ·Alnylam may terminate unilaterally; mutual termination for material breach.
• ·Upfront payment due within 30 days of Tenaya's invoice.

05-03-2026

Cumulus Media Inc. and its debtor affiliates have released a Disclosure Statement soliciting votes on a joint prepackaged Chapter 11 plan of reorganization in the U.S. Bankruptcy Court for the Southern District of Texas, with voting limited to Class 3 ABL Facility Claims, Class 4 2029 Secured Claims, and Class 5 Other Funded Debt Claims ahead of anticipated case commencement. Holders representing 72.05% of 2029 Debt Claims have committed to support the plan via a Restructuring Support Agreement, and the debtors' board strongly recommends acceptance by the April 7, 2026 voting deadline. The filing highlights ongoing challenges from a declining broadcast industry and liquidity pressures, with no quantified operational improvements noted.

• ·Record date for voting eligibility: February 23, 2026
• ·Voting deadline: 4:00 p.m. Central Time on April 7, 2026
• ·Debtors' service address: 780 Johnson Ferry Road, N.E., Suite 500, Atlanta, Georgia 30342
• ·Claims and noticing agent website: www.veritaglobal.net/cumulusmedia
• ·Anticipated bankruptcy court: Southern District of Texas, Houston Division

05-03-2026

Las Vegas Sands Corp. appointed Patrick Dumont as Chairman, Chief Executive Officer, President, and Treasurer effective March 1, 2026, and entered into new employment agreements effective March 2, 2026, through March 2, 2031, with Dumont, Randy Hyzak (EVP and CFO), and D. Zachary Hudson (EVP, Global General Counsel and Secretary). Dumont's base salary remains unchanged at $2.5M, while Hyzak and Hudson receive base salaries of $1.35M and $1.6M, respectively, with target incentives tied to 200-725% of base. No financial performance metrics or period-over-period changes are reported.

• ·Employment agreements include one-year non-competition and non-solicitation covenants and perpetual confidentiality covenants.
• ·Separation benefits provide 1x (base + target bonus) for termination without cause/good reason, 2x within 24 months of change of control, and 1x base for death/disability, plus pro-rata bonuses and benefits.
• ·Equity awards prior to March 2, 2026, follow existing terms; post-March 2 awards follow new agreement terms.
• ·Full agreements to be filed in Q1 2026 10-Q.

05-03-2026

Granite Ridge Resources, Inc. reported Q4 2025 total production up 27% YoY to 35,120 Boe/day (49% oil) and full-year production up 28% to 31,984 Boe/day, with Adjusted EBITDAX of $69.5M in Q4 and $315.0M for the year; however, it posted a Q4 net loss of $25.1M due to non-cash items, and lease operating expenses rose 29% per Boe YoY to $7.72/Boe. Proved reserves grew 15% to 62,347 MBoe, supported by acquisitions and extensions, while 2026 guidance projects 34,000-36,000 Boe/day (midpoint +9% YoY). The company invested $127.5M in Q4 capital expenditures and ended with $339.5M liquidity and 1.2x Net Debt to Adjusted EBITDAX.

• ·Q4 realized oil price $55.49/Bbl (92% of WTI at $59.64/Bbl); natural gas $1.81/Mcf (48% of Henry Hub at $3.75/Mcf).
• ·Production and ad valorem taxes 5.9% of sales in Q4 (6.1% full-year).
• ·G&A costs $8.0M in Q4 ($31.0M full-year), including non-cash stock-based comp.
• ·2026 guidance: acquisitions $20-30M, D&C capex $300-330M, total capex $320-360M, LOE $6.75-7.75/Boe, taxes 6-7% of revenue, cash G&A $25-27M.
• ·Conference call: March 6, 2026 at 10:00 AM CT; Piper Sandler Energy Conference: March 17, 2026.

05-03-2026

Trulieve Cannabis Corp. announced the termination without cause of Joy Malivuk as Chief Accounting Officer, effective May 28, 2026, following a 90-day notice period provided on February 27, 2026. The company simultaneously appointed Brett Walsh, its former Executive Corporate Controller, as the new Chief Accounting Officer effective February 28, 2026, with an annual base salary of $245,000. This leadership transition includes detailed severance provisions for both executives but no financial impact metrics were disclosed.

• ·Joy Malivuk termination notice date: February 27, 2026; effective date: May 28, 2026 (90-day notice period).
• ·Brett Walsh employment agreement effective: March 5, 2026; reports to Chief Financial Officer.
• ·Brett Walsh severance: 0.5x (base salary + greater of current target or prior actual bonus) + prorated bonus, paid over 6 months, plus 6 months COBRA; doubles to 1x post-Change of Control with lump sum payment and 12 months COBRA.
• ·Joy Malivuk post-termination: severance per employment agreement (filed May 10, 2023), COBRA subsidies, immediate vesting of equity (performance-based subject to certification).

05-03-2026

NewLake Capital Partners reported fourth quarter 2025 revenue of $12.3 million, down 1.4% YoY from $12.5 million due to vacancies at properties previously leased to AYR Wellness and Revolutionary Clinics, while full-year 2025 revenue increased 1.9% YoY to $51.1 million driven by acquisitions and rent escalations. AFFO declined 3.0% YoY in Q4 to $10.6 million ($0.51 per share) but rose modestly 0.3% for the full year to $43.8 million ($2.09 per share), with net income per share flat at $0.29 in Q4 and up slightly to $1.28 FY. The company declared a first quarter 2026 dividend of $0.43 per share and completed acquisitions totaling $1.7 million.

• ·Portfolio includes one property classified as Real Estate Held for Sale.
• ·Total liquidity of $106.3M includes $82.4M available under Revolving Credit Facility.
• ·No debt maturities until May 2027; $7.6M outstanding borrowings at 7.75% interest.
• ·Acquired two dispensaries from Cresco Labs in Ohio for $785K total and one from Curaleaf in PA for $950K via like-kind exchange.
• ·Hartford, CT property marketed for sale with lease amendments to C3 Industries.
• ·Cannabist operating under forbearance agreement extended through March 6, 2026.

05-03-2026

Methanex Corp (MEOH) filed its Form 40-F annual report for FY2025 ended December 31, 2025, including IFRS-based disclosures on equity (ordinary and preference shares), property, plant & equipment (buildings, ships, terminals, construction in progress), debt (unsecured notes at 5.125%-6.25%, term loans, limited recourse facilities), leases (ocean vessels, railcars), and share-based compensation (SARs, RSUs, PSUs). The filing details geographic methanol and ammonia operations across China, US, Europe, South America, Korea, Other Asia, Canada, Egypt, New Zealand, Chile, Trinidad, and subsidiaries like Atlas Methanol Company Unlimited and Firewater Natgasoline, with notes on tax losses (2015-2025), derivatives (gas, FX, Egypt supply), and New Zealand CGU sensitivities. No specific revenue, profit, or balance sheet totals provided in XBRL tags; comparisons structured for FY2025 vs FY2024 vs FY2023 across assets, liabilities, and equity.

• ·Unused tax losses disclosed for years 2015 through 2025
• ·Temporary differences in property plant & equipment, right-of-use assets, repatriation, and share-based comp
• ·Derivatives include North American natural gas forwards, Euro FX forwards, Egypt gas supply contract (Level 3 fair value)
• ·Leases: Ocean Vessel 1-Year Term, Ocean Vessel 8-Month Term, Railcar Lease 5-Year Term
• ·Term Loan A with Tranches 1 & 2 maturing June 27, 2025
• ·New Zealand CGU sensitivities to natural gas availability and methanol price forecasts

05-03-2026

TriSalus Life Sciences reported Q4 2025 revenue of $13.2M, up 60% YoY from $8.3M and 14% QoQ, with full-year 2025 revenue of $45.2M, up 53% YoY from $29.4M, exceeding original guidance. However, full-year gross margin declined to 84.6% from 86.1% due to lower manufacturing efficiency on new products, operating expenses rose with S&M up $2.9M and G&A up $3.5M YoY, and net loss attributable to common stockholders widened to $69.7M from $33.2M primarily from preferred stock conversion effects. The company raised $46M gross proceeds from a public offering post-Q4, ending 2025 with $20.4M in cash, and reaffirmed 2026 revenue guidance of $60-62M.

• ·R&D expenses decreased $2.7M YoY to $15.0M for FY 2025.
• ·S&M expenses increased $2.9M YoY to $28.7M for FY 2025.
• ·G&A expenses increased $3.5M YoY to $21.5M for FY 2025, including $1.8M accelerated stock-based compensation.
• ·Q4 gross margin improved to 86.7% from 85.3% YoY.
• ·Appointed Michael Stansky to Board in February 2026.
• ·Hosted KOL events on Nov 12, 2025 (Uterine Fibroids) and Dec 15, 2025 (Symptomatic Thyroid Disease).

05-03-2026

a.k.a. Brands Holding Corp. reported fourth quarter 2025 net sales growth of 3.1% to $164.0M and full year 2025 net sales up 4.4% to $600.2M, driven by 5.3% U.S. growth in Q4 and 7% for the year. However, Q4 net loss widened to $(14.5M) or $(1.35) per share from $(9.4M) or $(0.88) per share, with Adjusted EBITDA declining to $2.5M (1.5% margin) from $6.2M (3.9% margin); full year Adjusted EBITDA also fell to $19.7M (3.3% margin) from $23.3M (4.1% margin). The company announced eight new U.S. Princess Polly store leases, reduced inventory by 10%, and guided FY2026 net sales to $625-635M with Adjusted EBITDA of $27-29M.

• ·Q4 gross margin contracted slightly to 55.6% from 55.9% due to out-of-stocks during supply chain transition.
• ·Selling expenses rose to $51.0M (31.1% of sales) from $44.6M (28.0%) due to retail expansion.
• ·G&A expenses increased to $30.3M (18.5% of sales) from $24.9M (15.7%) due to non-routine legal matters.
• ·Debt remained flat at $111.1M vs. $111.7M YoY.
• ·Q1 2026 guidance: net sales $130-132M, Adjusted EBITDA $1.5-2.0M.
• ·FY2026 capex outlook: $18-20M.

05-03-2026

Pasqal Holding SAS announced a €340 million fundraise on March 4, 2026, achieving a €2 billion valuation as France's first quantum computing unicorn, with €170 million in private funds and €170 million in convertible financing as a prelude to a Nasdaq listing via merger with Bleichroeder Acquisition Corp. II this year and a Euronext listing in 2026-2027. This follows €100 million raised in 2023 and €145 million secured in 2025, supporting doubled production, hiring, and R&D amid competition from US giants like IBM, Microsoft, Google and European peers like IQM (valued at €1.8 billion). However, Quobly faces turbulence with suspended acquisition talks, highlighting sector consolidation needs and risks including regulatory approvals, shareholder redemptions, and technical challenges.

• ·Pasqal clients include EDF, Crédit Agricole, and Aramco (order for 200-qubit machine worth several tens of millions of euros in 2025)
• ·Roadmap targets 100 logical qubits by 2030
• ·Quobly entered exclusive negotiations with SealSQ for majority stake, later suspended
• ·Registration statement on Form F-4 to be filed with SEC

05-03-2026

SM Energy Company announced on March 4, 2026, the pricing of an upsized private offering of $1.0 billion aggregate principal amount of 6.625% senior notes due 2034. The press release is filed as Exhibit 99.1. No comparative financial metrics or performance declines were reported in this filing.

• ·Filing signed by James B. Lebeck on March 4, 2026
• ·Securities traded on New York Stock Exchange under symbol SM

05-03-2026

Brand Engagement Network Inc. (BEN) completed the closing of its previously announced AI licensing partnership with Valio Technologies (Pty) Ltd on March 4, 2026, which includes a $2.05 million AI licensing agreement and the establishment of Skye Africa Intelligence Pty Ltd to deploy BEN’s conversational AI technologies in select African markets. Tyler Luck, BEN’s Chief Executive Officer and Co-Founder, was appointed to the Board of Directors of Skye Africa Intelligence Pty Ltd on behalf of the Company. No negative financial impacts or declines were reported in this amendment to the original January 21, 2026 announcement.

• ·Originally announced on January 21, 2026
• ·Form 8-K/A filed on March 5, 2026

05-03-2026

ProCap Financial, Inc. (BRRWW) filed a DEFA14A additional proxy statement on March 05, 2026, containing standard disclaimers on forward-looking statements and clarifying that it does not constitute an offer to sell securities. The filing provides media contact Erica Chase and investor relations email. No specific proxy proposals, financial metrics, or material updates are detailed in the provided content.

05-03-2026

La Rosa Holdings Corp. adopted a Certificate of Designation on March 3, 2026, authorizing 100 shares of Series C Convertible Preferred Stock with a par value of $0.0001 per share, pursuant to a Securities Purchase Agreement. These shares rank senior to common stock in liquidation preferences (subject to senior/parity stock) and are convertible into common stock at a price of $1.176, with detailed mechanics including buy-in protections for holders. No specific issuance amounts or conversion volumes were disclosed, representing potential future dilution without immediate financial impact.

• ·Holders have conversion rights starting from Initial Issuance Date with Share Delivery Deadline of 1 Trading Day
• ·Company must pay 2% daily penalty for conversion failures post-Share Delivery Deadline
• ·Preferred shares rank junior to Senior Preferred Stock, parity with Parity Stock, senior to Junior Stock in liquidation

05-03-2026

Xanadu Quantum Technologies Inc. hosted an Analyst Day on March 4, 2026, discussing its proposed business combination with Crane Harbor Acquisition Corp. to form Xanadu Quantum Technologies Limited (NewCo) and go public on NASDAQ and TSX. The event highlighted Xanadu's Aurora scalable quantum computer (four server racks) and PennyLane software platform, with partnerships including Volkswagen, BMW, Toyota, Rolls-Royce, and Mitsubishi Chemical. Extensive forward-looking statements were tempered by risk disclosures, including historical net losses, going concern doubts, and potential failure to commercialize quantum technology.

• ·Aurora demonstrated real-time error correction decoding algorithms with photonics, peer-reviewed and published in Nature
• ·Vision includes scaling to hundred server racks networked in quantum data centers worldwide
• ·Risks include substantial doubt about Xanadu's ability to continue as a going concern and failure to obtain shareholder/regulatory approvals for the transaction

05-03-2026

Crane Harbor Acquisition Corp. filed definitive additional proxy materials (DEFA14A) on March 5, 2026, supplementing the February 27, 2026 proxy statement for the Extraordinary General Meeting on March 19, 2026, to update the estimated redemption price per SPAC Public Share to $10.33 (from initial $10.00 at IPO), reflecting Trust Account growth to $227.3 million from $220 million due to earned interest. This amendment clarifies procedures for SPAC Unit separation and redemption rights in connection with the proposed Business Combination and Continuance, with no other changes to the original proxy. The higher redemption price benefits redeeming shareholders but may indicate potential redemption pressure ahead of the merger.

• ·Supplement dated March 4, 2026
• ·Redemptions calculated as of two business days prior to Business Combination consummation
• ·Holders must separate SPAC Units into Class A Shares and Rights before redemption

05-03-2026

Canadian Pacific Kansas City Limited announced via press release that its wholly owned subsidiary, Canadian Pacific Railway Company, is issuing $600M of 4.000% notes due 2029 and $600M of 5.500% notes due 2056, for a total of $1.2B. The offering is expected to close on March 6, 2026, subject to customary closing conditions.

• ·Filing dated March 5, 2026, reporting event of March 4, 2026
• ·Securities registered: Common Shares on NYSE (CP) and TSX (CP); Perpetual 4% Debentures on NYSE (CP40) and LSE (BC87)

05-03-2026

ATN International reported Q4 2025 revenues of $184.2 million, up 2% YoY, while full-year revenues were flat at $728.0 million versus prior year. Adjusted EBITDA rose 8% to $50.0 million in Q4 and 3% to $190.0 million for the full year, with operating income improving to $28.4 million FY from a $(0.8) million loss; however, net loss widened to $(3.3) million in Q4 from prior income and totaled $(14.9) million FY. High-speed broadband homes passed grew 27% to 523,500 but broadband customers declined 4% to 194,900, while international mobile subscribers increased 3% to 399,200.

• ·2026 Adjusted EBITDA outlook $190M-$200M excluding US tower sale impact, which could reduce by $6M-$8M upon Q2 2026 initial closing.
• ·FY 2025 capex $105M-$115M expected (net of reimbursable).
• ·Net Debt Ratio 2.36x as of Dec 31, 2025.
• ·Quarterly dividend $0.275 per share paid Jan 9, 2026.
• ·No share repurchases in Q4 2025.

05-03-2026

Seaport Entertainment Group reported Q4 2025 total revenues of $29.5M, up 30.4% YoY from $22.6M, and full-year 2025 revenues of $130.4M, up 18.3% YoY from $110.2M, aided by Tin Building consolidation. However, Q4 net loss attributable to common stockholders improved 11.4% YoY to $36.9M (from $41.6M), and full-year loss improved 23.8% YoY to $116.7M (from $153.2M), with non-GAAP adjusted losses showing even stronger improvement (Q4 -8.9% to $17.5M; FY -49.2% to $54.1M). Recent developments include the February 2026 sale of 250 Water Street for $143.0M (net proceeds $76.1M) and a new $50M stock repurchase authorization.

• ·39% of consolidated debt fixed at 4.9% weighted-average rate; 61% floating at effective 8.3% post-swap as of Dec 31, 2025
• ·Weighted-average debt maturity of 7.2 years; no meaningful maturities until 2038 post-250 Water Street sale repayment
• ·Uplisted to NYSE, added to Russell 2000 and Microcap Indexes in 2025
• ·Conference call scheduled for March 5, 2026 at 8:30 AM ET

05-03-2026

CrowdStrike reported FY26 total revenue of $4.81B, up 22% YoY from $3.95B, driven by 21% growth in subscription revenue to $4.56B and 29% in professional services to $0.25B, with ARR reaching $5.25B (24% YoY growth). However, the company posted a net loss attributable to CrowdStrike of $162.5M, wider than the $15.2M loss in FY25, as operating expenses surged 26% to $3.89B, outpacing revenue growth and leading to an operating loss of $293M (vs. $116M prior year). Gross margins remained flat at 75%, while sales & marketing, R&D, and G&A expenses rose 20%, 29%, and 39% YoY, respectively.

• ·Subscription represented 95% of total revenue in FY26, flat YoY.
• ·Professional services gross margin declined 1pp to 18% in FY26.
• ·Provision for income taxes was $34.2M in FY26, down from $71.1M in FY25.

05-03-2026

Black Hawk Acquisition Corp, a SPAC, is seeking shareholder approval for its business combination with Vesicor Therapeutics, Inc., an early-stage biopharma developing the ecm-RV/p53 product candidate, via an Extraordinary General Meeting scheduled for 2026. Following a 69.2% redemption rate at the July 2025 extension vote, only 2,124,077 public shares remain outstanding with approximately $22.7M in the trust account, significantly limiting post-merger cash available after expenses. While the merger could provide funding for Vesicor's preclinical studies starting in H1 2026, uncertainties around PPM Investment completion, Nasdaq listing, and additional capital needs pose substantial risks.

• ·Extraordinary General Meeting redemption deadline: 5:00 p.m. ET two business days prior on [ ], 2026.
• ·Vesicor plans preclinical/IND-enabling studies in H1 2026 and potential regulatory process in H2 2026, contingent on funding.
• ·No securities issued or funding received under PPM Investment as of filing; may be waived but critical for Nasdaq listing.

05-03-2026

Enhabit reported Q4 2025 net service revenue of $270.4M, up 4.7% YoY from $258.2M, driven by 10.0% Hospice revenue growth to $63.6M and 3.2% Home Health growth to $206.8M, with Adjusted EBITDA rising 11.6% YoY to $28.0M; however, it posted a net loss of $38.7M due to $44.7M goodwill impairment, and Medicare Home Health revenue declined 4.9% YoY. The company announced a definitive agreement to be acquired by Kinderhook Industries for $13.80 per share (EV ~$1.1B), expected to close Q2 2026, and amended its credit facility to $315M term loan and $160M revolver maturing 2031. Balance sheet strengthened with $15M Q4 debt prepayment, reducing leverage to 3.7x.

• ·Home Health Non-Medicare admissions grew 16.0% YoY to 34,582.
• ·Opened 10 de novo locations in 2025.
• ·$125M total bank debt reduction from Q4 2023, saving $22M annualized cash interest.
• ·Full year 2025 net service revenue $1,060.0M, up from $1,034.8M.
• ·Cash from operations full year 2025: $70.7M, up from $51.2M.

05-03-2026

Moderna, Inc. entered into a Settlement Agreement on March 3, 2026, with Arbutus Biopharma Corporation and Genevant Sciences entities, resolving all worldwide patent infringement litigation related to Spikevax® and mRESVIA®, while securing a fully paid-up, royalty-free license for its infectious disease portfolio including mNEXSPIKE® and mCOMBRIAX®. The agreement requires a $950M noncontingent payment by July 8, 2026, and a potential additional $1.3B contingent payment based on the outcome of Moderna's appeal to the Federal Circuit regarding §1498 defenses for U.S. Government contract doses, providing litigation certainty but at a substantial near-term cost.

• ·Settlement includes mutual releases and covenants not to sue on Arbutus/Genevant patents for Moderna’s SM-102-based LNP infectious disease vaccines.
• ·If Moderna prevails fully on §1498 appeal, no contingent payment due; if affirmed against Moderna, full $1.3B due; Arbutus/Genevant must repay with interest if later overturned.
• ·Full Settlement Agreement to be filed as exhibit to Q1 2026 10-Q.

05-03-2026

Icahn Enterprises L.P. (IEP) filed a Form 8-K on March 5, 2026 (report date March 4, 2026) under Items 7.01 and 9.01, furnishing updated presentation materials (Exhibit 99.1) for use in investor meetings, media engagements, and speeches. The materials are not deemed 'filed' under Section 18 of the Exchange Act. The filing was signed by CFO Ted Papapostolou on behalf of Icahn Enterprises G.P. Inc.

• ·Securities: Depositary Units (IEP) registered on Nasdaq Global Select Market
• ·Commission File Number: 1-9516
• ·IRS Employer Identification No.: 13-3398766

05-03-2026

Pulmonx Corporation entered into a senior secured Credit Agreement and Guaranty dated March 2, 2026, with Perceptive Credit Holdings V, LP as initial lender and administrative agent, providing a term loan facility of up to $60M, including a $40M initial loan on the closing date and up to $20M in delayed draw commitments subject to conditions. The agreement includes financial covenants requiring minimum liquidity and minimum revenue, along with affirmative and negative covenants, representations, warranties, and events of default. No performance declines or flat metrics are reported, as this is a financing arrangement rather than operational results.

• ·Agreement filed as Exhibit 10.1 in 8-K on March 5, 2026
• ·Includes schedules for commitments, products, intellectual property, subsidiaries, indebtedness, liens, material agreements, and regulatory approvals
• ·Financial covenants: Minimum Liquidity (Section 10.01) and Minimum Revenue (Section 10.02)

05-03-2026

EPAM Systems, Inc. entered into a $300M accelerated share repurchase (ASR) agreement with Morgan Stanley & Co. LLC, receiving an initial delivery of 1,703,336 shares worth $240M based on the March 4, 2026 closing price. The ASR, authorized under the company's $1.0B share repurchase program, leaves $452.5M in remaining availability upon completion no later than Q2 2026. CEO Balazs Fejes highlighted confidence in EPAM's long-term growth and AI leadership, viewing the repurchase as value-enhancing.

• ·Final number of shares repurchased under ASR to be based on volume-weighted average share price during term, less a discount, subject to adjustments.
• ·ASR completion no later than second quarter of 2026.

05-03-2026

National Research Corporation announced on March 4, 2026, that it has surpassed $152 million in Total Recurring Contract Value (TRCV), representing an all-time high for the company. This milestone highlights robust growth in recurring revenue streams with no comparative prior period data provided in the filing.

05-03-2026

News Corporation disclosed via 8-K information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. No specific repurchase transactions or amounts were detailed in the filing itself, with details in Exhibits 99.1 and 99.2. The disclosures are made daily to ASX as required, alongside quarterly and annual reports.

• ·Event date: March 4, 2026
• ·Filing date: March 5, 2026
• ·Securities: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01) on Nasdaq Global Select Market

05-03-2026

Aptiv PLC announced the pricing of an upsized private offering of $1.6B aggregate principal amount of senior notes, consisting of $800M 6.125% notes due 2031 and $800M 6.375% notes due 2034, issued by subsidiaries Cyprium Corporation and Cyprium Holdings Luxembourg S.à r.l., ahead of spinning off the Electrical Distribution Systems segment via holding company Versigent Limited. The offering size was increased by $100M from the previously announced $1.5B. The notes are offered to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, with closing expected on March 18, 2026.

• ·Notes offered pursuant to Rule 144A and Regulation S exemptions
• ·Closing subject to customary conditions on March 18, 2026
• ·Press release issued pursuant to Rule 135c of the Securities Act

05-03-2026

Hippo Holdings Inc. reported total revenue of $468.6M for the year ended December 31, 2025, up 26% YoY from $372.1M, primarily driven by net earned premium growth of 39% to $380.1M and gross written premium increasing to $1,108.6M from $892.4M. The company achieved net income attributable to Hippo of $57.7M, reversing a $40.5M loss in 2024, with net loss ratio improving to 60% from 77% and combined ratio to 113% from 138%; however, insurance related expenses surged 48% to $131.3M, losses and loss adjustment expenses rose 10% to $229.9M, and commission income declined 19% to $51.3M.

• ·Book value per share increased to $16.97 in 2025 from $14.56 in 2024.
• ·Diluted adjusted earnings per share improved to $0.68 in 2025 from ($0.82) in 2024.
• ·Adjusted net income was $17.8M in 2025, compared to ($20.3M) loss in 2024.
• ·Catastrophe losses $61.5M in 2025 vs $58.0M in 2024 (up 6%).
• ·Non-catastrophe loss ratio improved to 45% in 2025 from 56% in 2024.

05-03-2026

Baytex Energy Corp. filed its Form 40-F annual report for the fiscal year ended December 31, 2025, incorporating the Annual Information Form, audited consolidated financial statements, MD&A, and supplemental oil and gas disclosures. The company reported 765,568,147 common shares outstanding at year-end, with effective disclosure controls and procedures and no material changes in internal controls over financial reporting. No specific financial performance metrics or period-over-period changes were detailed in the provided filing content.

• ·Filing date: March 05, 2026
• ·Fiscal year end: December 31, 2025
• ·Common shares trade on NYSE under symbol BTE
• ·Cash generating units include Viking and Lloydminster
• ·Disclosure controls and procedures confirmed effective as of December 31, 2025
• ·No changes in internal control over financial reporting during FY2025

05-03-2026

STEM, Inc. reported FY2025 revenue of $156.3M, up 8% YoY from $144.6M, driven by 29% growth in services and other revenue to $87.7M, though hardware revenue declined 11% to $68.6M. The company achieved GAAP net income of $137.8M versus a $854.0M loss in 2024, aided by a $220M gain on debt extinguishment and GAAP gross profit of $60.0M (38% margin) versus a $11.1M loss (-8% margin); however, it posted an operating loss of $55.7M, Adjusted EBITDA of $6.7M remained modest, and storage operating AUM fell slightly to 1.7 GWh from 1.8 GWh. Bookings rose 14% to $131.8M, CARR increased 4% to $67.2M, but total assets decreased to $308.9M from $437.4M amid metric redefinitions impacting comparability.

• ·Net cash provided by operating activities improved to $6.9M in FY2025 from ($36.7M) used.
• ·Convertible notes noncurrent decreased to $183.6M from $525.9M; senior secured notes added at $128.8M.
• ·Several key operating metrics (Bookings, Contracted backlog, CARR) redefined starting Q1 2025 to focus on executed purchase orders, reducing prior comparability.
• ·Cash and equivalents $48.9M at Dec 31, 2025, down from $56.3M.

05-03-2026

StubHub Holdings, Inc. reported revenue of $1.75B for the year ended December 31, 2025, a slight decline of 1.4% YoY from $1.77B in 2024. However, the company swung to a massive net loss of $1.91B from a near-breakeven loss of $2.8k in 2024, driven by general and administrative expenses surging to $1.71B (including $1.45B in stock-based compensation) from $387M. While cost of revenue decreased 6% and interest expense fell 22.1%, sales and marketing expenses rose 17.4% YoY.

• ·Operations and support expenses increased to $63.2M in 2025 from $59.5M in 2024.
• ·Loss from operations was $1.34B in 2025 versus income of $138M in 2024.
• ·Foreign currency losses of $89.7M in 2025 compared to gains of $41.1M in 2024.
• ·Revenue grew 27.6% from 2023 to 2024 but declined 1.4% in 2025.

05-03-2026

SandRidge Energy reported strong full-year 2025 production growth to 18.5 MBoe/d (+12% YoY Boe basis, +32% oil) driven by Cherokee acquisition and development, achieving adjusted EBITDA of $101.1M and proved reserves of 69.1 MMBoe (+10% YoY). However, realized commodity prices declined notably (oil $63.64/Bbl, -14% YoY), resulting in Q4 revenues of $39.4M (flat vs Q3 2025 and slightly up vs Q4 2024) and adjusted net income down 19% QoQ to $12.5M. The Board declared a $0.12/share cash dividend payable March 31, 2026, and issued 2026 guidance for 6.4-7.7 MMBoe production with $76-97M capex.

• ·Q4 2025 LOE $4.34/Boe, down from $6.43/Boe Q4 2024 due to non-recurring adjustments
• ·2026 guidance: LOE $39-47M, Adjusted G&A $10-12M, Oil production 1.2-1.7 MMBbls
• ·$68.3M remaining share repurchase authorization as of Dec 31, 2025
• ·Over four years without a recordable safety incident as of 2025

05-03-2026

Palladyne AI reported Q4 2025 revenue growth of 118% YoY to $1.7 million from $0.8 million, but full-year 2025 revenue declined 33% YoY to $5.2 million from $7.8 million, reflecting operational transformation via acquisitions while operating losses widened to $32.4 million from $26.9 million. The company posted FY2025 GAAP net income of $10.0 million versus a $72.6 million loss prior year, driven by a $37.7 million gain on warrant liabilities, and ended with $47.0 million in cash equivalents and marketable securities plus a $13.5 million backlog that grew over 30% to nearly $18 million by mid-February 2026. It reiterated 2026 revenue guidance of $24-27 million, implying 357-415% YoY growth.

• ·GAAP net loss Q4 2025 of $1.5 million improved from $53.0 million loss in Q4 2024.
• ·Non-GAAP net loss FY 2025 of $25.2 million widened from $22.6 million in FY 2024.
• ·Warrant liabilities decreased to $2.8 million from $51.4 million at Dec 31, 2024.
• ·Total stockholders' equity turned positive at $74.7 million from ($9.5 million) deficit at Dec 31, 2024.
• ·Conference call held March 5, 2026 at 8:00 a.m. ET.

05-03-2026

Shattuck Labs, Inc. reported total revenue of $1M for the year ended December 31, 2025, down 82.5% from $5.7M in 2024 primarily due to the absence of $5.7M in collaboration revenue. Research and development expenses decreased 47.5% to $35.3M, while general and administrative expenses fell 9.7% to $17.2M, resulting in a narrower net loss of $48.8M (35.3% improvement) compared to $75.4M in 2024. Cash and equivalents ended at $54.2M after a modest $3.2M decrease, bolstered by $44.6M in financing activities from stock sales.

• ·Cash and equivalents decreased $3.2M to $54.2M in 2025 vs $68.2M decrease to $57.4M in 2024.
• ·Shares outstanding increased to 63.3M from 47.7M due to $44.5M stock offering.
• ·Total assets stable at $91.0M; stockholders' equity rose to $82.4M from $79.6M.
• ·Net cash used in operating activities improved to $39.9M from $60.5M.

05-03-2026

Teads Holding Co. reported Q4 2025 revenue of $352.2M, up 50% YoY, and FY 2025 revenue of $1.3B, up 46% YoY, driven by the Legacy Teads acquisition, with Adjusted EBITDA reaching $36.5M (+115% YoY) in Q4 and $93.4M (+150% YoY) for the year. However, net losses widened significantly to $(428.2M) in Q4 and $(517.1M) for FY due to $352.1M goodwill impairment and other charges, while net cash from operations declined 83% YoY to $7.3M in Q4 and 89% to $7.6M for FY. The company executed a 10% headcount reduction for $35-40M annual savings and issued FY2026 Adjusted EBITDA guidance of ~$100M.

• ·Q1 2026 guidance: Ex-TAC gross profit $102M-$106M; Adjusted EBITDA breakeven to $3M.
• ·FY 2026 guidance: Adjusted EBITDA ~$100M.
• ·Branding customers utilizing omnichannel campaigns: 10% (up from 7% in Q1 2025).
• ·Q4 gross margin: 34.2% (vs 23.9% prior year); FY gross margin: 33.0% (vs 21.6%).
• ·Nonrecurring Q4 pre-tax expenses: $352.1M goodwill impairment, $3.4M acquisition/integration, $5.7M restructuring.

05-03-2026

Kura Oncology reported first net product revenue of $2.1M from KOMZIFTI in Q4 2025 (first five weeks post-approval), with total Q4 revenue of $17.3M but collaboration revenue declining 72% YoY to $15.2M; full-year total revenue grew 25% YoY to $67.5M. R&D expenses increased 23% YoY to $64.4M and SG&A rose 62% YoY to $39.1M in Q4, driving a net loss of $81.0M versus $19.2M in Q4 2024 (full-year net loss widened 60% to $278.7M). Cash, cash equivalents, and short-term investments stood at $667.2M as of Dec 31, 2025, down 8% from $727.4M prior year, with $180M anticipated collaboration payments extending runway to 2028.

• ·KOMZIFTI added to NCCN Guidelines as Category 2A for R/R NPM1-m AML.
• ·Orange Book listing with patents extending to July 2044.
• ·Cash runway sufficient into Q4 2027 standalone, to 2028 topline KOMET-017 with $180M milestones.
• ·KOMZIFTI FDA approval date: November 13, 2025.

05-03-2026

The Middleby Corporation issued a presentation on March 5, 2026, detailing its previously announced plan to separate its Food Processing Business into a standalone public company via a Spin-off. The presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) and is not deemed filed material. No financial metrics or period comparisons are provided in the filing.

05-03-2026

Brilliant Earth reported record Q4 FY2025 net sales of $124.4 million, up 4.1% YoY from $119.5 million, and full-year net sales of $437.5 million, up 3.6% YoY from $422.2 million, supported by total orders growth of 6.5% in Q4 and 13% for the year, plus 34% YoY fine jewelry bookings growth reaching 23% of total bookings. However, gross margins contracted 370 bps to 55.9% in Q4 and 280 bps to 57.5% for FY2025 amid precious metal price headwinds and tariffs, while Adjusted EBITDA declined 39.1% to $4.2 million in Q4 and 43.3% to $12.0 million for the year; the company posted GAAP net losses of $1.3 million in Q4 and $6.4 million for FY2025. Guidance calls for positive mid-single-digit YoY net sales growth in Q1 and FY2026, with Adjusted EBITDA profitable but slightly lower than FY2025.

• ·Repeat orders grew 15% YoY in Q4 FY2025 and 13% for FY2025
• ·Average Selling Price (ASP) grew YoY across the assortment in Q4 FY2025
• ·Fine jewelry bookings reached 23% of total bookings in Q4 FY2025
• ·Company headquartered in San Francisco, CA, serving customers in over 50 countries
• ·Q1 FY2026 Adjusted EBITDA Margin guidance: negative mid-single-digit %
• ·FY2026 Adjusted EBITDA outlook: profitable, slightly lower than FY2025 $12.0M

05-03-2026

U.S. GoldMining Inc. announced the appointment of Imola Götz as Vice President, Project Development on March 5, 2026, via a news release furnished as Exhibit 99.1 under Regulation FD Disclosure. The filing confirms the company's status as an emerging growth company and lists its securities: Common Stock (USGO) with $0.001 par value and Warrants (USGOW) exercisable at $13.00 per share, both on Nasdaq. No financial performance metrics or period comparisons were disclosed.

• ·Company incorporated in Nevada; principal offices at 1188 West Georgia Street, Suite 1830, Vancouver, BC, Canada, V6E 4A2.
• ·Commission File Number: 001-41690; IRS Employer Identification No.: 37-1792147.
• ·Telephone: (604) 388-9788.

05-03-2026

OLAPLEX reported Q4 FY2025 net sales growth of 4.3% to $105.1M, driven by Professional channel (+18.9% to $36.8M) and DTC (+6.6% to $43.6M), but Specialty Retail declined 14.5% to $24.7M; FY2025 net sales were nearly flat at +0.1% to $423.0M amid Professional (+5.5%) and DTC (+3.1%) gains offset by Specialty Retail's 8.3% drop. The company swung to a FY net loss of $9.3M from $19.5M income in FY2024, with Adjusted EBITDA falling 27.6% to $93.9M and SG&A rising 33.8%; FY2026 guidance projects net sales of $414-435M with Adjusted EBITDA margin of 21-22%.

• ·Cash decreased to $318.7M from $586.0M YoY; inventory down to $60.2M from $75.2M.
• ·Long-term debt reduced to $352.3M from $643.7M YoY.
• ·FY2026 guidance: Adjusted Gross Profit Margin 71-72%; Q1 expected below full-year trends with front-loaded marketing.

05-03-2026

Liquidia Corporation achieved strong YUTREPIA net product sales of $148.3M for FY2025 ($90.1M in Q4), driving total revenue to $158.3M (up >1,000% YoY from $14.0M) and marking the second consecutive profitable quarter with Q4 net income of $14.6M and positive adjusted EBITDA of $27.3M. However, service revenue declined 28.6% YoY to $10.0M due to lower Treprostinil Injection volumes, SG&A expenses surged 93% to $157.2M amid commercialization efforts, and FY2025 net loss was $68.9M (improved 46% from $128.3M in 2024 but still negative). Cash and equivalents ended at $190.7M, up $33M from Q3 2025 and 8% YoY.

• ·YUTREPIA FDA approval: May 23, 2025; commercial launch: June 2025
• ·Cost of product sales FY2025: $8.8M (none in 2024)
• ·More than half of 860 prescribers have prescribed YUTREPIA to at least 2 patients; 25% referred 5+ patients
• ·Ongoing YUTREPIA-related litigation with United Therapeutics

05-03-2026

BJ’s Wholesale Club Holdings reported Q4 FY2025 net sales of $5.45B, up 5.5% YoY, and full-year net sales of $21.0B, up 4.6% YoY, with membership fee income surging 10.9% to $129.8M in Q4 and 9.5% to $499.8M full year, alongside digitally enabled comp sales growth of 31%. However, comparable club sales grew modestly by 1.6% in Q4 and 1.0% full year (ex-gas 2.6% both periods), Q4 operating income declined slightly by 0.2%, and merchandise gross margin rate fell 50 bps in Q4 while remaining flat full year amid SG&A increases from expansions. Full-year net income rose 8.2% to $578.4M with adjusted EBITDA up 6.1% to $1.16B and diluted EPS up 9.5% to $4.38.

• ·Achieved 90% tenured member renewal rate during FY2025
• ·Opened 7 new clubs and 7 new gas stations in FY2025
• ·Q4 share repurchases: 1,264,000 shares for $117.7M; $749.7M remains available under program
• ·FY2026 guidance: Comparable club sales ex-gas +2.0% to 3.0%; Adjusted EPS $4.40-$4.60
• ·Cash and equivalents: $46.2M as of Jan 31, 2026 (up from $28.3M prior year)

05-03-2026

Altimmune reported cash, cash equivalents, and short-term investments of $274M as of December 31, 2025, up 107% YoY from $132M, strengthened further by $75M registered direct offering and $8M ATM in January 2026, providing runway for Phase 3 MASH trial initiation planned for 2026 and RECLAIM Phase 2 topline data in Q3 2026. Pemvidutide received FDA Breakthrough Therapy Designation for MASH based on positive IMPACT Phase 2b data showing fibrosis/inflammation improvements and additional weight loss. However, Q4 net loss widened 18% YoY to $27.4M driven by G&A expenses doubling to $10.5M, despite R&D decline; full-year net loss improved to $88.1M from $95.1M but revenues remained negligible at $41k.

• ·Jerry Durso appointed CEO, previously Chairman and Board member since Feb/Aug 2025.
• ·RECLAIM trial enrollment completed Nov 2025 ahead of schedule.
• ·RESTORE Phase 2 trial in ALD ongoing.
• ·FDA alignment on Phase 3 MASH design: 52-week, biopsy endpoints for accelerated approval.
• ·Common shares outstanding increased to 110.9M from 72.4M YoY.

05-03-2026

AZZ Inc. announced the appointment of Aaron Schapper and Charles Treadway as new independent directors effective April 8, 2026, bringing expertise in strategic growth, M&A, and ESG amid ongoing board refreshment. Dan Feehan announced his retirement from Chairman on February 28, 2026, succeeded by Dan Berce, and will continue as a director until July 2026 after a 26-year tenure including 7 years as Chairman. The refreshed board will have 8 members, 7 independent, with 4 added in the last 5 years.

• ·Appointments result of comprehensive search by Board with independent search firm.
• ·Schapper, age 52, prior roles at Valmont Industries and Orbit Irrigation.
• ·Treadway, age 60, prior CEO at Accudyne Industries and roles at Thomas & Betts.

05-03-2026

Victoria’s Secret & Co. reported Q4 FY2025 net sales of $2.27B, up 8% YoY exceeding guidance, and full-year net sales of $6.55B, up 5% YoY, with comparable sales growth of 8% and 5% respectively. Adjusted operating income significantly outperformed at $316M in Q4 (above $265M-$290M guidance, +6% YoY) and $403M for FY (+8% YoY despite $85M tariff pressure). However, reported operating income declined to $229M in Q4 (-15% YoY from $268M) and $271M for FY (-13% YoY from $310M), while direct channel sales were flat at 0% YoY for the full year.

• ·Q4 FY2025 Stores North America net sales $1.22B (+5.2% YoY); International $276M (+43.1% YoY)
• ·FY2025 Stores North America net sales +3.4% YoY; International +27.3% YoY
• ·Strategic review initiated for non-core DailyLook asset; continuing assessment of Adore Me
• ·FY2025 direct net sales included $20M negative impact from Q2 website closure
• ·Q1 FY2026 guidance: net sales $1.49B-$1.525B (+10-13% YoY), operating income $32M-$42M
• ·FY2026 guidance: net sales $6.85B-$6.95B (+5-6% YoY), operating income $430M-$460M

05-03-2026

CPI Card Group Inc. reported strong Q4 2025 results with revenue up 22% YoY to $153.1M and Adjusted EBITDA up 34% to $29.4M, driven by the Arroweye acquisition and higher contactless card sales; Debit and Credit segment revenue surged 40% to $128.9M. However, full-year net income declined 23% to $15M due to acquisition/integration costs and higher taxes, Prepaid Debit segment revenue dropped 27% in Q4 to $24.4M and 12% for the year to $93.6M, and gross profit margins contracted to 31.3% from 35.6%. Operating cash flow rose 37% to $60M, supporting a Net Leverage Ratio of 3.1x at year-end, with 2026 outlook projecting high single-digit revenue growth led by Integrated Paytech (>15%).

• ·Arroweye contributed $43M revenue and $6M Adjusted EBITDA in ~8 months post-acquisition on May 6, 2025.
• ·Acquired 20% equity in Karta for $10M on October 7, 2025, with option for additional 31%.
• ·Retired $20M Senior Notes principal on July 15, 2025 at 103% of par.
• ·Instant issuance solutions grew ~20% in 2025 with new referral agreement for access to 450+ FIs.
• ·2026 Adjusted EBITDA outlook includes ~$4M Integrated Paytech acceleration costs and ~$6M tariff expenses.
• ·Visa/Mastercard U.S. debit/credit cards in circulation CAGR 7.5% for 3-years ending Sep 30, 2025.

05-03-2026

Myers Industries reported Q4 2025 net sales flat at $204M YoY (0.0%), with gross profit up 2.8% to $68M and operating income up 38.3% to $20M, driven by Material Handling segment margin expansion (+200 bps to 19.0%); however, Distribution segment showed minimal sales growth (0.9%). Full year 2025 net sales declined 1.3% to $826M, though adjusted EBITDA rose 1.6% to $124M and free cash flow increased 23% to $67M, offset by Distribution segment sales down 5.1% and operating income down 127.9%. The company achieved $20M in annualized cost reductions via Focused Transformation and is progressing with the sale of Myers Tire Supply.

• ·Total debt reduced by $31M in FY 2025, ending with net leverage ratio of 2.4x.
• ·Cash flow from operations FY 2025: $87M; capital expenditures: $20M.
• ·Myers Tire Supply expected to qualify for discontinued operations in Q1 2026 reporting.
• ·2026 end market outlooks: Industrial moderate growth (41% of MH sales), Infrastructure strong growth (19%), Vehicle/Food & Beverage stable/slightly down.

05-03-2026

On March 5, 2026, Philip Morris International Inc. announced via press release that its Board of Directors declared a regular quarterly dividend of $1.47 per common share. The announcement is furnished under Item 7.01 and not deemed filed for liability purposes. The filing also lists the company's registered securities, including common stock (PM) and multiple series of notes with maturities from 2026 to 2044.

• ·Filing submitted by Darlene Quashie Henry on behalf of Philip Morris International Inc.
• ·Principal executive offices: 677 Washington Blvd, Ste. 1100, Stamford, Connecticut 06901.
• ·Telephone: (203) 905-2410.

05-03-2026

Cardinal Health, Inc. announced on March 2, 2026, that Mary Scherer, Senior Vice President and Chief Accounting Officer, intends to retire in February 2027. The company will initiate a search for her successor, and Ms. Scherer will remain in her role until the successor is identified and onboarded for a smooth transition. No immediate disruption to operations is indicated.

• ·Form 8-K filed on March 5, 2026

05-03-2026

Lexicon Pharmaceuticals reported Q4 2025 revenues of $5.5M, down 79% YoY from $26.6M due to lower licensing revenue, while full-year revenues increased 60% YoY to $49.8M driven by $45M Novo Nordisk upfront; net product sales of INPEFA declined 23% YoY to $4.6M for the year. R&D and SG&A expenses decreased significantly (28% and 74% YoY for full year), narrowing full-year net loss to $50.3M from $200.4M, but cash position fell to $125.2M from $238M as of Dec 31, 2025, bolstered post-period by over $100M from capital raise and Novo milestone. Pipeline advanced with sotagliflozin HCM enrollment over 50%, T1D NDA resubmission on track for 2026, and positive FDA meeting for pilavapadin Phase 3.

• ·SONATA-HCM enrollment surpassed 50%, completion mid-2026, topline Q1 2027.
• ·Pilavapadin End-of-Phase 2 FDA meeting successful; Phase 3 to include two 12-week studies with 10mg dose, primary endpoint change in average daily pain score.
• ·LX9851 IND-enabling activities completed; $10M Novo milestone received Feb 2026, up to $20M more in 2026.
• ·Viatris shipped first commercial sotagliflozin to UAE; submissions in Canada, Australia, New Zealand.

05-03-2026

Bank of New York Mellon Corp's 2026 DEF 14A proxy statement seeks advisory approval of 2025 NEO compensation, emphasizing strong performance under CEO Robin Vince with annualized adjusted revenue growth of 6%, noninterest expense growth of 3%, and operating EPS growth of 18% from 2022-2025, resulting in 178% total shareholder return outperforming the S&P 500 Financials Index by over 2.5x. Prior three-year say-on-pay proposals received average 95% stockholder support. No declines or flat metrics were highlighted in the disclosed performance data.

• ·Compensation for Mses. O’Connor and Robinson includes amounts for roles as Chair and member of the Board of BNY Mellon Government Securities Services Corp.
• ·Proxy seeks approval pursuant to Item 402 of Regulation S-K.

05-03-2026

Tango Therapeutics reported full year 2025 collaboration revenue of $62.4M, up 108% YoY from $30.0M, driven by Gilead agreement recognition, while R&D expenses decreased 8% YoY to $132.2M and net loss improved 22% to $101.6M from $130.3M. However, Q4 2025 collaboration revenue declined 100% to $0 from $5.4M YoY, license revenue was $0 for the year versus $12.1M prior, and Q4 net loss widened 26% to $38.7M; cash position remains strong at $343.1M as of Dec 31, 2025, funding operations into 2028 amid upcoming 2026 clinical milestones for vopimetostat.

• ·Appointment of Philippe Serrano as Chief Regulatory Officer.
• ·CEO succession: Barbara Weber retired, succeeded by Malte Peters; Weber becomes Executive Chair through 2026.
• ·Sung Lee appointed to Board of Directors in January 2026.
• ·Initial Phase 1/2 data from vopimetostat combinations expected in 2026.

05-03-2026

Invivyd reported Q4 2025 PEMGARDA net product revenue of $17.2M, up 25% YoY from $13.8M and 31% QoQ from $13.1M, with full-year 2025 revenue of $53.4M, more than doubling from $25.4M in 2024. R&D expenses dropped sharply 72% YoY to $38.3M, contributing to a reduced net loss of $52.5M versus $169.9M in 2024; however, SG&A expenses rose slightly 6% to $66.9M. Year-end cash stood at $226.7M after raising over $200M in 2H 2025, supporting ongoing DECLARATION Phase 3 trial for VYD2311 with top-line data expected mid-2026.

• ·Net loss per share improved to $0.30 in FY 2025 from $1.43 in FY 2024.
• ·FDA granted Fast Track designation to VYD2311 in December 2025.
• ·RSV market projected at $3-4B annually by 2030.
• ·IDMC recommended enrollment of pregnant/breastfeeding women in DECLARATION trial and removed contraception/safety visit requirements.

05-03-2026

Immatics N.V. swung to a net loss of €196.4M in 2025 from a €15.2M profit in 2024, primarily due to a 69% YoY revenue decline to €48.3M from collaboration agreements and a 24% increase in R&D expenses to €183.8M, leading to an operating loss widening to €182.0M. However, cash and equivalents rose 46% to €345.9M, bolstered by a €125.5M net cash inflow including €204.8M from investing activities, while total assets decreased to €562.3M and shareholders' equity fell to €484.1M.

• ·Direct external R&D expenses for TCR T-cell therapy Programs increased to €49.5M in 2025 from €25.9M in 2024.
• ·Share-based compensation in R&D decreased to €7.5M in 2025 from €9.6M in 2024.
• ·Net cash from financing activities €97.4M in 2025, down from €319.7M in 2024.
• ·Accumulated deficit widened to €786.0M as of Dec 31, 2025 from €589.5M.
• ·Auditor: PricewaterhouseCoopers GmbH (Firm ID: 1275)

05-03-2026

Climb Bio reported Q4 and FY 2025 financial results, with cash and equivalents at $160.7M providing runway into 2028, down from $212.5M at year-end 2024. Pipeline advanced with dosing completed in budoprutug subcutaneous Phase 1 (data H1 2026) and ongoing trials in pMN, ITP, SLE, and CLYM116 Phase 1 (data mid-2026), but R&D expenses surged 130% YoY in Q4 to $13.7M and 226% for FY to $46.7M, driving Q4 net loss to $17.5M from $8.4M while FY net loss improved to $59.9M from $73.9M due to absence of prior IPRD charge.

• ·Net loss per share Q4 2025: $(0.26) vs $(0.13) in Q4 2024
• ·Net loss per share FY 2025: $(0.88) vs $(1.53) in FY 2024
• ·Total operating expenses Q4 2025: $19.3M vs $10.9M Q4 2024
• ·Total assets Dec 31, 2025: $167.7M vs $217.2M Dec 31, 2024

05-03-2026

Janus International Group, Inc. (NYSE: JBI) announced the immediate appointments of Jeannine Lane and Paul Vasington to its Board of Directors on March 5, 2026. Ms. Lane, currently Executive Vice President, General Counsel and Corporate Secretary at Resideo Technologies, Inc., will chair the Nominating and Corporate Governance Committee, while Mr. Vasington, former CFO of Sensata Technologies, will join the Audit Committee and the newly established Innovation and Technology Committee. The company highlighted their expertise in enterprise risk, legal strategy, finance, and value creation to strengthen governance and support strategic growth.

• ·Ms. Lane has over 35 years of experience in global industrial manufacturing, consumer products, software, and wholesale distribution.
• ·Mr. Vasington served as CFO of Sensata Technologies from 2014 to 2023 and held finance roles at Honeywell from 2004 to 2014.

05-03-2026

GH Research PLC (GHRS) filed its 20-F Annual Report on March 05, 2026, disclosing standard sections including risk factors, operating review, and financial information without specific quantitative results provided in the excerpt. Key risks highlighted include lack of marketing and sales organization, no commercialization experience requiring significant future investments, and belief of being a PFIC for 2025 with likelihood continuing into 2026, potentially impacting U.S. investors adversely. Additional challenges noted involve establishing commercial infrastructure for GH001 and GH002, subject to regulatory approval, and strict DEA registration, inspection, and compliance requirements for controlled substances.

• ·Belief of PFIC status for 2025 taxable year, likely continuing in 2026 and future years.
• ·DEA registrations for facilities handling controlled substances must renew annually (except pharmacies every three years), with periodic inspections.
• ·Failure to comply with CSA and DEA regulations could lead to civil penalties, registration revocation, or criminal proceedings.

05-03-2026

ASP Isotopes Inc. issued a press release on March 5, 2026, announcing the appointment of Nate Salpeter, Ph.D., as Chief Technology Officer of Quantum Leap Energy LLC. The disclosure is made under Regulation FD (Item 7.01) with the press release attached as Exhibit 99.1. No financial metrics, performance data, or other quantitative details are provided in the filing.

05-03-2026

Berkshire Hathaway Inc. commenced repurchasing shares of its Class A and Class B Common Stock on March 4, 2026, under its long-standing policy when the price is below conservatively determined intrinsic value, as disclosed for transparency amid leadership transition. Repurchases may occur via open-market or privately negotiated transactions, including Rule 10b5-1 plans, but there is no obligation for any specific number of shares and activity may be suspended without notice. No specific repurchase amounts or volumes were disclosed.

• ·Filing made pursuant to Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• ·Securities traded on New York Stock Exchange under symbols BRK.A, BRK.B, BRK27, BRK28, BRK30, BRK34, BRK35, BRK39, BRK41, BRK59.
• ·No obligation to update repurchase disclosures except as required by periodic reports (Form 10-Q, 10-K) or law.

05-03-2026

HUTCHMED reported total revenue of $549M for the year ended December 31, 2025, down 13% YoY from $630M amid declines in Oncology/Immunology revenue (down 21% to $286M, with products like Fruzaqla -19%, Sulanda -45%) and flat Other Ventures revenue at $263M. However, net income attributable to the company surged to $457M from $38M, boosted by a $477M gain on divestment of equity investees, while R&D expenses fell 30% to $148M. The balance sheet showed total assets at $1.8B (up 38% YoY) with short-term investments rising to $1.3B, though cash equivalents dropped to $71M.

• ·PRC foreign-invested enterprises must reserve at least 10% of after-tax profits until reserves reach 50% of registered capital, limiting dividends.
• ·Basic EPS $0.53 for 2025 vs $0.04 for 2024.
• ·Total shareholders’ equity $1.3B as of Dec 31, 2025, up 62% YoY.

05-03-2026

Ranpak Holdings Corp (NYSE: PACK) reported Q4 2025 net revenue of $111.9 million, up 6.6% YoY from $105.0 million, driven by automation equipment sales (+35.3% to $13.8 million) and void-fill (+7.6% to $52.3 million), while wrapping grew 11.7% but cushioning declined 4.5% to $34.3 million. However, Adjusted EBITDA fell 5.1% YoY to $24.0 million, gross margin dropped to 32.6% from 39.4%, and net loss widened to $9.5 million from $8.0 million. Full year 2025 net revenue increased 7.1% to $395.0 million, but Adjusted EBITDA declined 5.5% to $79.2 million and net loss expanded to $38.3 million from $21.5 million.

• ·2026 guidance: net revenue $415-445M (5.1%-12.7% growth); Adjusted EBITDA $83.5-95M (5.4%-19.9% growth).
• ·Void-fill systems installed base: 88.8 thousand (+3.6% YoY).
• ·Wrapping systems installed base: 22.9 thousand (+1.3% YoY).
• ·Conference call scheduled for March 5, 2026 at 8:30 a.m. ET.

05-03-2026

Bioventus Inc. reported Q4 2025 revenue of $157.9M, up 2.8% YoY on a reported basis and 10.0% organically, driven by 15.1% growth in Pain Treatments and 3.4% in Surgical Solutions; however, Restorative Therapies declined 26.0% due to the Advanced Rehabilitation Business divestiture, and full-year 2025 revenue fell 0.9% to $568.1M despite 7.5% organic growth with Surgical Solutions up 7.6% but Restorative Therapies down 30.4%. Profitability strengthened with Q4 Adjusted EBITDA up 30% to $36.7M, GAAP EPS $0.21 from $0.00, and cash from operations surging 97% to $38M, while FY Adjusted EPS rose 21.4% to $0.68. 2026 guidance anticipates $600M-$610M revenue (6-7% growth), Adjusted EPS $0.73-$0.77 (7-13% increase), and $82M-$87M cash from operations.

• ·Q4 U.S. revenue $139.5M +3.2% YoY reported, +10.1% organic.
• ·FY U.S. revenue $502.1M -0.9% YoY reported, +6.9% organic.
• ·Q4 International Surgical Solutions revenue down 8.6% to $6.7M.
• ·FY International revenue $66.0M -0.7% YoY reported, +11.5% organic.
• ·Advanced Rehabilitation Business divestiture: Q4 2025 $0.1M vs. 2024 $10.3M; FY 2025 $0.9M vs. 2024 $45.4M.

05-03-2026

REGENXBIO reported Q4 2025 revenues of $30.3M, up 43% YoY from $21.2M, and full-year 2025 revenues of $170.4M, up 105% YoY from $83.3M, driven by Nippon Shinyaku collaboration and higher royalties; however, Q4 net loss widened 31% YoY to $67.1M from $51.2M due to elevated R&D expenses (up 18% to $59.6M) and G&A (up 11% to $22.4M), while full-year net loss improved 15% to $193.9M from $227.1M. Cash and equivalents declined slightly 2% YoY to $240.9M from $244.9M, funding operations into early 2027, amid pipeline progress like RGX-202 data in Q2 2026 but setbacks including FDA holds on RGX-111/RGX-121 and a CRL for RGX-121.

• ·RGX-202 Phase I/II patients (n=4) improved average 7.4 NSAA points vs cTAP at 18 months (up from 6.6 at 12 months).
• ·ALTITUDE trial Dose Level 3 (n=15): 50% achieved ≥2-step DRSS improvement at 2 years; ≥70% risk reduction in vision-threatening complications vs historical controls.
• ·Pivotal enrollment complete for RGX-202 (n=30) in Oct 2025; confirmatory trial (n=30) ongoing.
• ·FDA clinical holds on RGX-111 (neoplasm case) and RGX-121 in Jan 2026; CRL for RGX-121 BLA in Feb 2026.
• ·Company plans FDA engagement on RGX-121 path forward; pre-BLA meeting mid-2026.

05-03-2026

Compass Therapeutics, Inc. (CMPX) filed its 10-K annual report on March 05, 2026, highlighting significant commercialization risks, including dependence on third-party payors for coverage and reimbursement, compliance with extensive U.S. federal, state, and foreign laws (e.g., anti-kickback, false claims, GDPR effective May 2018), and the need to establish marketing, sales, and distribution infrastructure. The company has never generated revenue from product sales and may never be profitable, while facing manufacturing risks such as delays, shortages, and potential recalls. Under equity compensation plans, 1.0 million shares of common stock are issuable upon vesting of restricted stock units.

• ·Equity compensation values exclude weighted average exercise price calculation per disclosure.
• ·Risks include post-approval requirements like REMS that could limit promotion, advertising, distribution, or sales.

05-03-2026

Lakeland Financial Corp (LKFN) filed its DEF 14A proxy statement on March 5, 2026, for the annual shareholder meeting on April 14, 2026, at 3:30 p.m. ET, held virtually. Proposals include the election of 13 director nominees, non-binding approval of executive officer compensation, and ratification of Crowe LLP as independent auditors for the year ending December 31, 2026, with the board recommending a FOR vote on all items.

• ·Shareholders can request proxy materials by March 31, 2026, via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com.
• ·Virtual meeting access: www.virtualshareholdermeeting.com/LKFN2026.

05-03-2026

For the year ended December 31, 2025, Distribution Solutions Group reported consolidated revenue of $1.98B, up 9.8% YoY from $1.80B, with strong growth in Gexpro Services (+12.7% to $497M) and Canada Branch Division (+77.1% to $221M), while Lawson (+2.6% to $481M) and TestEquity (+1.6% to $783M) showed modest increases. Operating income improved to $78.3M (4.0% margin) from $56.0M (3.1%), and net income swung to a profit of $8.3M from a $7.3M loss; however, adjusted EBITDA was essentially flat at $175.2M (vs. $175.3M) and gross margin declined slightly to 33.4% from 34.0%.

• ·Lawson end markets: Automotive 31%, Manufacturing 14%; Product categories: Aftermarket automotive supplies 21%, Fastening systems 16%.
• ·TestEquity end markets: Electronics manufacturing 31%, Aerospace and defense 20%.
• ·Interest expense stable at ~$55M YoY.
• ·Depreciation and amortization increased to $80.9M from $74.4M.

05-03-2026

CorMedix Inc. reported Q4 2025 net revenue of $128.6 million, up 312% YoY from $31.2 million, driven by $91.2 million from DefenCath and $37.4 million from the Melinta portfolio, with net income of $14.0 million and adjusted EBITDA of $77.2 million. Full-year 2025 revenue reached $311.7 million (616% YoY growth from $43.5 million), achieving net income of $163.0 million versus a $17.9 million loss in 2024. However, Q4 operating expenses surged 182% YoY to $48.2 million due to Melinta integration, and full-year operating expenses doubled to $125.6 million.

• ·2026 guidance: net revenue $300-320M, adjusted EBITDA $100-125M
• ·Melinta acquisition closed August 2025
• ·Phase 3 ReSPECT topline data expected Q2 2026
• ·TPN Phase 3 study targeted completion H1 2027
• ·Q4 diluted EPS $0.16 vs $0.20 YoY (slight decline due to share count)
• ·Tax expense Q4 2025: $42.4M from utilization of deferred tax assets
• ·Cash, cash equivalents and restricted cash: $145.8M at Dec 31, 2025 vs $40.8M at Dec 31, 2024

05-03-2026

Arvana Inc. (AVNI) filed an S-1 registration statement on March 5, 2026, for its IPO, reporting FY2024 revenue of $67,964, nearly flat but down 0.5% YoY from $68,276 due to hurricanes and vessel repairs that curtailed charter fishing services. Net loss improved significantly by 66% to $447,495 from $1,316,573, driven by a 23.1% reduction in operating expenses to $406,236 and 91% lower other expenses; however, gross profit declined 19.1% to $33,644 amid higher costs of service, total assets fell to $202,176 from $216,549, and working capital deficit stood at $969,980 with expected continued losses.

• ·Acquired Down2Fish Charters LLC on February 3, 2023, contributing to 2023 other expenses.
• ·Charter services curtailed in Q3 2023 and halted in Q4 2023 due to vessel repairs under warranty.
• ·Capital expenditures in 2023 included property and equipment from Down2Fish acquisition.
• ·Expects revenue increase next 12 months as vessels return to service, but higher operating expenses and continued net losses.

05-03-2026

FTC Solar reported Q4 2025 revenue of $32.9M, up 26% QoQ and 149% YoY, with non-GAAP gross margin improving to 23.4% from -25.6% YoY, marking one of the highest in company history, alongside full-year 2025 revenue growth of 110% to $99.7M. The company secured a 1GW U.S. supply agreement and an 840MW deal with Lubanzi in South Africa, boosting its contracted backlog to $491M. However, it posted a GAAP net loss of $33.7M due to a $26.4M warrant liability change, with Q1 2026 revenue guidance of $20-25M indicating a seasonal QoQ decline and ongoing Adjusted EBITDA losses.

• ·Cash increased to $21.1M from $11.2M YoY; accounts receivable rose to $55.7M.
• ·Product revenue Q4 2025: $26.2M (up from $10.4M YoY); Service: $6.7M (up from $2.8M YoY).
• ·Non-GAAP Adjusted EBITDA loss improved to $0.3M from $9.8M YoY.
• ·Q1 2026 non-GAAP gross margin guidance: -2.5% to 9.2%; Adjusted EBITDA loss $(9.6M) to $(5.9M).

05-03-2026

Ciena reported fiscal Q1 2026 revenue of $1.43B, up 33% YoY from $1.07B, with adjusted EPS rising 111% to $1.35; Optical Networking drove growth to $1.02B (up from $728M). However, GAAP gross margin dipped 0.2 points to 43.8%, operating expenses increased 11.5% to $436.1M, and Blue Planet Automation revenue declined to $20.4M from $26M YoY. The company raised FY2026 revenue guidance to $5.9B-$6.3B (28% YoY growth at midpoint) and repurchased $80.5M in shares.

• ·Three customers each >10% of revenue totaled 47.4% in Q1 FY2026.
• ·Q2 FY2026 revenue guidance: $1.5B +/- $50M.
• ·Cash increased to $1.12B from $1.09B QoQ as of Jan 31, 2026.

05-03-2026

Intensity Therapeutics, Inc. filed an 8-K on March 05, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), indicating release of financial results or non-GAAP measures. The filing size is 289 KB with Acc-no: 0001567264-26-000011, but no specific revenue, earnings, or period-over-period metrics are detailed in the provided EDGAR index. Recent filings include multiple prior 8-Ks, 10-Qs, and 10-Ks, suggesting ongoing reporting cadence.

• ·CIK: 0001567264
• ·SIC: 2836 - BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
• ·State of Inc.: DE
• ·Fiscal Year End: 12/31
• ·Mailing/Business Address: 1 Enterprise Drive, Suite 430, Shelton, CT 06484
• ·Phone: 203-221-7381

05-03-2026

Aligos Therapeutics reported a sharply reduced net loss of $24.2M for the year ended December 31, 2025, compared to $131.2M in 2024 (-82% YoY), primarily due to a $60.2M gain from the change in fair value of 2023 Common Warrants and slight declines in operating expenses (total OpEx -3% to $90.2M). However, total revenue fell 45% YoY to $2.2M amid a complete drop in collaboration revenue (-100%) and customer revenue decline (-39% to $2.2M), while cash and equivalents decreased to $18.3M from $37.0M with operating cash burn of $82.5M. The company raised $101.6M net via PIPE financing, boosting total assets to $88.5M (+26%) and flipping stockholders' equity to a positive $53.5M from a $29.0M deficit.

• ·Net cash used in investing activities increased to $37.8M in 2025 from $18.3M in 2024, driven by short-term investment purchases.
• ·Stock-based compensation expense declined to $5.0M in 2025 from $8.5M in 2024.
• ·Net loss per share improved to ($2.45) in 2025 from ($20.94) in 2024.
• ·Restricted cash remained flat at $110K.

05-03-2026

Delta Air Lines announces key leadership changes, including Peter Carter's promotion to President, Dan Janki's appointment as Chief Operating Officer (previously CFO), Erik Snell's move to Chief Financial Officer, Ranjan Goswami's naming as Chief Marketing and Product Officer, and Alain Bellemare adding Chairman of Delta TechOps to his role as EVP and President – International. These changes follow the retirement of John Laughter, longtime EVP Chief of Operations and President of Delta TechOps, effective April 30, 2026, after over 30 years, and Alicia Tillman's departure as Chief Marketing Officer for external opportunities. CEO Ed Bastian emphasized the moves strengthen the executive team and reflect Delta's deep talent bench to drive long-term growth.

• ·All new appointees (Carter, Janki, Snell, Goswami) report directly to CEO Ed Bastian.
• ·John Laughter's career started as an aircraft liaison engineer in TechOps.

05-03-2026

First Business Financial Services, Inc. highlighted strong 2025 performance in its proxy statement for the April 24, 2026 Annual Meeting, with core deposit and loan balances growing 11% and 8% YoY over 2024, respectively, total revenue up 10%, and efficiency ratio improving to 58.78%. The company reported over 14% growth in pre-tax pre-provision earnings, EPS, and tangible book value per share, alongside a robust ROATCE of 15.3%, all exceeding strategic targets. Five-year TSR through December 31, 2025 reached 235%, outperforming peers (66% median), Russell 2000 (73%), and S&P 500 Banks (125%).

• ·2026 Annual Meeting virtually on April 24, 2026 at 10:00 a.m. CDT via www.meetnow.global/M6YH2SP
• ·Proposals: Elect three Class I directors to serve until 2029 Annual Meeting; approve 2026 Equity Incentive Plan; non-binding advisory vote on compensation
• ·Leadership transition: Dave Seiler to assume CEO role in May 2026 following Corey Chambas retirement (announced May 2025)
• ·Peer group: publicly traded banks with assets between $1.75B and $7.0B

05-03-2026

Rand Capital reported full year 2025 total investment income of $6.5 million, down from $8.6 million in 2024 primarily due to portfolio repayments and slower deal originations, while Q4 2025 income decreased 40% YoY to $1.3 million amid a 46% drop in interest income. Portfolio fair value fell 32% to $48.5 million across 20 companies, with debt investments rising to 79% but yield declining to 11.3% from 13.8%; however, net investment income per share increased 35% YoY to $1.80, the company ended with over $23 million liquidity, no debt, net assets of $52.2 million, and paid $1.72 per share in dividends.

• ·On February 25, 2026, declared quarterly dividend of $0.29 per share, payable March 25, 2026 to shareholders of record March 11, 2026.
• ·Senior secured revolving credit facility matures 2027 with up to $25M capacity and no borrowings outstanding as of Dec 31, 2025.
• ·New Q4 investment in Bauer: 13% term loan and warrants for 12% ownership interest.

05-03-2026

Sysco Corporation announced that Executive VP and CFO Kenny Cheung will step down effective March 6, 2026, to join a Fortune 10 company, with Brandon Sewell appointed as Interim CFO; Cheung will remain until April 17, 2026, to ensure a smooth transition. The company highlighted Cheung's contributions to finance organization improvements and ROIC discipline, while praising Sewell's deep experience leading U.S. finance, supply chain, and merchandising. Sysco reaffirmed FY2026 adjusted EPS guidance at the high end of $4.50-$4.60, sales growth of 3%-5%, Q3 2026 consensus adjusted EPS of $0.94, and USFS local case growth of at least 2.5% YoY.

• ·Sysco generated sales of more than $81B in FY2025 ended June 28, 2025.
• ·Sewell joined Sysco in 2014 with 12 years tenure, holds degrees from Brigham Young University and Duke Fuqua.

05-03-2026

Acorn Energy reported full-year 2025 total revenue of $11.5M, up 4.5% YoY from $11.0M, driven by a 22.1% increase in monitoring revenue to $5.6M, though hardware revenue declined 8.0% YoY to $5.9M; Q4 revenue fell 32.6% YoY to $2.4M due to a 58.5% drop in hardware sales. Gross margin improved 400bps to 76.8% with operating income slightly up to $2.0M, but net income attributable to stockholders decreased 60.1% to $2.5M from $6.3M, primarily due to a smaller $0.5M deferred tax benefit versus $4.4M in 2024.

• ·Cash position increased to $4.5M at Dec 31, 2025 from $2.3M at year-end 2024.
• ·Generated $2.1M net cash from operating activities in 2025, more than double 2024.
• ·Operating expenses rose 13% YoY to $6.8M in 2025 due to higher SG&A and R&D.
• ·Strategic partnership with AIO-systems grants exclusive North American rights; first demo unit expected by end of March 2026, meaningful revenue H2 2026.
• ·Targets 20% average annual revenue growth over next 3-5 years.

05-03-2026

Reviva Pharmaceuticals Holdings, Inc. amended its Amended and Restated Certificate of Incorporation to implement a one-for-20 reverse stock split of its Common Stock, effective 12:01 a.m. Eastern Time on March 9, 2026. The Reverse Split reclassifies every 20 shares of Old Common Stock into 1 share of New Common Stock, with no reduction in authorized shares, and applies to convertible securities or rights. The amendment was duly adopted by the Board of Directors and stockholders per Delaware General Corporation Law, with fractional shares rounded up to the nearest whole share.

• ·Reverse Split executed on March 4, 2026, and filed on March 5, 2026.
• ·Old Common Stock certificates automatically represent New Common Stock post-Effective Time, subject to fractional adjustment.
• ·Reverse Split applies to securities or rights convertible into, exchangeable for, or exercisable for Old Common Stock.

05-03-2026

Okta, Inc. reported total revenue of $2.9B for the year ended January 31, 2026, up 12% YoY from $2.6B in 2025, primarily driven by 12% subscription revenue growth to $2.9B, while professional services revenue grew 18% to $64M. Gross profit increased 13% to $2.3B with gross margin expanding to 77%, leading to operating income of $149M and net income of $235M, a sharp turnaround from a $74M operating loss and $28M net income in 2025. However, R&D expenses declined slightly by 1% to $639M, sales and marketing rose 5% to $1.0B, and G&A remained flat at $448M.

• ·Subscription revenue represented 98% of total revenue in FY2026, unchanged from FY2025.
• ·Total cost of revenue increased 7% YoY to $661M in FY2026.
• ·Stock-based compensation expense decreased to $544M in FY2026 from $565M in FY2025.
• ·Restructuring and other charges fell to $4M in FY2026 from $11M in FY2025.

05-03-2026

McKesson Corporation announced that Executive Vice President and CFO Britt Vitalone will retire after a 20-year career, including over eight years as CFO, with Kenny Cheung succeeding him effective May 29, 2026. Vitalone will remain as a strategic advisor to support the transition and the planned separation of McKesson’s Medical Surgical Solutions into an independent company. The announcement highlights Vitalone's contributions to financial performance and capital allocation amid the company's strong third quarter results with record revenue and adjusted operating profit.

• ·Filing date: March 5, 2026
• ·Vitalone's tenure: 20 years at McKesson, more than 8 years as CFO
• ·Cheung previously served as EVP and CFO at Sysco

05-03-2026

Splash Beverage Group, Inc. announced the execution of a non-binding letter of intent for a business combination with Medterra CBD, LLC, a leading manufacturer and multi-brand operator of federally compliant cannabinoid wellness products. Medterra serves over 2 million customers across the United States and internationally. The press release detailing the LOI is furnished as Exhibit 99.1.

• ·The letter of intent is non-binding.
• ·Announcement date: March 5, 2026.

05-03-2026

Ambiq Micro reported FY 2025 net sales of $72.5M, down 4.7% YoY despite sequential growth in every quarter, with Q4 net sales reaching a record $20.7M, up 14.2% QoQ and 2.0% YoY. Gross margins expanded significantly to 44.3% GAAP (up 12.4 pts YoY) and 45.0% non-GAAP, driving the highest-ever FY gross profit of $32.1M (up 32.1% YoY), though operating expenses rose 10.4% YoY to $71.6M and net loss narrowed to $36.5M (14.0% improvement). Q1 2026 guidance projects net sales of $21.0-22.0M with non-GAAP gross margin of 44-45%.

• ·Cash and equivalents increased to $140.3M at Dec 31, 2025 from $61.0M at Dec 31, 2024.
• ·Q1 2026 non-GAAP operating expense guidance: $18.0M to $18.5M.
• ·Q1 2026 non-GAAP net loss per share guidance: ($0.39) to ($0.33).
• ·Conference call replay available through March 12, 2026.

05-03-2026

The Toro Company reported fiscal 2026 Q1 net sales of $1.036 billion, up 4% YoY from $995 million, driven by 7.2% growth in the Professional segment to $824 million, though the Residential segment declined 6.8% to $206 million. Adjusted EPS increased 14% YoY to $0.74, beating expectations, with $133 million returned to shareholders and full-year guidance raised to 3-6.5% sales growth and $4.40-$4.60 adjusted EPS; however, adjusted gross margin fell to 33.4% from 34.1% due to higher costs.

• ·Tornado acquisition expected to add ~2% to FY26 net sales and be modestly accretive to adjusted EPS
• ·Professional segment margin improved to 16.7% from 16.5%; Residential margin declined to 6.4% from 7.8%
• ·SG&A expense as % of sales improved to 24.1% from 25.9%
• ·Interest expense $14.2M, down $0.8M YoY
• ·Fiscal 2026 earnings conference call on March 5, 2026 at 10:00 a.m. CT

05-03-2026

CytoDyn Inc. disclosed unregistered sales of equity securities exceeding 5% of shares outstanding as of January 9, 2026, primarily through a private placement concluding on February 27, 2026, raising approximately $17.5M from 81.4M units at $0.2153 each. Additional cash inflows included $1.0M from a direct sale of 3.95M shares, $0.1M from 0.46M units, and $0.2M from 0.8M shares under a SEPA, while 5.9M shares were issued in exchange for $1.5M in convertible notes without new cash. The transactions provide significant capital but involve substantial dilution from over 92M new shares issued.

• ·Warrants to investors: 5-year term, $0.26 exercise price.
• ·Placement agent warrants: 10-year term, $0.2153 exercise price, cashless exercise provision.
• ·Deal price of $0.2153 equals 90% of lower VWAP from Jan 30 and Feb 27, 2026 closings.
• ·Reliance on Reg D Rule 506, Section 4(a)(2), and Section 3(a)(9) exemptions.
• ·Company to file resale registration for placement shares and warrants.

05-03-2026

Sirius XM Radio LLC completed a cash tender offer for any and all of its outstanding $1B 3.125% Senior Notes due 2026, with $498.9M (49.89%) validly tendered at $994.64 per $1,000 principal, excluding $70.6M subject to guaranteed delivery procedures. The repurchase is funded partly by $1.25B of newly issued 5.875% senior notes due 2032, which closed on March 4, 2026. Remaining untendered notes will be redeemed or defeased using proceeds and cash on hand.

• ·Notes commenced tender offer on February 26, 2026; expired March 4, 2026 at 5:00 p.m. NYC time
• ·Settlement payment for valid tenders expected March 5, 2026; guaranteed delivery payment expected March 9, 2026
• ·Notes callable at 100.000% of principal plus accrued interest; mature September 1, 2026
• ·CUSIP Numbers: 82967NBL1, U82764AU2, 82967NBN7

05-03-2026

Global Payments Inc. filed this 8-K on March 5, 2026, to provide audited combined and consolidated financial statements of Worldpay Holdco, LLC (acquired 100% in January 2026 from Fidelity National Information Services, Inc. and GTCR LLC affiliates) as of December 31, 2025 and 2024, for the year ended December 31, 2025, the eleven-month period ended December 31, 2024 (Successor), and the one-month period ended January 31, 2024 (Predecessor). The filing also includes unaudited pro forma condensed combined financial information for Global Payments as of and for the year ended December 31, 2025, following the simultaneous divestiture of its Issuer Solutions business to FIS. This updates investors on the financial data related to these transactions for incorporation into registration statements.

• ·Securities registered: Common stock (GPN) and 4.875% Senior Notes due 2031 (GPN31A) on New York Stock Exchange.
• ·Consent of KPMG LLP provided for Worldpay financial statements.

05-03-2026

PacBio (NASDAQ: PACB) announced on March 5, 2026, the appointment of Christopher Gibson, Ph.D., co-founder and Chairman of Recursion (NASDAQ: RXRX), to its Board of Directors to strengthen expertise in AI-driven biology and data tools for HiFi sequencing. CEO Christian Henry stated that Gibson's experience scaling AI-native life sciences will support PacBio's vision of integrating sequencing, computation, and data-driven discovery. Gibson expressed enthusiasm for leveraging PacBio's high-quality long-read sequencing datasets with AI analytics to accelerate healthcare advancements.

• ·Filing date: March 05, 2026
• ·PacBio products are for Research Use Only, not for diagnostic procedures

05-03-2026

On February 27, 2026, Valerie O. Murray, President of Beacon Trust Company and Executive Vice President and Chief Wealth Management Officer of Provident Bank (subsidiaries of Provident Financial Services, Inc.), announced her resignation effective May 22, 2026, to pursue other opportunities, with no disagreement on company matters. Under the Separation Agreement, she will be on garden leave from March 27 to May 22, 2026, continuing to receive base salary and benefits, and is entitled to a $1.2M lump sum payment subject to conditions including a release of claims. The company expressed appreciation for her leadership and contributions.

• ·Filing date: March 5, 2026
• ·Garden leave period: March 27, 2026 to May 22, 2026
• ·Resignation announcement date: February 27, 2026

05-03-2026

Classover Holdings, Inc. (KIDZW) filed an 8-K on March 05, 2026, covering Items 3.03 (material events, potentially impairments), 5.03 (charter or bylaws amendments), and 9.01 (financial statements and exhibits), categorized under Charter/Bylaws Amendments as a Material Event. No specific financial metrics, period-over-period comparisons, improvements, declines, or flat performance were disclosed in the provided filing index. The filing size is 562 KB with no quantitative impacts detailed.

• ·CIK: 0002022308
• ·SIC: 8200 - SERVICES-EDUCATIONAL SERVICES
• ·Mailing/Business Address: 8 THE GREEN STE B, DOVER DE 19901
• ·Phone: 530-574-6789
• ·Fiscal Year End: December 31
• ·File/Film Number: 001-42588 / 26724283

05-03-2026

Aditxt, Inc. amended its Certificate of Incorporation to implement a 1-for-8 reverse stock split, effective March 6, 2026, at 4:01 p.m. Eastern Time, whereby every eight shares of old common stock will automatically convert into one share of new common stock. Fractional shares will be rounded up to a whole share, with the amendment duly approved by stockholders pursuant to Delaware General Corporation Law Section 242.

• ·Original Certificate of Incorporation filed with Delaware Secretary of State on September 28, 2017.
• ·Amendment inserts new Subsection (e) into ARTICLE IV, SECTION I.

05-03-2026

Six Flags Entertainment Corporation announced definitive agreements to divest seven parks to EPR Properties for $331M in cash consideration, with the divested parks generating $260M in net revenue and $45M in Adjusted EBITDA from 4.5M guests in FY2025. Proceeds, after taxes and expenses, will pay down debt and slightly improve the leverage ratio while sharpening focus on higher-return remaining parks. No significant guest impact expected during transition, with operations continuing normally through 2026.

• ·Transaction expected to close by end of Q1 or beginning of Q2 2026, subject to closing conditions and third-party approvals.
• ·EPR retains Six Flags brand usage through end of 2026.
• ·Perella Weinberg Partners acted as financial advisor; Weil, Gotshal & Manges LLP as legal counsel to Six Flags.
• ·Parks currently total 26 amusement parks, 15 water parks, and 9 resort properties across 16 states in U.S., Canada, and Mexico, plus one managed in Saudi Arabia.

05-03-2026

Ondas Inc. (Nasdaq: ONDS) announced on March 5, 2026, the appointment of David Chinn, a Senior Partner at McKinsey & Company with over two decades of experience in defense, government, and advanced technology strategy, to the Board of Directors of its Ondas Autonomous Systems (OAS) business unit. The appointment is intended to support OAS's global expansion in defense and national security platforms, including autonomous aerial, ground, and counter-UAS solutions. No financial impacts or performance metrics were disclosed.

• ·David Chinn will retire from McKinsey later in 2026.
• ·OAS portfolio includes operating companies: American Robotics, Airobotics, Apeiro Motion, Roboteam Ltd., and Sentrycs.

05-03-2026

AGCO CORP filed an 8-K on March 05, 2026, under Items 5.02 (Director/Officer Departure/Election) and 9.01 (Financial Statements and Exhibits), announcing an officer or director change with an attached press release (EX-99.1). The content details are largely unreadable due to formatting issues, providing no specific names, roles, or financial impacts. No quantitative metrics or period-over-period comparisons are discernible.

• ·Filing Type: 8-K
• ·Subcategory: Director/Officer Departure/Election

05-03-2026

Kulicke and Soffa Industries, Inc. held its 2026 Annual Meeting on March 4, 2026, where shareholders elected Peter T. Kong and Jon A. Olson as directors until the 2027 Annual Meeting, ratified PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending October 3, 2026, and approved executive compensation on a non-binding advisory basis. All proposals passed with strong majorities: directors received 91% and 98% 'For' votes (excluding broker non-votes), auditors 99% 'For', and compensation 94% 'For'. Broker non-votes totaled 2,845,447 for director elections and compensation vote.

05-03-2026

NCR Atleos Corporation commenced a Consent Solicitation on March 5, 2026, from holders of its 9.500% Senior Secured Notes due 2029 to amend the indenture, specifically to ensure the pending merger with The Brink’s Company does not trigger a 'Change of Control' provision. The Merger Agreement was executed on February 26, 2026, and completion of the merger is not conditioned on the success of the Consent Solicitation. The announcement includes extensive forward-looking statement cautions highlighting risks such as regulatory approvals, integration challenges, financing, and potential business disruptions.

• ·Merger Agreement dated February 26, 2026
• ·Company's Annual Report on Form 10-K for year ended December 31, 2025, filed February 27, 2026
• ·Brink’s Annual Report on Form 10-K for year ended December 31, 2025, filed February 26, 2026

05-03-2026

Zillow Group's Board of Directors authorized an additional $1.25B share repurchase program on March 4, 2026, bringing remaining capacity to $1.3B after recent activity. From January 1 to March 4, 2026, the company repurchased 3.8M Class A shares at a weighted average price of $47.84 and 9.7M Class C shares at $45.92, totaling $626M. This move signals long-term confidence in the business, with no declines or flat metrics reported in repurchase activity.

• ·Class A shares repurchased at weighted average price of $47.84 per share
• ·Class C shares repurchased at weighted average price of $45.92 per share

05-03-2026

Merlin Labs, the target of Inflection Point Acquisition Corp. IV's proposed business combination, announced the successful completion of its Preliminary Design Review (PDR) for the C-130J autonomy program under a $105M IDIQ contract with U.S. Special Operations Command (USSOCOM), marking a key technical milestone toward production-ready reduced aircrew capability. This approval validates Merlin's integration design and airworthiness approach, enabling transition to the Critical Design stage. Merlin reports over $100M in total awarded contracts from military customers.

• ·Next contract stages include Critical Design Review, system integration, ground testing, and takeoff-to-touchdown flight demonstrations.
• ·Filing references proposed business combination; definitive proxy statement/prospectus filed February 12, 2026.

05-03-2026

Quantum Computing Inc. (QUBT) completed its acquisition of NuCrypt, LLC on March 5, 2026, for $5M in cash and shares, establishing NuCrypt as a wholly-owned subsidiary to advance quantum communications commercialization. The deal integrates NuCrypt's quantum optics patents and products, enhancing QCi's photonics portfolio and roadmap, with no immediate financial metrics or performance comparisons disclosed. The combined entity plans to showcase technologies at the OFC Conference March 17-19, 2026.

• ·NuCrypt founded in 2003.
• ·Prior acquisition of Luminar Semiconductor, Inc. in February 2026.
• ·NuCrypt's technologies used by customers across Australia, Canada, and Europe.

05-03-2026

QuantumScape Corporation appointed Ross Niebergall to its Board of Directors on March 4, 2026, with his term expiring at the next annual stockholder meeting. Dr. Niebergall, an experienced executive in defense sector R&D and technology commercialization, has held senior roles at L3Harris Technologies, RTX Corporation, and others, and currently serves on the board of V2X, Inc. He is eligible for standard non-employee director compensation, including $80,000 annual cash and initial equity awards of 40,973 RSUs vesting over three years and 6,402 pro-rated RSUs.

• ·No committee appointments for Dr. Niebergall at this time.
• ·Initial RSUs vest one-twelfth quarterly over three years starting May 15, 2026; pro-rated RSUs vest on the earlier of one-year anniversary or day before next annual meeting.
• ·No family relationships or material interests under Item 404(a) of Regulation S-K.

05-03-2026

World Mobile Group Ltd converted payable notes into 1,277,018 shares of Cuentas Inc. common stock, acquiring approximately 18.5% ownership and becoming the company's largest shareholder, signaling strong confidence in Cuentas' platform. This deepens their strategic alliance, with Cuentas holding 51% ownership in both World Mobile LLC and World Mobile Media Group LLC. The WMTx crypto token ecosystem demonstrates robust momentum, generating over 1.5 billion tokens in average daily trading volume over the last 30 days.

05-03-2026

Invech Holdings, Inc. entered into an Equity Financing Agreement and Registration Rights Agreement with GHS Investments, LLC on March 3, 2026, providing access to up to $10M in equity financing upon S-1 effectiveness, through put notices for common stock priced at 80% of the lowest traded price over the prior 10 trading days. Each put ranges from $10,000 to $500,000, limited to 200% of average daily trading volume and a 4.99% beneficial ownership cap, over 24 months or until the full commitment is reached. No historical financial performance data or period-over-period comparisons are provided in the filing.

• ·Puts restricted to at least 10 trading days following a prior closing.
• ·Post-NASDAQ uplisting, purchase price adjusts to 90% of VWAP with $1.00 floor.
• ·Company to file S-1 registration statement for resale of shares.

05-03-2026

WEBTOON Entertainment Inc. (Nasdaq: WBTN) elevated Yongsoo Kim from Chief Strategy Officer and Head of Global WEBTOON to President, effective March 5, 2026, to lead global operations, accelerate innovation, growth, and execution; Kim also joins the Board of Directors and will report to Founder & CEO Junkoo Kim. Under Kim's prior leadership since late 2022, the company achieved its successful 2024 IPO, a 2025 collaboration with The Walt Disney Company, and launched initiatives like Video Episodes and expanded Creator programs. The company reports approximately 160 million monthly active users across its global platforms.

• ·Yongsoo Kim joined WEBTOON Entertainment in late 2022 and led the 2024 IPO.
• ·Prior roles for Yongsoo Kim: Principal at KKR, founding team of Tesla’s Korea operations, Engagement Manager at McKinsey & Company.
• ·Yongsoo Kim holds a Bachelor of Business Administration from Yonsei University and serves as director at LD Carbon.

05-03-2026

Linear Minerals Corp, a metal mining company based in Vancouver, Canada, filed an amended Form 20-F annual report for the fiscal year ended March 31, 2025, on March 5, 2026. The filing primarily contains entity metadata, including address, CIK 0001066130, SIC 1000, and historical name changes, with no financial statements or performance metrics provided in the content. No period-over-period comparisons or quantitative financial data are available.

• ·Business address: 700 West Georgia St., 25th Floor, Vancouver, A1 V7Y 1B3, phone 604-375-6005
• ·Fiscal year end: March 31
• ·SEC file number: 000-29870
• ·Name change dates: FE Battery Metals Corp. on 2023-08-01; First Energy Metals Ltd on 2018-01-05; Agave Silver Corp. on 2013-10-15

05-03-2026

AAON, Inc. announced that its Board of Directors declared a regular quarterly cash dividend of $0.10 per share, equivalent to $0.40 annually. The dividend is payable on March 30, 2026, to stockholders of record as of the close of business on March 18, 2026. No changes or declines in dividend policy were mentioned.

• ·Press release announcing the dividend furnished as Exhibit 99.1
• ·Filing signed on March 5, 2026

05-03-2026

On March 4, 2026, Fastly, Inc.'s Audit Committee dismissed Deloitte & Touche LLP as its independent auditor and approved the appointment of KPMG LLP for the fiscal year ending December 31, 2026, though KPMG has not yet accepted. Deloitte's audits for fiscal years 2024 and 2025 contained no adverse opinions or disagreements, but a material weakness in internal controls disclosed in the 2024 10-K was noted (now remediated as of December 31, 2025). Deloitte provided a letter on March 5, 2026, confirming agreement with these disclosures.

• ·KPMG is in the process of standard client evaluation procedures and has not accepted the engagement as of the filing date.
• ·The material weakness in internal controls over financial reporting was discussed with Deloitte and the Audit Committee.

05-03-2026

Pinterest, Inc. filed an 8-K on March 5, 2026, disclosing under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 3.02 unregistered sales of equity securities, and Item 9.01 financial statements and exhibits. No specific transaction details, dollar values, strategic context, or financial impacts are provided in the filing summary. This is a multi-item filing with no disclosed positive or negative metrics.

05-03-2026

05-03-2026

Decoy Therapeutics Inc., originally incorporated as Flex Pharma, Inc. on February 26, 2014, amended its Certificate of Incorporation to authorize 110M total shares (100M Common Stock and 10M Preferred Stock, each with $0.0001 par value) and effected a 1-for-12 reverse stock split without changing authorized share totals. The reverse split consolidates every 12 old shares into 1 new share effective 5:00 p.m. ET on March 6, 2026, with cash payments in lieu of fractional shares based on the Nasdaq closing price. No performance metrics or financial changes are reported.

05-03-2026

On March 4, 2026, Match Group, Inc. informed Hesam Hosseini, its Chief Operating Officer and Chief Executive Officer of Evergreen & Emerging Brands, that the COO role is being eliminated effective June 2, 2026, leading to his departure from the company after over 15 years of service. The announcement follows discussions between Mr. Hosseini and the company. It was signed by Sean Edgett, Chief Legal Officer and Secretary, on March 5, 2026.

• ·Event reported date: March 4, 2026
• ·Filing date: March 5, 2026
• ·Company address: 8750 North Central Expressway, Suite 1400, Dallas, TX 75231
• ·Telephone: (214) 576-9352

05-03-2026

Textron Inc. filed a DEFA14A additional proxy statement on March 5, 2026, for its upcoming shareholder meeting related to the fiscal year ended January 3, 2026. Shareholders are asked to vote on the election of 12 director nominees, ratification of the independent registered public accounting firm, and an advisory resolution approving executive compensation. Proxy materials can be accessed online or requested in paper/email form prior to April 15, 2026.

• ·Fiscal year end: January 3, 2026
• ·Proxy material request deadline: April 15, 2026
• ·Proxy voting methods: www.ProxyVote.com, 1-800-579-1639, sendmaterial@proxyvote.com

05-03-2026

Nokia reported solid 2025 performance with net sales growing 3.5% YoY to EUR 19,889M from EUR 19,220M in 2024, alongside comparable operating profit and strong free cash flow in line with expectations, and total shareholder return reaching 197.49% (rebased to 100 at Dec 2020). However, net sales remained below the 2022 peak of EUR 23,761M after declines in 2023 and 2024, reflecting ongoing challenges. Leadership transitioned with Justin Hotard joining as President and CEO on April 1, 2025, receiving EUR 7.3M in actual remuneration versus EUR 4.0M for Pekka Lundmark in 2024.

• ·2026 STI for CEO based on comparable operating profit in constant currency and free cash flow, with Board discretion on health & safety and workforce composition.
• ·2026 LTI metrics: relative TSR (50%), cumulative EPS (40%), GHG emission reduction (10%).
• ·Former CEO Pekka Lundmark continued as Advisor until December 31, 2025; notice period paid out until February 9, 2026.
• ·2022 LTI awards to Pekka Lundmark and GLT members fully lapsed.

05-03-2026

OFG Bancorp filed Amendment No. 1 to its 10-K for the fiscal year ended December 31, 2025, solely to correct the cover page checkbox for well-known seasoned issuer status (now marked No) and to add Sarbanes-Oxley certifications as exhibits. No changes were made to financial statements, disclosures, or other content from the original filing on February 25, 2026. The aggregate market value of common stock held by non-affiliates was $1.915B as of June 30, 2025, based on 44,741,933 shares at $42.80 per share.

• ·Registrant is a large accelerated filer but not a well-known seasoned issuer.
• ·Incorporated in Commonwealth of Puerto Rico (EIN: 66-0538893); principal offices at 254 Muñoz Rivera Avenue, San Juan, Puerto Rico 00918.
• ·Common shares ($1.00 par value) trade on NYSE under symbol OFG.
• ·Original 10-K filed February 25, 2026; amendment filed March 5, 2026.

05-03-2026

Wiley reported Q3 FY2026 revenue of $410M, up 1% YoY GAAP but flat adjusted at constant currency due to 3% growth in Research Publishing offset by 2% CC decline in Learning and 3% CC drop in Research Solutions. Adjusted EBITDA rose 12% to $105M with 250 bps margin expansion to 25.7%, Adjusted Operating Income up 22% to $70M, and YTD free cash flow improved sharply to $56M from a prior year use of $1M. The company guides to the high end of its Adjusted EBITDA margin (25.5-26.5%) and Adjusted EPS ($3.90-$4.35) outlook while reaffirming revenue growth and $200M FCF target.

• ·Net Debt-to-EBITDA ratio improved to 1.7 from 2.0 YoY.
• ·Article submissions up 26% and output up 11% YTD in Research.
• ·Lifetime AI revenue surpassed $100M.
• ·Q3 GAAP EPS $0.56 vs prior loss of ($0.43).
• ·FY2026 outlook reaffirms low-single digit Adjusted Revenue growth from FY2025 $1.66B base.

05-03-2026

Greif, Inc. and subsidiaries (Greif Packaging LLC, Greif International Holding B.V., Greif Beheer B.V.) entered into a Third Amended & Restated Credit Agreement on February 27, 2026, amending and restating the prior Second Amended & Restated Credit Agreement dated March 1, 2022, which provided an initial aggregate principal amount of $2.415B. The new agreement refinances existing loans under updated terms, with the Term A-2 Loans to be repaid in full concurrently with the closing of a CoBank Credit Agreement. No changes in facility sizes or negative impacts on liquidity were disclosed.

• ·SEC 8-K filing date: March 05, 2026
• ·CUSIP numbers: Deal 39762JAX2, Term A-1 Loan 39762JBA1, Global Revolving Credit Facility 39762JAY0, U.S. Revolving Credit Facility 39762JAZ7
• ·Prior agreement date: March 1, 2022
• ·Term A-2 Facility termination and full repayment on Restatement Effective Date concurrent with CoBank Credit Agreement closing

05-03-2026

Global Crossing Airlines Group Inc. reported total revenue growth of 10.1% YoY to $246.3M for the year ended December 31, 2025, driven by ACMI revenue surging 42.8% to $175.8M, while Charter revenue declined sharply 34.8% to $62.3M and total Charter block hours fell 39.6%. Operating income improved to a positive $8.9M from a $1.1M loss, with operating expenses up only 5.6% to $237.4M despite rises in salaries (18.8%) and maintenance (44.7%), but the company recorded a net loss of $2.6M (improved from $11.4M) amid higher interest expense (28.5%). Cash from operations rose significantly to $28.1M, supporting total assets of $203.1M up from $166.7M.

• ·Cash and cash equivalents increased to $16.7M from $12.3M as of Dec 31, 2025.
• ·Stockholders’ deficit remained relatively flat at approximately $29.5M.
• ·Total block hours grew 16.5% to 33,564.
• ·Aircraft rent expense nearly flat at $57.4M (-0.4%).
• ·Loss per share improved to $(0.05) from $(0.19).

05-03-2026

C2 Blockchain, Inc. filed an 8-K announcing the adoption of Amended and Restated Articles of Incorporation, approved by the Board of Directors and a majority of voting shareholders on March 4, 2026. The amendments authorize 1.52B total shares (1.5B Common Stock and 20M Preferred Stock, with 5M designated as Series A Preferred Stock offering 100 votes per share and convertible into 100 Common shares). No financial impacts or operational changes are disclosed; provisions include cumulative voting, indemnification, and transactions with interested directors.

• ·Series A Preferred Stock has liquidation preference equal to par value, then participates on as-converted basis.
• ·Cumulative voting enabled for director elections upon notice.
• ·Resident agent: Registered Agents Inc., 401 Ryland Street, Suite 200-A, Reno, NV 89502.

05-03-2026

OneIM Acquisition Corp., a blank check company, announced on March 5, 2026, that commencing March 6, 2026, holders of its units (OIMAU) may elect to separately trade Class A Ordinary Shares (OIM) and Warrants (OIMAW) on the Nasdaq Global Market. Each unit consists of one Class A ordinary share, par value $0.0001, and one-sixth of one redeemable warrant exercisable for one share at $11.50. Units not separated will continue trading under OIMAU, with no fractional warrants issued upon separation.

• ·Transfer agent: Continental Stock Transfer & Trust Company
• ·Company address: 11th Floor, 390 Park Avenue, New York, NY 10022
• ·Phone: (646) 222-9570
• ·EIN: 98-1883783
• ·Cayman Islands incorporation

05-03-2026

Valhi, Inc. (VHI) filed an 8-K on March 5, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, furnishing a press release entitled 'Valhi Declares Quarterly Dividend' issued the same day, attached as Exhibit 99.1. The filing incorporates the press release by reference but notes it is not 'filed' for liability purposes under Section 18 of the Exchange Act.

05-03-2026

Starlink AI Acquisition Corp (OTAI) filed an S-1/A registration statement on March 5, 2026, for an IPO of 10,000,000 units at $10 each, with net proceeds of $100M (or $115M if over-allotment exercised) to be held in a trust account for an initial business combination. The sponsor will purchase 171,600 private units for $1.716M, resulting in 12,821,600 ordinary shares outstanding post-offering, with initial shareholders owning 20%. No operational financials or period comparisons are provided, as this is a pre-business combination SPAC filing.

• ·Founder shares purchased for $0.0145 per share; up to 375,000 subject to forfeiture if over-allotment not exercised.
• ·Rights entitle holder to one-eighth ordinary share upon business combination; must hold multiples of eight.
• ·Transfer restrictions (lock-up) on founder shares and private units until 180 days post-initial business combination or earlier triggers.
• ·Initial shareholders waive redemption rights and will vote in favor of business combination.

05-03-2026

Capstone Companies, Inc. (CAPC) secured $250,000 in working capital funding on March 4, 2026, via an unsecured promissory note from eBliss Global, Inc., bearing 7% simple annual interest due in a lump sum on March 4, 2027. The note includes a 90-day 'no shop' provision granting eBliss exclusive rights to discuss potential mergers, acquisitions, or joint ventures for the first 60 days, with a special committee of independent directors formed to oversee talks. No agreements or commitments exist, and the company emphasizes the exploratory nature with no assurance of any transaction.

• ·Note dated March 3, 2026
• ·90-day 'no shop' period starting around March 4, 2026, with 60-day exclusivity for superior proposals thereafter
• ·eBliss anticipates e-bike production start at Utica, New York factory in 2026

05-03-2026

California Water Service Group disclosed that Greg A. Milleman, Vice President of Rates and Regulatory Affairs, notified the company of his intention to retire after 13 years of service, with the effective retirement date to be determined later. The company anticipates announcing a replacement prior to his retirement. No immediate operational or financial impacts were mentioned.

• ·Date of earliest event reported: March 2, 2026
• ·Filing date: March 5, 2026

05-03-2026

Carter Bankshares, Inc. reported net interest income growth of 14.3% YoY to $130.8M in 2025 from $114.5M in 2024, with net interest margin expanding to 2.82% from 2.57% and average earning assets rising to $4.64B. Loan portfolio averaged $3.76B, up from $3.56B, driven by commercial real estate and construction loans. However, noninterest expenses increased 6.4% to $117.1M, outpacing 4.8% growth in noninterest income to $22.4M, while insurance commissions declined 26.0% and total liquidity sources fell to $1.23B from $1.39B.

• ·Highly Liquid Assets to Uninsured Deposits declined to 59.8% in 2025 from 66.8% in 2024.
• ·Federal Home Loan Bank Borrowings decreased to $110.9M average in 2025 from $222.7M in 2024.
• ·Pretax Net Interest Income sensitivity: +200 bps change results in -1.0% impact in 2025.

05-03-2026

FatPipe, Inc. (FATN) filed an 8-K on March 5, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing a shareholder letter providing updates on the company's business strategy, operations, and outlook. The letter, dated March 5, 2026, is furnished as Exhibit 99.1. The filing was signed by CEO Ragula Bhaskar.

• ·Registrant is an emerging growth company.
• ·Common Stock trades under symbol FATN on Nasdaq Capital Market.
• ·Commission File Number: 001-42546; IRS Employer Identification No.: 27-1113325.

05-03-2026

Uwharrie Capital Corp reported net income attributable to common shareholders of $10.8M for 2025, up 15.5% YoY from $9.3M, driven by net interest income growth of 8.1% to $38.9M and noninterest income up 15.7% to $11.3M; total assets expanded 6.0% to $1.20B with loans held for investment up 3.5% to $690M. However, certain noninterest income streams declined, including interchange fees down 8.3% to $1.1M and other banking fees down 9.8% to $0.9M, while noninterest expenses rose 7.4% to $34.8M. EPS basic increased 18.3% YoY to $1.49.

• ·Provision for credit losses increased to $726K in 2025 from $528K in 2024.
• ·Allowance for credit losses on loans: $6.4M (2025) vs $5.8M (2024).
• ·Accumulated other comprehensive loss improved to $(16.6M) from $(24.7M) YoY.

05-03-2026

Home BancShares, Inc. (HOMB) reported record 2025 financial results, including total loans of $15.7B, stockholders' equity of $4.3B, net income of $475M (ROAA 2.10%), and diluted EPS of $2.41. The company announced the acquisition of Mountain Commerce Bancorp, Inc. (MCBI) on December 8, 2025, expected to close in Q2 2026, providing entry into Tennessee markets including Knoxville, Nashville, and Johnson City. West Texas operations have improved post-Happy State Bank acquisition, with no ongoing legal expenses, while total shareholder return since 2006 turned a $1,000 investment into $24,581.

• ·Net Interest Margin: 4.51%
• ·Efficiency Ratio: 40.88%
• ·Tangible Book Value per Share (non-GAAP): $14.60
• ·Dividends per Share: $0.805
• ·Shareholders’ Meeting: April 16, 2026
• ·MCBI acquisition expected to be immediately triple accretive

05-03-2026

LEE Enterprises, Incorporated (LEE) filed a DEFA14A Definitive Proxy Statement on March 05, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing is marked as definitive additional materials with no fee required. No specific proposals, financial data, or other substantive details are included in the provided filing header.

05-03-2026

BioLargo, Inc. (BLGO) filed an 8-K on March 5, 2026, disclosing a slide deck presentation (Exhibit 99.1) to be presented at a webcast investor conference on March 5, 2026, at 9:00 AM Pacific Time, and a press release (Exhibit 99.2) published on the same date. The information under Item 7.01 and the exhibits is not deemed 'filed' and will not be incorporated by reference into future SEC filings. No financial or operational metrics were detailed in the filing itself.

• ·Securities registered: Common Stock (BLGO) on OTCQX
• ·Address: 14921 Chestnut St., Westminster, California 92683
• ·Telephone: (888) 400-2863

05-03-2026

Twin Vee PowerCats Co. (VEEE) filed an S-3/A amendment to its shelf registration statement (No. 333-292661) on March 5, 2026, to register potential future issuances of common stock, preferred stock, debt securities, warrants, and related instruments. The filing lists various incorporated exhibits, including forms of warrants from prior 8-Ks, a specimen preferred stock certificate, indenture forms, legal opinions, and auditor consents. It was signed by CEO Joseph C. Visconti and directors in Ft. Pierce, Florida.

• ·File No. 001-40623
• ·Incorporated exhibits reference prior filings: March 31, 2022; September 30, 2022; August 16, 2022; June 14, 2023; May 12, 2025; February 23, 2026
• ·Legal counsel: Sichenzia Ross Ference Carmel LLP
• ·Auditor: Grassi & Co., CPAs, P.C.

05-03-2026

Grid Dynamics reported record Q4 2025 revenues of $106.2 million (+5.9% YoY, +1.9% QoQ) and full-year revenues of $411.8 million (+17.5% YoY from $350.6 million), driven by strong TMT (+27.5% YoY) and Finance verticals, with AI representing 25% of Q4 revenues and exceeding $90 million for the year (+30% YoY). However, GAAP gross margin declined to 34.0% from 36.9% YoY, Non-GAAP net income fell to $8.7 million from $10.3 million in Q4, and verticals like CPG/Manufacturing decreased 4.3% YoY while Healthcare/Pharma and Other remained flat. Guidance for Q1 2026 projects revenues of $103.0-104.0 million (slight QoQ decline) and FY 2026 revenues of $435.0-465.0 million (+9.3% YoY at midpoint).

• ·Share repurchase: 0.2 million shares for $2.0M in Q4 2025; $48.0M remaining authorization.
• ·Cash from operations: $40.6M in FY 2025 (+34.4% from $30.2M in FY 2024).
• ·Q1 2026 guidance: Non-GAAP EBITDA $12.0-13.0M; basic shares 85.0-86.0M, diluted 87.0-88.0M.
• ·TMT vertical: 28.3% of Q4 revenues; Retail: 28.7%; Finance: 22.9%; CPG/Manufacturing: 10.2%; Healthcare/Pharma: 2.6%; Other: 7.3%.

05-03-2026

Solitario Resources Corp. reported a narrowed net loss of $3.8M for 2025 compared to $5.4M in 2024, driven by lower exploration expenses (-31% YoY to $2.8M) and G&A (-17% YoY to $1.6M), while total operating expenses declined 27% YoY to $4.4M. Total assets grew 9% YoY to $25.0M, supported by short-term investments surging 68% to $7.6M, however marketable equity securities dropped 78% to $0.3M and cash remained flat at $0.08M. Shareholders' equity increased 10% YoY to $24.7M amid share issuances, though operating cash use improved modestly to $3.6M from $5.1M.

• ·Shares issued via ATM net: 1,007k shares for $0.73M in 2025 vs 1,802k for $1.22M in 2024.
• ·Private placement: 7.1M shares for $4.4M in 2025.
• ·Net cash provided by financing: $5.3M in 2025 vs $1.3M in 2024.
• ·Investing cash used $1.8M in 2025 (driven by $3.1M net purchase of short-term investments) vs provided $3.9M in 2024.

05-03-2026

ParkOhio Holdings Corp reported net sales of $1,599.1 million for 2025, down 3% YoY from $1,656.2 million, with declines across all segments: Supply Technologies -3%, Assembly Components -4.5%, and Engineered Products -2.2%. Operating income fell 23% to $66.3 million, driven by sharp drops in Engineered Products operating income to $6.6 million (1.4% margin from 3.7%) and asset impairment charges of $8.9 million; however, Supply Technologies held steady at 9.7% operating margin and gross margin remained flat at 17.0%. Income attributable to common shareholders declined 41% to $24.8 million ($1.77 diluted EPS), though operating cash flow improved to $42.3 million.

• ·Cash provided by operating activities increased to $42.3M in 2025 from $35.0M in 2024.
• ·Gross debt rose slightly to $635.7M in 2025 from $628.7M in 2024, but net debt as % of capitalization improved to 58% from 60%.
• ·Restructuring and other special charges increased 31% YoY to $6.4M in 2025.
• ·Decrease in cash and cash equivalents was $8.3M in 2025 vs $1.7M in 2024.

05-03-2026

Galaxy Enterprises Inc. (GLEI), a real estate agents and managers firm, filed an S-1/A on March 5, 2026, to register 3,920,000 shares of common stock for resale by 40 selling shareholders at prevailing or negotiated prices between $0.01 and $1.00, with no proceeds to the company. The company has 4,170,000 shares issued and outstanding held by 37 stockholders, trading on the OTC Markets Pink Limited Market under 'GLEI', but warns of no active liquid market, penny stock restrictions limiting sales, and $10,000 annual compliance costs that could force cessation of operations if unabsorbable.

• ·Shares acquired by selling shareholders in private placement exempt under Regulation D on June 7, 2021
• ·Fiscal year end: July 31
• ·No dilution to existing shareholders from this offering
• ·No authorized preferred stock, warrants, options, or convertible securities
• ·Company has never declared or paid cash dividends and does not anticipate doing so
• ·Par value of common stock: $0.0001 per share

05-03-2026

Tejon Ranch Co. issued a press release on March 5, 2026, announcing the release of its fourth quarter and full year 2025 operating and financial results before the market opens on March 19, 2026. The company will host a conference call on March 19, 2026, at 5:00 p.m. Eastern Time for shareholders and interested parties, with instructions for advance question submission and registration provided in the press release.

05-03-2026

L.B. Foster's net sales rose 1.7% YoY to $540M in 2025 from $531M in 2024, bolstered by 14.9% growth in the Infrastructure segment to $234M, while the Rail segment declined 6.5% to $306M. Gross profit fell 3.6% to $114M with margin contracting 110 bps to 21.1%, and operating income edged up 6.7% to $22M; however, net income plummeted 83% to $7.5M from $43M due to a $38M swing to tax expense. Operating cash flow improved significantly to $36M from $23M.

• ·Diluted EPS declined to $0.69 from $3.89 YoY.
• ·Total assets decreased to $330M from $334M.
• ·Outstanding borrowings on revolving credit facility: $42M; letters of credit: $0.9M as of Dec 2025.
• ·Critical audit matter identified on revenue recognition for long-term contracts using input method.
• ·Shares outstanding decreased to 10.1M from 10.6M due to treasury stock purchases.

05-03-2026

Intrepid Potash, Inc. reported total sales of $298.3M for 2025, up 17.2% YoY from $254.7M, with gross margin surging 88.5% to $54.8M from $29.1M and net income turning positive at $11.2M versus a $212.8M loss in 2024. Potash sales volumes increased 20.4% to 289K tons while Trio® volumes rose 19.3% to 303K tons with higher prices ($367/ton vs $311); however, Potash average price declined 6.4% to $353/ton and cash flows from operations fell 23.1% to $55.8M from $72.5M.

• ·Total assets increased to $632.2M from $594.5M; stockholders' equity rose to $491.4M from $474.4M.
• ·Potash production volumes declined slightly to 280K tons from 295K tons.
• ·Trio® production volumes increased to 273K tons from 251K tons.

05-03-2026

Quest Water Global, Inc. (QWTR) reported a significantly larger net loss of $291,413 for the three months ended September 30, 2025, compared to $137,329 in the prior year (112% YoY increase), driven by new marketing expenses and higher management fees. For the nine months ended September 30, 2025, the net loss edged up 3.4% YoY to $630,907 from $610,054, while total expenses rose modestly to $630,907. Stockholders' deficit widened to $2.94M from $2.26M YoY amid continued cash burn from operations funded by related party advances.

• ·Management fees for nine months ended Sep 30, 2025: $401,250 (up from $371,250 YoY)
• ·Stock-based compensation: $99,200 in Q3 2025 (nine months total includes prior periods)
• ·Cash and equivalents end of nine months: $9 (down from $12 YoY)
• ·Computer equipment fully depreciated to $0 net book value as of Sep 30, 2025

05-03-2026

Ardagh Metal Packaging S.A. (AMBP) reported FY2025 revenue of $5.5B, up 12% YoY from $4.9B, with gross profit rising 8% to $681M and operating profit increasing 21% to $244M, driven by 91% of revenues from stable Europe/North America markets and over 80% backed by multi-year contracts. However, net finance expenses surged 25% to $240M due to higher Senior Facilities interest ($158M, +13%), leading to profit before tax declining to $4M from $10M and a slim $11M net profit versus a $3M loss in 2024. The company highlighted its $1.8B growth investment plan (2021-2024) and sustainability targets approved in 2022.

• ·Sales, general and administration expenses increased slightly to $299M from $288M YoY.
• ·Intangible amortization decreased to $138M from $140M YoY.
• ·Income tax credit of $7M in 2025 vs charge of $13M in 2024.

05-03-2026

NCS Multistage Holdings, Inc. reported total revenues of $183.6M for the year ended December 31, 2025, up 13.0% YoY from $162.6M, driven by strong U.S. growth of 33.5% but tempered by modest 4.7% growth in Canada. Net income rose 219.9% to $26.0M, boosted by a $9.2M tax benefit, while operating income increased 143.7% to $10.5M; however, services gross margin declined to 45.0% from 48.7%, and other countries services revenues fell 31.1% YoY.

• ·Net cash provided by operating activities increased to $22.2M in 2025 from $12.7M in 2024.
• ·U.S. services revenues surged 87.8% YoY to $18.0M.
• ·Product sales revenues grew 13.1% YoY to $127.9M, with Other Countries up 126.1%.
• ·Provision for litigation of $0.9M in 2025.
• ·Filing date: March 05, 2026 for year ended December 31, 2025.

05-03-2026

RTX Corporation announced that director James A. Winnefeld Jr. resigned effective March 5, 2026, with no dispute or disagreement regarding company operations, policies, or practices. As a result, the Board size will decrease from 11 to 10 members.

05-03-2026

Grove Collaborative Holdings reported Q4 2025 revenue of $42.4 million, down 14.3% YoY due to fewer DTC orders (539k, -25%) and ecommerce migration disruptions, though partially offset by $2.9 million in QVC revenue from 8Greens; Adjusted EBITDA turned positive at $1.6 million versus a $1.6 million loss prior year, with Gross Margin up 60bps to 53.0% and OpEx down 29.7% to $24.1 million. Full year 2025 revenue declined 14.6% to $173.7 million, with Net Loss improving to $11.7 million but Adjusted EBITDA worsening to -$2.2 million. For FY2026, guidance calls for revenue of $140-150 million (further decline) and breakeven Adjusted EBITDA.

• ·Plastic Intensity improved to 0.88 pounds per $100 revenue in Q4 2025 from 1.02 prior year.
• ·Cash position $11.8M as of Dec 31, 2025, down from $12.3M at Sep 30, 2025.
• ·DTC Net Revenue Per Order $70 in Q4 2025 vs $67 prior year.
• ·FY2026 guidance expects revenue trough in Q1 with sequential improvement.
• ·Investor conference call on March 5, 2026 at 5:00pm ET.

05-03-2026

Cedar Realty Trust, Inc. reported a net loss of $1.9M for the year ended December 31, 2025, compared to a $4.5M profit in 2024, primarily due to a 14.1% decline in revenues to $29.7M, higher impairment charges of $5.8M (up 442.8%), and a reduction in properties owned from 16 to 12. However, Same-Property NOI grew slightly to $17.1M from $16.8M with flat occupancy at 92.4%, FFO increased to $19.3M (per share $1.41 from $0.52), and AFFO turned positive at $1.0M; the company also repurchased 4,244 shares of Series C Preferred Stock for $69K in October 2025.

• ·Same-Property occupancy flat at 92.4% (end of 2025 and 2024).
• ·Aggregate gross leasable area declined to 1,943,176 sq ft from 2,352,528 sq ft.
• ·Cash flows from operating activities down to $8.0M from $9.5M; financing activities outflow increased to $52.7M from $20.3M.
• ·Total liabilities slightly up to $158.8M from $160.7M despite property sales.
• ·Preferred stock equity down to $76.2M from $139.8M.

05-03-2026

Camp4 Therapeutics' revenue surged 436% YoY to $3.5M in 2025 from $0.65M, driven by research and collaboration agreements, while R&D expenses remained flat at approximately $38.2M-$38.8M. However, net loss widened 55% to $80.4M from $51.8M primarily due to a $29.8M unfavorable change in fair value of derivative tranche liability, despite improved operating cash use to $29.6M from $45.6M and a strengthened cash position of $109.5M. Stockholders' equity declined to $47.7M from $63.1M amid significant share issuance.

• ·Derivative tranche liability recorded at $44.8M as of Dec 31, 2025.
• ·Issuance of 31.7M common shares in private placement and registered direct offering in 2025, net proceeds $57.3M.
• ·Initial public offering in 2024 converted preferred stock and raised net $72.4M.
• ·Net loss per share improved to ($2.65) from ($11.04) due to increased shares outstanding.
• ·Impairment of right-of-use asset $0.5M in 2025.

05-03-2026

Rumble Inc. reported full-year 2025 revenue surpassing $100M for the first time, with Q4 revenue at $27.1M, up 9% QoQ from $24.8M but down 10% YoY from $30.2M amid declines in advertising and audience monetization. MAUs reached 52M in Q4, up 11% QoQ, and ARPU rose 2% to $0.46 QoQ, however Adjusted EBITDA loss widened to $16.0M from $13.4M YoY, and net loss was $32.7M despite improvement from prior year's $236.8M. The company secured a $100M ad commitment from Tether, launched Rumble Shorts topping 1M daily views, and is on track to acquire Northern Data in Q2 2026, adding ~22,400 NVIDIA GPUs.

• ·Audience Monetization revenues decreased $2.8M YoY due to $5.5M drop in advertising, tipping, and hosting fees, partially offset by $2.7M increase in subscriptions and licensing.
• ·Sales and marketing expenses surged 92% YoY to $7.3M, driven by higher marketing/PR ($2.8M increase).
• ·Northern Data acquisition includes globally distributed data centers; voluntary public exchange offer S-4 confidentially filed Jan 6, 2026.
• ·Rumble Cloud partnerships with three NFL teams: Cleveland Browns, Miami Dolphins, Tampa Bay Buccaneers.

05-03-2026

Evommune, Inc. (EVMN) reported FY2025 revenue growth of 86% YoY to $13M from $7M, primarily from license revenue, while completing an IPO with $157M net proceeds and converting all convertible preferred stock, boosting total assets to $225M and cash equivalents to $44.1M. However, operating expenses increased 22% YoY to $94.1M driven by 15% higher R&D ($74M) and 57% higher G&A ($20M), resulting in a widened net loss of $68.9M (up 3% YoY) and increased operating cash use to $76.4M. EVO301 R&D expenses declined sharply to $7.1M from $19.7M, while EVO756 R&D rose to $35.2M.

• ·Convertible preferred stock fully converted to common stock upon IPO, eliminating $257M non-cash liability.
• ·Stockholders' equity swung from ($144.2M) deficit in 2024 to $205.6M surplus in 2025.
• ·Property and equipment, net declined to $0.99M from $1.33M.
• ·Weighted average shares outstanding increased to 6.14M from 1.51M, reducing basic/diluted loss per share to ($11.22) from ($45.29).

05-03-2026

Caribou Biosciences reported Q4 and FY 2025 financial results, with licensing and collaboration revenue increasing 12% YoY to $11.2M for the full year, driven by prior IP licenses, while R&D expenses decreased 16% to $109.4M and G&A expenses fell 18% to $37.9M due to workforce reductions and pipeline prioritization. However, GAAP net loss remained relatively flat at $148.1M for FY2025 (vs. $149.1M in 2024), including a $21.3M non-recurring non-cash impairment charge, and cash reserves dropped 43% to $142.8M, sufficient into 2H 2027 but prompting exploration of funding options for the vispa-cel pivotal trial. Clinical updates highlighted positive data for vispa-cel in 2L LBCL and CB-011 dose expansion in r/r MM, with additional data expected in 2026.

• ·Non-GAAP FY 2025 net loss of $126.8M ($1.36 per share) excludes $21.3M impairment, improving from $149.1M ($1.65 per share) in FY 2024.
• ·Q4 2025 GAAP net loss per share $0.28 vs. $0.39 in Q4 2024.
• ·Cash expected to fund operations into 2H 2027, including CB-011 dose expansion and vispa-cel pivotal trial start-up activities.

05-03-2026

Traeger, Inc. reported FY 2025 total revenues of $559.5 million, down 7.4% YoY from $604.1 million but above the high end of guidance, driven by consumables growth of 6.9% to $127.5 million while grills fell 8.2% to $298.0 million and accessories declined 16.3% to $134.0 million. Q4 revenues dropped 13.8% to $145.4 million, with grills down 22.3% and accessories down 17.9%, though consumables rose 15.8% and Adjusted EBITDA improved 5.4% to $19.4 million; FY Adjusted EBITDA decreased 14.5% to $70.0 million amid a $74.7 million goodwill impairment. Project Gravity is on track for $64-70 million in annualized savings by end-2026, with FY 2026 guidance for revenues of $465-485 million and Adjusted EBITDA of $50-60 million.

• ·North America revenues decreased 5.1% YoY in FY 2025 and 13.0% in Q4 2025; Rest of World down 27.3% FY and 21.6% Q4.
• ·FY 2026 guidance: Q1 revenues $92-97M, Adjusted EBITDA $3-7M; Free Cash Flow at least $30M.
• ·Cash and cash equivalents $19.6M (up from $15.0M); Inventory $98.8M (down from $107.4M) at Dec 31, 2025.
• ·Restructuring costs: $21.8M FY 2025, $12.2M Q4 2025 related to Project Gravity.

05-03-2026

Hawthorn Bancshares, Inc. (HWBK) filed its 10-K annual report on March 5, 2026, covering the fiscal year ended December 31, 2025, with comparative data for 2024 and 2023 across banking and fiduciary/trust segments. The filing discloses detailed loan portfolio segments including commercial financial/agricultural, real estate construction (residential and commercial), real estate mortgages (residential and commercial), and installment/consumer loans, along with securities holdings, property/equipment, derivatives, and subordinated notes. No specific numerical financial metrics such as revenue growth, declines, or balance sheet totals are provided in the extracted XBRL tags.

• ·Filing covers periods: FY2025 (Jan 1 - Dec 31, 2025), FY2024, FY2023, with some Q4 2025 data.
• ·Loan classifications include Pass, Watch, Special Mention, Substandard, Doubtful; nonperforming and past due receivables tracked by segment.
• ·Securities categories: US Treasury, US Government Agencies/Sponsored Enterprises, States/Political Subdivisions, Mortgage-Backed, Other Debt, Equity.
• ·Trusts issued: Exchange Statutory Trust Two (Mar 17, 2005), Exchange Statutory Trust One (Mar 17, 2004).
• ·Shelf registration referenced as of July 2, 2025; 2025 Repurchase Plan authorized June 5, 2025.

05-03-2026

Owlet reported record FY 2025 revenue of $105.7M, up 35.4% YoY from $78.1M, with gross profit of $53.5M and margin improving slightly to 50.6%, alongside Adjusted EBITDA of $2.0M versus a $1.8M loss in FY 2024. However, Q4 gross margin declined 596 bps to 47.6% due to tariff impacts despite 29.6% revenue growth to $26.6M, operating loss narrowed to $4.9M but net loss was flat at $9.2M, and FY net loss widened to $39.7M including a $26.6M non-cash warrant adjustment. For 2026, the company guides FY revenue to $126-130M (19-23% growth) and Adjusted EBITDA to $3-5M, though Q1 Adjusted EBITDA is expected at $(2.5)-(1.5)M.

• ·Q4 2025 net loss per share $0.39 vs $0.63 in Q4 2024
• ·FY 2025 net loss per share $2.31 vs $1.57 in FY 2024
• ·Q1 2026 guidance: revenue $20-21M, gross margins 50-52%, Adjusted EBITDA $(2.5)-(1.5)M
• ·FY 2026 gross margins guidance 49-52% including tariff impacts
• ·Conference call on March 5, 2026 at 4:30 p.m. ET

05-03-2026

Contineum Therapeutics reported Q4 2025 financial results with cash, cash equivalents, and marketable securities of $262.9M, sufficient for operations into mid-2029, bolstered by $93.0M net proceeds from an upsized public offering of 8.1M shares; R&D expenses decreased 2% YoY to $12.8M while G&A rose 8% YoY to $4.4M, resulting in a Q4 net loss of $15.2M versus $14.6M prior year. The company initiated patient dosing in the PROPEL-IPF Phase 2 trial for PIPE-791 in IPF and expects topline data from a PIPE-791 Phase 1b chronic pain trial in Q2 2026. Full-year 2025 net loss widened to $60.0M from $42.3M in 2024 amid higher operating expenses.

• ·PROPEL-IPF is a 26-week trial with primary endpoint of change in forced vital capacity (FVC mL); NCT07284459.
• ·PIPE-791 Phase 1b pain trial initiated dosing March 2025; NCT06810245.
• ·J&J Moonlight-1 Phase 2 for PIPE-307 in MDD began recruiting Dec 2024; NCT06785012.
• ·Class A shares outstanding: 31.2M at Dec 31, 2025 (up from 19.1M); Class B: 6.1M (down from 6.7M).

05-03-2026

Guidewire Software reported Q2 FY2026 total revenue of $359.1M, up 24% YoY, driven by 33% growth in subscription and support revenue to $237.2M and 30% increase in services revenue to $62.4M; however, license revenue declined 7% YoY to $59.5M. ARR reached $1.121B, reflecting 22% YoY growth, with strong profitability including GAAP operating income of $38.4M (vs $11.7M prior) and the company raising its FY2026 outlook across key metrics. Cash and equivalents decreased to $1.351B from $1.483B at prior quarter-end amid share repurchases.

• ·GAAP net income $60.1M in Q2 FY2026 vs net loss of $37.3M in Q2 FY2025.
• ·Non-GAAP diluted EPS $1.17 in Q2 FY2026 vs $0.51 prior year.
• ·Q3 FY2026 outlook: Total revenue $352M-$358M; FY2026 total revenue $1.438B-$1.448B.
• ·FY2026 operating cash flow outlook $360M-$375M.

05-03-2026

BCP Investment Corp (BCIC) reported total assets of $523.6M as of December 31, 2025, up 15.4% YoY from $453.6M, driven by portfolio fair value growth to $501.0M (+23.7% YoY) bolstered by the $153.4M LRFC Acquisition; net asset value rose 17.2% YoY to $209.2M. However, total investment income declined slightly 2.0% YoY to $61.2M, with core investment income dropping 12.7% YoY to $54.3M amid lower interest and CLO income, while net expenses decreased 6.2% YoY to $36.0M. Unrealized gains on investments improved to $6.5M from $1.0M in 2024.

• ·Non-controlled/non-affiliated investments fair value: $409.7M (Dec 31, 2025) vs $327.6M (Dec 31, 2024), +25.1% YoY
• ·Total liabilities increased to $314.5M (+14.3% YoY) from $275.1M, with new debt issuances including $72.6M 2030 Notes
• ·Realized losses on investments: $21.4M in 2025 vs $29.4M in 2024

05-03-2026

ESS Tech reported FY2025 revenue of $1.6 million, down 75% YoY from $6.3 million due to shifts to new Energy Base offerings, lower sales volumes, and legacy contract settlements, while Q4 revenue was negative at -$1.6 million versus $2.9 million in Q4 2024. However, net loss improved to $63.4 million from $86.2 million, Adjusted EBITDA loss narrowed 38% to -$44.3 million from -$71.3 million, and operating expenses fell 33% to $29.7 million. The company advanced leadership reset with new CEO Drew Buckley and CFO Kate Suhadolnik, acquired VoltStorage GmbH's IP, secured a $9.9 million contract and progress on projects like SRP 50 MWh and Google Project New Horizon, and bolstered liquidity via $40 million Yorkville financing, $8.6 million ATM, and $15 million registered direct offering.

• ·Q4 2025 net loss of $24.0 million slightly worse than $23.5 million in Q4 2024.
• ·R&D expenses decreased $3.5 million YoY, sales/marketing down $5.3 million, G&A down $5.9 million in FY2025.
• ·50 MWh deployment at SRP Copper Crossing under 10-year agreement.
• ·Manufacturing for Project New Horizon to begin 2026, delivery targeted December 2027.
• ·Three tier 1 foundational projects expected to begin delivery in 2027.
• ·Drew $10 million second tranche from Yorkville on February 27, 2026; $1.5 million outstanding on first tranche as of March 1, 2026.

05-03-2026

Sachem Capital Corp. announced on March 4, 2026, a quarterly dividend of $0.05 per common share (par value $0.001), payable March 30, 2026 to shareholders of record on March 15, 2026. The company also declared $0.484375 per share on its 7.75% Series A Cumulative Redeemable Preferred Stock (liquidation preference $25.00), payable on the same date to record holders on March 15, 2026, representing the full accrual from December 30, 2025 through March 29, 2026.

• ·Filing submitted on March 5, 2026 under Items 8.01 and 9.01.
• ·Press release attached as Exhibit 99.1.

05-03-2026

Keysight Technologies reported Q1 FY2026 revenue of $1.6B, up 23% YoY driven by 25% growth in products and 19% in services; however, operating income rose only 14% to $248M due to cost increases outpacing revenue in areas like cost of products (+30%) and SG&A (+24%), resulting in margin compression to 15.5% from 16.8%. Net income surged 66% to $281M primarily from an $83M tax benefit versus prior $30M expense, boosting diluted EPS to $1.63 from $0.97. Operating cash flow improved 17% to $441M, while the company repurchased $87M in shares.

• ·Tax provision was a benefit of $83M vs $30M expense YoY due to discrete items.
• ·Interest expense increased to $29M from $20M YoY.
• ·Acquired business for $1.564B total consideration on Oct 15, 2025, with $711M goodwill.
• ·Small acquisition of $16M in current quarter cash flows.
• ·Total assets $11.481B as of Jan 31, 2026, up from $11.301B at Oct 31, 2025.

05-03-2026

Marvell Technology, Inc. reported record Q4 FY26 net revenue of $2.219B, up 22% YoY and $19M above guidance midpoint, with GAAP gross margin of 51.7% and non-GAAP of 59.0%. FY26 net revenue reached a record $8.195B, up 42% YoY, with GAAP EPS of $3.07, up 81% YoY. Q1 FY27 outlook projects net revenue of $2.4B +/-5%, with continued acceleration from data center and AI demand.

• ·Q4 FY26 GAAP diluted EPS: $0.46; non-GAAP: $0.80
• ·FY26 GAAP diluted EPS: $3.07; non-GAAP: $2.84
• ·Q1 FY27 GAAP gross margin outlook: 51.4%-52.4%; non-GAAP: 58.25%-59.25%
• ·Q1 FY27 GAAP operating expenses: ~$872M; non-GAAP: ~$575M
• ·Q1 FY27 GAAP diluted EPS outlook: $0.31 +/- $0.05; non-GAAP: $0.79 +/- $0.05
• ·Non-GAAP tax rate for Q4 FY26: 10.0%

05-03-2026

EyePoint Pharmaceuticals reported total revenues of $31.4M for FY 2025, down 28% YoY from $43.3M, with product sales declining 50% to $1.6M and license/collaboration revenues dropping 57% to $16.7M, though royalty income surged 708% to $13.0M. Operating expenses rose 45% to $274.8M, primarily due to a 66% increase in R&D to $221.0M, resulting in a net loss of $232.0M, up 77% from $130.9M in FY 2024. Cash and equivalents stood at $101.8M as of Dec 31, 2025, with net cash used in operations worsening to $240.1M and stockholders' equity declining to $306.1M.

• ·Marketable securities decreased to $204.3M from $271.2M as of Dec 31, 2025.
• ·Total current assets down to $328.7M from $383.3M.
• ·Stock-based compensation expense $27.9M in FY 2025 vs $36.7M in FY 2024.
• ·Issuance of common stock net of costs: 13.7M shares raising $172.9M in FY 2025.

05-03-2026

Applied Optoelectronics, Inc. (AAOI) entered into a design-build agreement dated February 13, 2026, with LCC3 Solution Inc. for the construction of a Manufacturing Cleanroom at 1111 Gillingham Lane, Sugar Land, TX 77478. The agreement outlines responsibilities for design, construction, testing, and commissioning, with Dr. Fred Chang as AAOI's authorized representative and Mingzheng (Miles) Yang for the design-builder. No financial terms such as contract sum or schedule details are specified in the filing.

• ·Agreement effective as of February 13, 2026; SEC 8-K filed March 05, 2026.
• ·Project location: 1111 Gillingham Lane, Sugar Land, TX 77478.
• ·AAOI address: 13139 Jess Pirtle Blvd., Sugar Land, TX 77478.
• ·LCC3 Solution Inc. address: 7165 Colleyville Blvd. Suite 101, Colleyville, TX 76034.
• ·Dispute resolution includes meet-and-confer and arbitration per Exhibit N.

05-03-2026

Amalgamated Financial Corp. (AMAL) reported total assets of $8.5B as of December 31, 2025, up from $8.3B in 2024, with net interest income growing 5.4% YoY to $297.8M on higher loan volumes (+$25.2M interest income) and total interest income up 5.2% to $422.2M at a 5.09% yield. However, non-interest income declined 6.9% YoY to $30.9M amid losses on securities sales and equity investments, while non-interest expenses rose 7.9% to $172.2M driven by higher compensation, professional fees, and technology costs; nonperforming assets also edged up slightly to $28.7M or 0.32% of assets.

• ·Average total loans grew to $4,720M in 2025 from $4,479M in 2024 (+5.4% YoY).
• ·Nonaccrual loans in commercial portfolio rose to $22.1M from $16.0M YoY.
• ·Allowance for credit losses on loans to total loans declined to 1.16% from 1.29% YoY.
• ·Service charges on deposit accounts dropped sharply to $17.5M from $32.2M YoY.

05-03-2026

AerSale reported Q4 2025 revenue of $90.9M, down 4.0% YoY from $94.7M due to lower flight equipment sales ($20.9M from 4 engines vs $31.0M from 6), though excluding those sales revenue grew 9.8% driven by USM, leasing, and MRO; Adjusted EBITDA rose 17.1% to $15.2M. For FY2025, revenue declined 2.8% to $335.3M from $345.1M amid fewer engine sales (13 vs 20+1 aircraft), but Adjusted EBITDA surged 38.2% to $46.1M with margin expansion to 31.5% from 30.1% and excluding flight equipment sales revenue grew 18.7%. Profitability improved significantly with GAAP net income up 99.7% to $5.4M in Q4 and 46.6% to $8.6M FY, though TechOps revenue fell 4.5% FY and some MRO facilities saw declines.

• ·Q4 Asset Management revenue down 11.1% to $56.9M; ex-flight equipment up 9.1% to $36.0M
• ·Q4 TechOps revenue up 10.7% to $34.0M, offset by declines at Roswell NM and Goodyear AZ MRO facilities
• ·FY Asset Management revenue $211.6M vs $215.5M
• ·Revolving credit facility: $67.2M available on $180M line, expandable to $200M
• ·Cash used in operating activities FY2025: $23.0M
• ·Conference call: March 5, 2026 at 4:30 pm ET

05-03-2026

Smith & Wesson Brands reported Q3 FY26 net sales of $135.7 million, up 17.1% YoY from $115.9 million, with gross margin expanding to 26.2% from 24.1% and net income rising 78.5% to $3.8 million. Handgun unit shipments to the sporting goods channel surged 28% despite a 2.2% YoY decline in NICS background checks, reflecting market share gains. However, nine-month FY26 net income declined 52.9% YoY to $2.3 million despite 3.5% sales growth to $345.5 million.

• ·Authorized $0.13 per share quarterly dividend, payable April 2, 2026 to shareholders of record March 19, 2026.
• ·Q4 FY26 sales guidance: up 10-12% YoY over Q4 FY25.
• ·Inventories decreased to $175.3M as of Jan 31, 2026 from $189.8M at FY25 end.
• ·9M FY26 net cash from operations: $39.6M vs $(48.1M) prior year.

05-03-2026

Texas Roadhouse, Inc. (Nasdaq: TXRH) appointed Lisa Ingram, CEO and Chair of White Castle System, Inc., to its Board of Directors on March 5, 2026. Ms. Ingram, who has led White Castle since 2015, oversees 340 restaurants in 14 states and 6 manufacturing plants supplying consumer products nationwide. Jerry Morgan, Texas Roadhouse CEO, highlighted her restaurant industry expertise and people-first leadership approach.

• ·Lisa Ingram is a fourth-generation family member leading the 105-year-old White Castle brand, considered the nation's first fast-food hamburger chain.
• ·Lisa Ingram holds a Bachelor of Business Administration from Southern Methodist University and an MBA from Ohio State University.
• ·Lisa Ingram serves as Chair of the Board of OhioHealth and on the board of M/I Homes (NYSE: MHO).
• ·Texas Roadhouse first opened in 1993.

05-03-2026

DUKE Robotics Corp. (DUKR) filed a Certificate of Change with the Nevada Secretary of State on March 4, 2026, effecting a 1-for-25 reverse stock split of its common stock, with no change to authorized shares of 350M common (par $0.0001) or 10M preferred (par $0.0001). The split becomes effective March 6, 2026, at 12:01am, with fractional shares rounded up to the nearest whole share on a per-shareholder basis. Stockholder approval has been obtained.

• ·Nevada Business Identification Number (NVID): NV20151076168
• ·Certificate filed on March 4, 2026; 8-K filing date March 5, 2026

05-03-2026

Athena Technology Acquisition Corp. II deposited $497.74 into its trust account on March 4, 2026, to extend the deadline for consummating its initial business combination by one month, from March 14, 2026, to April 14, 2026. This represents the seventh of up to nine potential monthly extensions permitted under the company's Amended and Restated Certificate of Incorporation. No other material financial impacts or performance metrics were reported.

• ·Company is an emerging growth company.
• ·Fiscal year end: December 31.
• ·SEC file number: 001-41144.

05-03-2026

CIMG Inc. entered into an Amended and Restated Equity Transfer Agreement on February 27, 2026, to acquire 100% of Daren Business Technology Limited (100 ordinary shares) from Shelei Jiang for zero cash consideration, with closing expected by March 31, 2026, subject to customary conditions. Post-closing, the Company may issue up to 74,487,896 common shares to seller designees Dundas Technology Limited and Kellyview Investment Limited by April 10, 2026, contingent on stockholder approval and audited revenue targets through September 30, 2029; unmet targets result in forfeiture, but full issuance would cause significant dilution with no assurance of approval.

• ·Acquisition amends and restates prior Equity Transfer Agreement dated February 11, 2026.
• ·Award Shares subject to Nasdaq Listing Rule 5635 stockholder approval and transfer restrictions with leak-out tied to RMB-denominated revenue targets.
• ·Shares, if issued, rely on Regulation S and Section 4(a)(2) exemptions as restricted securities.
• ·Filed as Exhibit 10.1: full A&R Equity Transfer Agreement.

05-03-2026

Gevo reported full-year 2025 revenue of $161 million, up dramatically from $17 million in 2024, fueled by record low-carbon ethanol production of 69 million gallons (+3% YoY) and $52 million in production tax credit sales. Fourth-quarter highlights included positive cash flow from operations of $20 million, Adjusted EBITDA of $7.7 million (third consecutive positive quarter), and total cash position of $117 million (up $9 million from prior quarter); however, the company posted a Q4 operating loss of $2.2 million. Strategic progress included the January 2025 acquisition of Red Trail Energy assets (now Gevo North Dakota), debt consolidation in February 2026 releasing restricted cash, and advancements in SAF projects and carbon credits monetization of 140,000 tons.

• ·Gevo North Dakota CCS asset certified by Puro.Earth as thousand-year permanence well and received 'A' rating from BeZero Carbon.
• ·U.S. DOE EDF loan guarantee conditional commitment extended for potential ATJ SAF project financing.
• ·Luverne facility divestiture expected to save $3M in costs in 2026.
• ·Secured multi-year offtake for CDR credits and contracted Scope 1/3 credits for 15M gallons/year future SAF production.
• ·Total assets increased to $719M at YE2025 from $584M at YE2024.

05-03-2026

Beam Therapeutics Inc. mutually terminated its License Agreement with Bio Palette Co., Ltd., dated March 27, 2019, effective March 2, 2026, due to Bio Palette's planned dissolution. This termination activates a standby exclusive license from Kobe University for the same base editing patent rights, ensuring continuity without future payments owed. The agreement covered licenses for human disease treatments worldwide (excluding microbiome in Asia) and vice versa for microbiome products in Asia.

• ·Original License Agreement filed as Exhibit 10.7 to Form S-1 on September 27, 2019
• ·Kobe-Bio Palette License dated May 9, 2017
• ·Standby License Agreement dated February 9, 2026

05-03-2026

Bridger Aerospace reported record 2025 full-year revenue of $122.8 million, up 25% YoY from $98.6 million, Adjusted EBITDA of $45.3 million (+21% YoY), and positive net income of $4.1 million versus a $15.6 million loss in 2024. However, Q4 2025 revenue fell 45% YoY to $8.5 million from $15.6 million, with a widened net loss of $15.1 million (vs. $12.8 million) and Adjusted EBITDA of negative $9.5 million (vs. negative $2.9 million). The company completed a $331.5 million financing package including a $100 million delayed draw facility and initiated 2026 guidance of $135-145 million revenue (10-18% growth at midpoint) and $55-60 million Adjusted EBITDA.

• ·Cost of revenues increased to $71.1M in 2025 from $57.5M in 2024.
• ·SG&A expenses rose to $13.4M in Q4 2025 from $7.7M in Q4 2024.
• ·Added first two Spanish Scoopers and four additional air surveillance aircraft.
• ·2026 guidance excludes $14.0M non-recurring return to service revenue from 2025.

05-03-2026

Eagle Point Income Company Inc. filed a DEFA14A definitive additional proxy material on March 5, 2026, urging stockholders to vote ahead of the Special Meeting of Stockholders. The notice directs shareholders to contact proxy tabulator EQ Fund Solutions at (800) 290-6426 (9:00 am - 10:00 pm ET, Monday-Friday) using their Investor ID to cast votes. It is signed by Courtney Fandrick, Secretary, with no financial or performance metrics disclosed.

• ·Company address: 600 Steamboat Road, Suite 202, Greenwich, CT 06830
• ·Investor contact details include Investor ID, Security ID, Shares owned, and Household ID (placeholders provided)

05-03-2026

aTyr Pharma reported FY 2025 net loss of $74.1M, worsening 16% YoY from $64.0M due to increased R&D expenses ($60.2M, +11% YoY) and G&A ($17.6M, +28% YoY), with revenues declining to $0.190M from $0.235M. Cash position improved to $80.9M from $75.1M, providing runway for ongoing programs. Phase 3 EFZO-FIT™ missed primary endpoint of corticosteroid reduction but showed statistical benefits in secondary measures like KSQ-Lung (p=0.0479); FDA meeting set for mid-April 2026, while Phase 2 EFZO-CONNECT™ enrollment remains on track for H1 2026.

• ·Phase 3 EFZO-FIT™ evaluated 3.0 mg/kg and 5.0 mg/kg efzofitimod vs placebo; primary endpoint missed (change in mean daily oral corticosteroid dose at week 48).
• ·Secondary benefits at 5.0 mg/kg: KSQ-Lung (p=0.0479), Fatigue Assessment Scale (p=0.0226), KSQ-General Health (p=0.0197), complete steroid withdrawal with KSQ-Lung improvement (p=0.0196).
• ·Phase 2 EFZO-CONNECT™: 2:2:1 randomization to 270 mg, 450 mg efzofitimod or placebo IV monthly for 6 doses.

05-03-2026

AI Technology Group Inc. completed the acquisition of 100% of AVM Biotechnology Inc. (AVMN) on December 15, 2025, issuing 100 common shares to Biomed 360 Solutions Corp., making AVMN a wholly-owned subsidiary in a tax-free reorganization under Section 368. This Amendment No. 1 to the original 8-K corrects and increases AVMN's outstanding convertible debentures to $1.587M (up $0.462M) convertible into 634,800 common shares of the Corporation (up 50,000 shares), introducing potential shareholder dilution. Financial statements and pro forma information for AVMN will be filed within 71 days.

• ·Shares issued in acquisition are restricted securities under Rule 144, exempt under Section 4(a)(2).
• ·AVMN financial statements and pro forma info to be filed by amendment within 71 calendar days per Regulation S-X.

05-03-2026

Iridium Communications Inc. declared a cash dividend of $0.15 per share on its common stock, payable on March 31, 2026, to stockholders of record as of March 16, 2026. The Board of Directors approved the dividend on March 5, 2026. No comparative financial metrics or prior period data were disclosed.

• ·Filing submitted pursuant to Item 7.01 Regulation FD Disclosure.

05-03-2026

Castellum, Inc. reported 2025 unaudited revenue of $52.9 million, up 15.2% YoY from $44.8 million in 2024, driven by organic growth from prime contract wins. Operating loss improved to $2.8 million from $7.2 million, and net loss narrowed to $2.5 million from $10.1 million, with Adjusted EBITDA rising slightly to $1.0 million from $0.8 million. However, the company still posted losses, though cash increased to $14.9 million and debt plummeted to $0.4 million from $10.7 million.

• ·Cash to debt ratio improved from 1x as of Dec 31, 2024 to 37x as of Dec 31, 2025.
• ·Other income of $0.6 million in 2025 vs. other expense of $2.7 million in 2024.
• ·Fully audited 10-K expected on or before March 9, 2026.
• ·2025 growth entirely organic since last acquisition (GTMR) in 2023.

05-03-2026

Pattern Group Inc. reported record FY2025 revenues of $2.5B, up 39% YoY from $1.8B, with Q4 revenues reaching $723M, up 40% YoY, alongside record NRR of 124% (up from 116%), non-Amazon revenue of $183M (up 60%), and international revenue of $266M (up 63%). Adjusted EBITDA rose 52% YoY to $153M, and net cash from operations increased 41% to $99M. However, GAAP net income declined 76% to $16M from $68M due to $104M in stock-based compensation and IPO-related costs, with operating income falling 71% to $25M and FY EPS at $(1.36). The company announced a $100M share repurchase program.

• ·Total assets increased to $948M as of Dec 31, 2025 from $664M at end of 2024.
• ·Inventory grew to $295M as of Dec 31, 2025 from $264M.
• ·Q1 2026 Revenue guidance: $710M to $720M (31-33% YoY growth).
• ·Q1 2026 Adjusted EBITDA guidance: $41M to $42M (22-24% YoY growth).
• ·Acquired business for $19M net of cash in 2025.

05-03-2026

Mobile Infrastructure Corp reported total revenues of $35.1M for the year ended December 31, 2025, down 5.2% YoY from $37.0M, with managed property revenue up modestly 2.8% to $28.6M but offset by sharp declines in base rental income (-12.9% to $5.4M) and percentage rental income (-64.2% to $1.1M). Net Operating Income fell 8.5% to $20.7M amid a surge in impairment charges to $3.8M (from $0.2M) and higher interest expense (up 37.7% to $19.0M), resulting in a net loss of $23.7M versus $8.4M in 2024. The company outlined objectives to optimize RevPAS and pursue acquisitions but highlighted ongoing risks from parking demand fluctuations and high debt levels.

• ·Total other expense increased 107.8% YoY to $20.6M in 2025.
• ·Loss on sale of real estate was $0.1M in 2025 versus gain of $2.7M in 2024.

05-03-2026

Omada Health reported fourth quarter 2025 revenue of $76 million, up 58% YoY from $48 million, and full-year revenue of $260 million, up 53% YoY from $170 million, driven by 55% member growth to 886,000. The company achieved positive net income of $5 million in Q4 (vs. $8 million loss prior year) and positive Adjusted EBITDA of $6 million for the full year (vs. $29 million loss), with gross margins expanding to 71% in Q4 (from 67%) and 66% for the year (from 61%). However, full-year net loss narrowed but remained at $13 million (vs. $47 million prior), and 2026 guidance projects slower revenue growth of 22% to $312-322 million with Adjusted EBITDA of $7-15 million.

• ·Cash and cash equivalents increased to $222M from $76M as of Dec 31, 2024.
• ·Total assets $305M as of Dec 31, 2025 (vs $151M prior year).
• ·Operating expenses for FY 2025: R&D $41M, Sales & Marketing $90M, G&A $52M.
• ·Supported more than 2M members since launch across 2,000+ employers/health plans.

05-03-2026

GoPro reported FY 2025 revenue of $652 million, down 19% YoY, driven by a 21.5% decline in hardware revenue to $545 million, while subscription and service revenue was nearly flat at $106 million (down 1%). Q4 2025 revenue was flat YoY at $202 million, but camera sell-through dropped 19% to 625,000 units and gross margins fell to 31.8% GAAP (down 290 bps), with subscriber count ending at 2.36 million (down 7%). However, operating expenses were reduced by $93 million (26% YoY), cash flow from operations improved by $104 million, and net losses narrowed significantly to $93 million GAAP (from $432 million), alongside plans to launch GP3 AI-enabled processors in Q2 2026.

• ·Cash and cash equivalents declined to $49.7M from $102.8M YoY.
• ·Inventory reduced to $78.4M from $120.7M YoY.
• ·Short-term debt $19.6M as of Dec 31, 2025 (down from $93.2M).
• ·Adjusted EBITDA Q4 2025 positive $1M (from negative $14M YoY); FY 2025 negative $29M (improved from negative $72M).

05-03-2026

SunOpta Inc. (STKL) filed a DEFA14A definitive additional proxy material on March 5, 2026, consisting of a town hall presentation to employees regarding the proposed acquisition by Refresco pursuant to an Arrangement Agreement dated February 6, 2026. The agreement involves SunOpta, Pegasus BidCo B.V., and 2786694 Alberta Ltd. No financial terms, performance metrics, or period-over-period comparisons are provided in this filing.

• ·Town hall presentation delivered on March 5, 2026
• ·Filed by the Registrant (SunOpta Inc.)

05-03-2026

On February 27, 2026, AeroVironment Inc.'s Compensation Committee approved the Non-Qualified Deferred Compensation Plan, effective March 1, 2026, allowing key employees including named executive officers and non-employee directors to defer up to 75% of base salaries, cash bonuses, or director fees. The plan includes 100% immediate vesting with no company matching contributions, distributions upon retirement in lump sum or installments over 2 or 10 years, and a rabbi trust for assets subject to creditor claims. Additionally, Trace Stevenson and Mary Clum were approved as participants in the amended Executive Severance Plan.

• ·Plan distributions: lump sum upon separation before retirement, death, or disability; optional after 4+ years from deferral
• ·Company to pay all administrative costs and establish a rabbi trust; assets subject to general creditor claims
• ·Executive Severance Plan amended and restated as of December 3, 2024; described in proxy statement filed August 13, 2025

05-03-2026

Research Frontiers Inc (REFR) reported a widened net loss of $2.05M in 2025 versus $1.31M in 2024, driven by a 16% YoY decline in fee income to $1.12M while operating expenses rose 20% to $2.64M and research and development expenses increased 7% to $0.61M. Cash and cash equivalents fell sharply 67% to $0.66M from $1.99M, with total assets dropping 44% to $2.25M and shareholders' equity declining 64% to $0.93M from $2.60M. Net cash used in operating activities more than doubled to $1.33M from $0.79M.

• ·Royalties receivable reserves increased to $1.38M in 2025 from $1.25M in 2024.
• ·Credit loss expense rose to $154k in 2025 from $25k in 2024.
• ·Directors fees and expenses increased to $338k in 2025 from $176k in 2024.

05-03-2026

ALT5 Sigma Corporation regained Nasdaq compliance on three issues: filing its delayed 10-Q for the period ending September 27, 2025 (filed January 12, 2026, confirmed January 13, 2026); reconstituting its Audit Committee with the appointment of Tim Stanley as independent director and Chair (announced February 6, 2026, confirmed March 3, 2026); and holding its 2025 Annual Meeting of Stockholders on February 27, 2026 (confirmed March 3, 2026). All Nasdaq notices are now closed with no further actions required. This resolves prior deficiencies in listing rules 5250(c)(1), 5605(c)(2)(A), and 5620(a).

• ·10-Q Notice received November 19, 2025; compliance plan filed December 21, 2025.
• ·Audit Committee Notice received December 3, 2025.
• ·Annual Meeting Notice received January 7, 2026; extension until March 2, 2026.
• ·Nasdaq letters attached as Exhibits 99.1, 99.2, and 99.3.

05-03-2026

On February 27, 2026, The Crypto Company entered into a Subscription Agreement with accredited investor Juan Betancourt to sell and issue 34,782,609 shares of common stock (par value $0.001) for an aggregate purchase price of $40,000 in an unregistered offering under Regulation D. This provides the company with $40K in cash proceeds but involves substantial dilution to existing shareholders due to the large number of shares issued at a very low effective price. The agreement includes customary representations, warranties, and covenants.

• ·Shares sold without registration under the Securities Act, relying on Regulation D exemption and state blue sky laws.
• ·Investor represented as accredited and acquiring shares for investment, not resale; appropriate legends to be affixed.
• ·Form of Subscription Agreement filed as Exhibit 10.1.

05-03-2026

Orion Properties Inc. (ONL) reported total revenues of $147.6M for the year ended December 31, 2025, down 10.4% YoY from $164.9M, primarily due to a 10.5% decline in rental income and a reduced portfolio of operating properties (58 vs. 69). While occupancy improved to 78.7% from 73.7% and leased rate rose to 80.7% from 74.7%, net loss attributable to common stockholders widened to $(139.3M) or $(2.48) per share from $(103.0M) or $(1.84) per share, with FFO dropping 48.3% to $24.3M and Core FFO declining 23.1% to $43.7M amid surging impairments of $99.4M (up 109.1%).

• ·Investment-grade tenants declined to 66.7% from 74.4% as of Dec 31, 2025.
• ·Total capital expenditures rose to $60.0M in 2025 from $24.1M in 2024.
• ·Rentable square feet leased in 2025 totaled 924k vs 1,086k in 2024.
• ·Weighted average remaining lease term increased to 5.7 years from 5.2 years.

05-03-2026

Phio Pharmaceuticals reported increased operating expenses of $9.22M for 2025 (up 24.8% YoY from $7.39M), driven by R&D (+26.8% to $4.62M) and G&A (+22.9% to $4.60M), resulting in a wider net loss of $8.70M (up 21.7% YoY from $7.15M). However, strong financing activities provided $23.64M in net cash, boosting cash and equivalents to $21.03M (up 290.9% from $5.38M) and total assets to $21.49M. Common shares outstanding surged to 11.62M from 1.73M due to issuances and warrant exercises.

• ·Net cash used in operating activities increased to $7.98M in 2025 from $7.11M in 2024.
• ·Interest income, net was $0.52M in 2025 vs $0.23M in 2024.
• ·Diluted net loss per share improved to $(1.45) in 2025 from $(9.08) in 2024 due to increased share count.
• ·Stock-based compensation expense was $0.48M in 2025 vs $0.15M in 2024.
• ·Offering costs for common stock and warrants issuance in 2025 totaled $2.9M.

05-03-2026

Costco Wholesale Corporation reported second quarter fiscal 2026 net sales of $68.24B, up 9.1% YoY from $62.53B, with comparable sales rising 7.4% (adjusted 6.7%), driven by strong Other International (13.0%) and digitally-enabled sales (22.6%), while U.S. comp sales grew more modestly at 5.9%. Net income increased to $2.04B ($4.58 diluted EPS) from $1.79B ($4.02), and year-to-date sales grew 8.7% to $134.22B. February net sales rose 9.5% to $21.69B, positively impacted by a 0.5% shift from later Lunar/Chinese New Year.

• ·Operates 924 warehouses globally, including 634 in U.S./Puerto Rico, 114 in Canada, and expansions in Other International.
• ·Membership fees Q2: $1.36B (up from $1.19B YoY).
• ·Cash provided by operating activities for 24 weeks: $7.68B (up 28% YoY).
• ·Total assets as of Feb 15, 2026: $83.64B (up from $77.10B at Aug 31, 2025).
• ·Conference call scheduled for March 5, 2026 at 2:00 p.m. PT.

05-03-2026

ArriVent BioPharma reported a significantly widened net loss of $166.3M for the year ended December 31, 2025, up 107% from $80.5M in 2024, primarily due to R&D expenses nearly doubling to $153.4M (+94%) and G&A rising 58% to $24.2M. While total assets increased 21% to $333.2M bolstered by $203.1M in financing inflows and short-term investments growing to $267.3M, cash and equivalents declined 39% to $45.5M amid heightened operating cash burn of $160.6M. Interest income also decreased 19% to $11.2M.

• ·Accumulated deficit increased to $404.6M as of Dec 31 2025 from $238.3M as of Dec 31 2024.
• ·Short-term investments rose to $267.3M as of Dec 31 2025 from $144.6M as of Dec 31 2024.
• ·Financing activities provided $203.1M in 2025 vs $186.6M in 2024.
• ·Investing activities used $71.2M in cash in 2025 vs $192.5M in 2024.

05-03-2026

Quanex Building Products reported Q1 FY2026 net sales of $409.1M, up 2.3% YoY from $400.0M, with Hardware Solutions up 2.4%, Custom Solutions up 4.8%, but Extruded Solutions flat due to lower volumes offset by pricing and FX. However, Adjusted EBITDA fell to $27.4M (6.7% margin) from $38.5M (9.6%), net loss improved to $4.1M from $14.9M but Adjusted Net Loss was $0.3M versus $9.0M income, and free cash flow deteriorated to ($31.5M) from ($24.1M) amid macroeconomic pressures and operational costs. The company issued FY2026 guidance for net sales of $1.84B-$1.87B and Adjusted EBITDA of $240M-$245M.

• ·Total debt of $717.5M and leverage ratio of 2.8x Net Debt to LTM Adjusted EBITDA as of January 31, 2026.
• ·Liquidity of $331.6M as of January 31, 2026, including $62.3M cash.
• ·Cash dividend per share of $0.08.
• ·Conference call scheduled for March 6, 2026, at 11:00 a.m. ET.

05-03-2026

Kingstone Companies, Inc. reported record Q4 and FY 2025 results, with net premiums earned surging 37.5% YoY to $49.5M in Q4 and 45.6% to $187.1M for the year, net income up 122% to $40.8M, diluted EPS of $2.88 (+95%), and book value per share up 75% to $8.28 amid a net combined ratio improvement to 64.2% in Q4 and 75.0% for FY. Direct premiums written grew 14.1% in Q4 to $82.8M and 14.8% for FY to $277.8M, with policies in force up a modest 3.6% to 80,432. However, net investment gains remained negative in Q4 (flat YoY) and declined sharply for FY from a gain to a $0.3M loss.

• ·Updated 2026 guidance: direct premiums written growth 16% to 20%, underlying combined ratio 74% to 76%, net income per share diluted $2.20 to $2.90.
• ·Conference call scheduled for March 6, 2026 at 8:30 a.m. Eastern Time.
• ·2029 goal: $500M in direct premiums written.
• ·Expansion into California starting Q2 2026.
• ·Catastrophe sensitivity: each 1 pt catastrophe loss ratio impacts ~$0.13 per diluted share after tax.

05-03-2026

Gap Inc. reported fourth quarter fiscal 2025 net sales of $4.2 billion, up 2% YoY with comparable sales up 3% for the eighth consecutive quarter, and full year net sales of $15.4 billion, up 2% YoY, delivering operating income of $1.1 billion (7.3% margin). However, gross margin declined 80 basis points in Q4 to 38.1% and 50 basis points full year to 40.8%, primarily due to tariff impacts, while Athleta net sales fell 11% in Q4 and 10% full year. The company generated $1.3 billion in operating cash flow, ended with $3.0 billion in cash equivalents, announced a new $1 billion share repurchase authorization, and outlook for FY2026 net sales growth of 2-3%.

• ·Online sales represented 42% of Q4 total net sales (up 5% YoY) and 39% full year (up 4% YoY).
• ·Store sales flat in Q4, up 1% full year.
• ·Banana Republic full year net sales down 1% YoY despite 3% comp growth.
• ·FY2026 outlook: adjusted diluted EPS $2.20-$2.35 (vs $2.13 FY2025), capex ~$650M.
• ·Q1 FY2026 dividend increased 6% to $0.175 per share.

05-03-2026

Allient Inc reported revenue of $554.5M for 2025, up 5% YoY from $530.0M, driven by strong Industrial demand in power quality solutions for data centers but partially offset by declines in the Vehicle segment due to lower power sports and truck demand. Gross profit rose 10% to $181.7M with margin expansion to 32.8%, operating income surged 46% to $44.0M, and net income increased 67% to $22.0M or $1.32 per diluted share; however, restructuring costs more than doubled to $4.0M, other expenses rose sharply, and backlog grew only 1% to $232.9M. Net debt improved to $139.7M from $188.1M, supported by operational cash flows.

• ·U.S. sales were 55% of total revenue in both 2025 and 2024.
• ·Quarterly dividend of $0.03 per share paid each quarter of 2025 and 2024, totaling $0.12 per share annually; payout ratio 9% in 2025 vs 15% in 2024.
• ·Bookings increased 15% YoY to $550.9M.
• ·Foreign currency impact favorable by $6.5M on 2025 revenue; revenue excluding FX $548.0M.
• ·Effective tax rate 23.3% in 2025 vs 21.9% in 2024.

05-03-2026

Entravision Communications Corp reported consolidated net revenue of $447.6M for the year ended December 31, 2025, up 23% YoY from $365.0M, driven by explosive 90% growth in Advertising Technology & Services to $270.9M; however, Media revenue declined 20% to $176.7M and direct operating expenses for that segment were nearly flat at $109.6M. Operating loss widened 60% to $83.4M from $52.0M, impacted by a $55.4M impairment charge, $25.2M loss on lease abandonment, and $2.8M restructuring costs, resulting in a net loss of $79.2M that improved from $148.9M in 2024 but remained negative with EPS of $(0.87). Cash and equivalents fell to $59.4M from $95.9M, total assets decreased to $387.5M, and stockholders' equity dropped to $55.4M from $146.0M.

• ·Cash flow from operating activities $10.6M in 2025, down from $74.7M in 2024.
• ·Capital expenditures $6.8M in 2025 vs $7.5M in 2024.
• ·Dividends declared $0.20 per common share in 2025, unchanged from prior years.
• ·Basic and diluted EPS $(0.87) in 2025 vs $(1.66) in 2024.
• ·Net cash used in financing activities $41.0M in 2025.

05-03-2026

J.B. Hunt Transport Services, Inc. announced on March 5, 2026, that its common stock ($0.01 par value, symbol JBHT) has been approved for dual listing on Nasdaq Texas, LLC, with trading expected to commence on March 6, 2026. The company's principal listing will continue on the Nasdaq Global Select Market tier of the Nasdaq Stock Market LLC under the same symbol. This update was furnished under Regulation FD with an attached press release.

05-03-2026

BBOT reported Q4 and FY 2025 financial results with cash and equivalents of $425.5M, providing runway into 2028, and highlighted positive preliminary clinical data including 65% ORR for BBO-8520 monotherapy in KRASG12C NSCLC and a confirmed PR in PDAC for BBO-11818. However, net loss widened to $38.8M in Q4 2025 (up ~97% YoY) and $134.0M for FY 2025 (up ~80% YoY), driven by R&D expenses rising 95% to $38.1M in Q4 and 66% to $121.2M for the year due to clinical and manufacturing costs. Updated data readouts across all three programs are expected in H2 2026.

• ·BBO-8520 received FDA Fast Track designation on January 9, 2025 for KRASG12C mutated metastatic NSCLC.
• ·83% of BBO-8520 monotherapy patients eligible for 6-month follow-up remained on treatment ≥6 months.
• ·BBO-11818 showed 56% tumor reduction in PDAC patient with confirmed PR.
• ·BBO-10203 showed no hyperglycemia and full target engagement in Phase 1 trial.

05-03-2026

Perpetua Resources Corp. filed an 8-K announcing Amendment No. 1 to the Engineering, Procurement, and Construction Management Services Agreement between Perpetua Resources Idaho, Inc. and Hatch Ltd., effective February 28, 2026, with details in Exhibit 10.1 (portions redacted and schedules omitted). No specific financial terms, contract prices, budgets, or performance impacts were disclosed in the filing. Forward-looking statements reference uncertainties around scope, contract price, control budget, and POX/O2 System allocation.

• ·Filing date: March 5, 2026
• ·Agreement execution date: February 28, 2026
• ·Items reported: 1.01 (Entry into Material Definitive Agreement), 9.01 (Financial Statements and Exhibits)

05-03-2026

Total revenues grew 53% YoY to $14.6M in 2025 from $9.5M in 2024, driven by collaboration revenues surging 67% to $13.6M, though royalties, license and other revenues declined 30% to $0.9M. Operating expenses increased 65% to $51.2M, including a $14.8M impairment of intangible assets and R&D up 42% to $17.7M, while G&A was nearly flat up 2%; this contributed to a net loss attributable to Lineage of $63.5M or $(0.28) per share, widening sharply from $18.6M or $(0.09) due to a $35.7M unfavorable change in warrant liability. Cash and equivalents decreased to $40.8M from $45.8M, with shareholders' equity dropping to $43.3M from $77.0M.

• ·Cash used in operating activities improved to $(18.9M) from $(23.1M) YoY.
• ·Financing activities provided $27.0M in 2025 vs $35.9M in 2024.
• ·Warrant liabilities increased to $43.9M as of Dec 31, 2025 from $6.2M.
• ·Intangible assets, net decreased to $31.7M from $46.5M.
• ·Income tax benefit of $5.3M in 2025.

05-03-2026

Weave Communications, Inc. reported revenue growth of 17% YoY to $239M for the year ended December 31, 2025, from $204M in 2024, primarily driven by subscription and payment processing revenue which rose 17% to $229M. However, net loss was nearly flat at $28.1M versus $28.3M prior year, operating expenses increased 14% to $203M, and onboarding revenue declined 2% to $3.5M while gross margins remained deeply negative in onboarding (-153%) and phone hardware (-9%) segments. Total gross margin improved slightly to 72% from 71%.

• ·Stock-based compensation expense remained flat at $32.1M in 2025 vs. $32.2M in 2024.
• ·Incurrence of $1.7M in acquisition transaction costs and $0.9M in amortization of acquisition-related intangibles in 2025 (none in 2024).

05-03-2026

Regional Management Corp. entered into a Program Management Agreement (PMA) with Column National Association on March 2, 2026, establishing a new installment lending program where Column serves as lender of secured and unsecured loans in select states, and the Company acts as program manager and servicer, receiving marketing, processing, and servicing fees while paying platform and usage fees. Column retains control over underwriting, credit risk, and program oversight, with loans held for an initial period before potential sale to the Company. The PMA includes monthly financial covenants on liquidity and net worth, with an initial term ending March 31, 2031, and automatic two-year renewals unless terminated with 365 days' notice.

• ·The Company must establish and maintain a risk management program, including a compliance management system.
• ·Column holds originated loans for a specified hold period, serviced by the Company; post-hold, Column may offer to sell loans to the Company, which must purchase except in limited circumstances.
• ·Filing submitted on March 5, 2026, reporting event of March 2, 2026.

05-03-2026

NextCure reported full year 2025 financial results showing cash, cash equivalents, and marketable securities at $41.8M, down 39% from $68.6M in 2024 due to $49.6M cash used in operations including SIM0505 license fees, though sufficient to fund into H1 2027. R&D expenses rose 8% YoY to $44.9M from license costs and milestones, while G&A fell 19% to $12.7M; net loss was nearly flat at $55.8M versus $55.7M prior year. Positive clinical momentum includes Q2 2026 Phase 1 dose escalation data and dose optimization initiation for SIM0505 in ovarian cancer, plus H2 2026 update for LNCB74.

• ·SIM0505 acquired from Simcere in June 2025 with $18.5M license fees and milestones in R&D; NextCure holds exclusive global rights excluding Greater China.
• ·LNCB74 co-developed 50-50 with LigaChem Biosciences.
• ·Total assets $50.2M as of Dec 31, 2025 (down from $80.9M); stockholders' equity $34.9M (down from $65.5M).
• ·One-for-twelve reverse stock split on July 14, 2025.
• ·Plans to double U.S. trial sites for SIM0505 and expand to Canada and Europe in H2 2026.

05-03-2026

ContextLogic Holdings Inc. reported a Q4 FY25 net loss of $13M, widening from $2M in Q4 FY24 due to $15M G&A expenses, while full-year FY25 net loss improved to $23M from $75M in FY24 amid zero revenue in both years compared to $43M prior. As of Dec 31, 2025, cash and equivalents were $77M (up from $66M) with marketable securities at $141M (up from $83M), totaling $218M in liquidity. Post-period, the company completed its $907.5M acquisition of US Salt on Feb 26, 2026, advancing its business ownership platform strategy.

• ·Q4 FY25 G&A expenses breakdown: $7M employee-related (including $6M cash bonus and stock-based compensation for former CEO departure), $7M for strategic transactions including US Salt, $1M legal and other.
• ·FY25 net cash used in operating activities: $16M (improved from $94M FY24), with $72M proceeds from redeemable convertible Preferred Units.
• ·Total liabilities as of Dec 31, 2025: $7M (up from $5M Dec 31, 2024).
• ·Acquisition of US Salt announced Dec 8, 2025, completed Feb 26, 2026.

05-03-2026

Averin Capital Acquisition Corp., a blank check company, announced the partial exercise of its IPO over-allotment option on March 5, 2026, with underwriters purchasing 3,386,008 additional units at $10.00 each, generating $33.86M in gross proceeds. This brings total public offering units to 28,386,008 and total gross proceeds (including original IPO of 25M units for $250M and private placement of 200k units for $2M) to $283.86M, all placed in a trust account. No negative performance metrics were reported.

• ·Underwriters retain 45-day over-allotment option to purchase up to 363,992 additional units.
• ·Private Placement Units are not redeemable and exercisable on cashless basis, identical to IPO units except as disclosed in S-1 (File No. 333-293082).
• ·IPO registration statement effective February 18, 2026.

05-03-2026

CleanSpark, Inc. held its Annual Meeting of stockholders on March 3, 2026, achieving a quorum with 228,081,207.58 votes present, representing 68.19% of total voting power from 255,750,361 common shares and 78,750,000 preferred votes. All five director nominees were elected, though support varied significantly with S. Matthew Schultz receiving 159.7M votes for and only 3.7M withheld, while Larry McNeill and Dr. Thomas L. Wood each saw about 32M withheld votes amid 64.6M broker non-votes. Proposal 2 to ratify BDO USA, P.C. as auditors for the fiscal year ending September 30, 2026, passed overwhelmingly with 226M votes for versus just 1M against and 1.1M abstentions.

• ·Record date for Annual Meeting: January 9, 2026
• ·Warrants exercisable for 0.069593885 shares of common stock per warrant

05-03-2026

Galaxy Gaming, Inc. (GLXZ) provided an update on its pending merger with Evolution Malta Holding Limited via Galaga Merger Sub, Inc., originally agreed on July 18, 2024 (amended November 25, 2025), stating active engagement with gaming regulators to meet the Gaming Approval Closing Condition and anticipating closure prior to the July 17, 2026 Outside Date. No completion has occurred yet, with termination possible if unmet by the Outside Date. The filing includes extensive cautionary language on risks such as regulatory delays, operational disruptions, and potential termination.

• ·Merger Agreement filed as Exhibit 2.1 on July 18, 2024 8-K
• ·Amendment No. 1 filed as Exhibit 2.1 on November 25, 2025 8-K
• ·Gaming regulatory approvals remain the key unsatisfied closing condition

05-03-2026

Metagenomi, Inc. reported collaboration revenue declining 52% YoY to $25.2M in FY2025 from $52.3M in FY2024, primarily due to drops from Ionis (-19% to $24.6M), elimination of Moderna revenue, and Affini-T (-82% to $0.6M), resulting in a widened net loss of $87.9M versus $78.1M prior year. However, total operating expenses decreased 14% to $121.2M driven by lower R&D (-14% to $94.4M) and G&A (-16% to $26.8M), while net cash used in operations improved to $88.9M outflow from $109.1M, leading to a $14.3M net cash increase. Stockholders' equity stood at $158.6M, down from $234.9M, with total assets at $221.1M.

• ·Moderna collaboration revenue dropped to $0 from $18.7M in FY2024.
• ·Affini-T collaboration revenue declined to $0.6M from $3.1M.
• ·Cash and cash equivalents increased to $41.7M from $27.4M, but available-for-sale marketable securities fell to $119.1M from $220.9M.
• ·Stock-based compensation expense decreased to $11.9M from $16.2M.
• ·Net cash provided by investing activities was $103.5M in FY2025 versus ($88.2M) use in FY2024.

05-03-2026

On February 28, 2026, David J. Shulkin, M.D. notified the Board of Directors of OraSure Technologies, Inc. (OSUR) of his resignation as director and member of the Compensation Committee, effective March 2, 2026. The resignation is not due to any dispute or disagreement with the Board, the Company, or its management. The Board expressed thanks for Dr. Shulkin's years of service and contributions.

• ·Filing signed on March 5, 2026.

05-03-2026

Nutex Health reported robust full-year 2025 results with total revenue surging 82.4% YoY to $875.3 million, driven by hospital division revenue up 188.0% to $844.2 million, Adjusted EBITDA up 152.6% to $259.6 million, and net cash from operations at $248.1 million. However, Q4 2025 revenue fell 41.1% YoY to $151.7 million due to a $55.0 million arbitration true-up and prior period award timing, with operating income down sharply to $30.9 million and Adjusted EBITDA declining 80.8% to $16.6 million; mature hospital visits were flat at +1.3% FY and declined 0.3% in Q4. The company announced a second stock repurchase program of up to $25.0 million over the next six months.

• ·Diluted EPS $10.48 FY 2025 vs. $9.69 FY 2024
• ·Remediated all previously disclosed material weaknesses in internal controls over financial reporting in 2025
• ·Submitted 50-60% of claims through IDR process, prevailing in over 85% of determinations with 85% collection rate
• ·Conference call scheduled for March 6, 2026 at 9:30 a.m. CT
• ·Total assets $918.5M and equity $423.4M as of Dec 31, 2025

05-03-2026

On March 3, 2026, the Compensation Committee of DMC Global Inc. approved cash-based long-term incentive awards to named executive officers James O’Leary (CEO), Eric Walter (CFO), Ian Grieves (President, DynaEnergetics), and Antoine Nobili (President, NobelClad), substituting for equity awards due to insufficient shares available under the 2025 Omnibus Incentive Plan. The time-based cash awards vest one-third annually over three years, while Grieves and Nobili received performance-based cash awards tied to Adjusted EBITDA and Free Cash Flow targets (0-200% payout potential); O’Leary and Walter also got equity performance awards consistent with prior practices. No specific award values were disclosed.

• ·Cash Awards granted pursuant to new award agreements approved by the Committee.
• ·Performance goals for Grieves and Nobili based on three-year Adjusted EBITDA and Adjusted Free Cash Flow targets specific to DynaEnergetics or NobelClad.

05-03-2026

Core Laboratories Inc. adopted its First Amended and Restated Bylaws on February 27, 2026, effective under Delaware law, with updates to provisions on registered offices, stockholder meetings (annual and special), record dates, notices, quorums, proxies, and nomination procedures. The filing under Items 5.03 and 9.01 of Form 8-K on March 05, 2026, discloses no financial impacts or material changes beyond standard governance refinements. No quantitative performance metrics, improvements, declines, or flat results are reported.

• ·Bylaws permit Board to adjourn, postpone, reschedule, or cancel stockholder meetings without reason
• ·Stockholder notice for nominations/business: 90-120 days prior to annual meeting anniversary
• ·Quorum: majority voting power of outstanding shares; abstentions/broker non-votes count for quorum presence

05-03-2026

TransDigm Group Incorporated held its 2026 Annual Meeting of Stockholders on March 5, 2026, electing ten directors (David A. Barr, Jane M. Cronin, Michael Graff, Sean P. Hennessy, W. Nicholas Howley, Michael J. Lisman, Gary E. McCullough, Peter J. Palmer, Michele L. Santana, Robert J. Small), ratifying Ernst & Young LLP as independent auditors for the fiscal year ending September 30, 2026, and approving executive compensation on an advisory basis. All proposals passed with strong majority FOR votes ranging from 46.2M to 51.6M, though support varied with Gary E. McCullough receiving the highest WITHHOLD votes at 4,029,140. Broker non-votes were consistent at 2,616,917 for director elections.

• ·Proposal 1 director elections: FOR votes ranged from 46,187,687 (McCullough) to 49,861,805 (Lisman); WITHHOLD from 355,022 (Lisman) to 4,029,140 (McCullough)
• ·Proposal 2: ABSTAIN 12,544 votes
• ·Proposal 3: ABSTAIN 20,962 votes; AGAINST 1,612,610 votes

05-03-2026

Fair Isaac Corporation (FICO) filed a Certificate of Amendment to its Restated Certificate of Incorporation, approved by the Board and stockholders at the 2026 Annual Meeting of Stockholders. The amendments remove Section 6(d), which previously required a 66-2/3% supermajority vote of voting power to amend or repeal Article 6, and add a new Article 8 providing exculpation for officers from monetary damages for breaches of fiduciary duty, subject to standard exceptions (e.g., duty of loyalty breaches, bad faith, improper benefits). The certificate was executed on March 4, 2026, with the 8-K filed on March 5, 2026.

• ·Amendments adopted in accordance with Section 242 of the Delaware General Corporation Law (DGCL).
• ·Annual Meeting held upon notice in accordance with Section 222 of the DGCL.

05-03-2026

On March 4, 2026, the Board of Directors of Rush Enterprises, Inc. approved cash bonus payments totaling $5.3M to four key executives for 2025 fiscal year performance, with CEO W. M. 'Rusty' Rush receiving $3.5M. The Compensation Committee also approved stock option grants totaling 65,000 shares and restricted stock awards (RSAs) totaling 114,400 shares under the 2007 Long-Term Incentive Plan, vesting in three equal annual installments starting from the first or third anniversary of the March 13, 2026 grant date. Senior Advisor Michael J. McRoberts will receive additional RSAs valued at $250,000 based on Class B stock price.

• ·Cash bonuses payable on March 13, 2026.
• ·Stock options exercise price equals Class A closing price on March 13, 2026 grant date; vest in three equal annual installments starting third anniversary.
• ·RSAs are for Class B shares; vest in three equal installments starting first anniversary.
• ·Compensation based on review of 2025 fiscal year operating results and competitive market data.

05-03-2026

Matador Resources Company (NYSE: MTDR) announced the expiration of its cash tender offer for any and all of its $500M outstanding 6.875% Senior Notes due 2028, with $419.7M (84%) validly tendered and accepted for purchase at $1,019.75 per $1,000 principal plus accrued interest. The company expects to settle payments on March 5, 2026, for most notes and March 9, 2026, for $4.5M subject to guaranteed delivery procedures. Matador intends to redeem any remaining notes on April 15, 2026, and cancel all accepted notes.

• ·Tender Offer expired at 5:00 p.m., New York City time, on March 4, 2026.
• ·Interest on accepted Notes ceases to accrue on the Settlement Date.

05-03-2026

At AECOM's 2026 Annual Meeting on March 3, 2026, stockholders elected eight director nominees with strong majorities (FOR votes ranging from 83.2M to 105.7M shares), ratified Ernst & Young LLP as auditors for FY ending September 30, 2026 (104.9M FOR), and approved executive compensation on an advisory basis (99.1M FOR). However, Bradley W. Buss faced significant opposition with 21.9M AGAINST votes, while others had minimal dissent. The Board also declared a quarterly cash dividend of $0.31 per share, payable April 17, 2026 to shareholders of record on April 1, 2026.

• ·Proxy statement filed January 20, 2026
• ·All directors elected to serve until 2027 annual meeting
• ·Fiscal year for auditors ends September 30, 2026

05-03-2026

Samsara Inc. reported Q4 FY2026 revenue of $444.3 million, up 28% YoY (27% constant currency), with ending ARR reaching $1.890 billion, up 30% YoY, and achieving GAAP profitability of $0.04 per share for the second consecutive quarter. However, GAAP and non-GAAP gross margins both declined 1 percentage point to 76% and 77%, respectively, while operating cash flow and adjusted free cash flow margins remained flat at 14-16%. Full year FY2026 revenue grew 30% YoY to $1.619 billion, though GAAP operating margin was still negative at -3%.

• ·Q4 net cash provided by operating activities $69.7M, up from $53.9M YoY, margin flat at 16%.
• ·FY2026 adjusted free cash flow $208.7M, margin 13%, up from 9% YoY.
• ·Q1 FY2027 guidance: revenue $454M-$456M (+24% YoY), non-GAAP operating margin 15%.
• ·FY2027 guidance: revenue $1.965B-$1.975B (+21-22% YoY), non-GAAP net income per share diluted $0.65-$0.69.

05-03-2026

Atea Pharmaceuticals reported Q4 and FY 2025 financial results, showing cash and investments declining 33.6% to $301.8M from $454.7M amid ongoing R&D investments, with full-year R&D expenses up 2.7% to $148.0M (nearly flat YoY) and G&A down 32.6% to $32.9M, resulting in a narrower FY net loss of $158.3M versus $168.4M prior year but a wider Q4 loss of $44.9M from $33.5M. The company advanced its global Phase 3 HCV program, completing enrollment of over 880 patients in the North American C-BEYOND trial (topline mid-2026) and nearing completion in C-FORWARD (topline year-end 2026), while expanding its pipeline with HEV lead AT-587 entering clinic mid-2026. Phase 2 data reinforced BEM/RZR's potential with 98% SVR12 in per-protocol population.

• ·C-BEYOND enrollment completed December 2025; C-FORWARD enrollment expected mid-2026.
• ·AT-587 and AT-2490 showed 30-150-fold higher potency against HEV vs sofosbuvir and ribavirin in vitro.
• ·Approximately 450,000 patients/year in US/Europe with conditions risking chronic HEV (3% at risk).

05-03-2026

Trio Petroleum Corp updated its Prospectus Supplement for an ATM Agreement with Ladenburg Thalmann & Co. Inc. via three amendments filed March 3-5, 2026, reflecting cumulative sales of 15,348,345 shares of common stock for $13,376,774 since January 9, 2026, leaving $4,000,000 available for sale out of a maximum aggregate offering of $17,377,000. This represents significant share issuance and dilution for existing shareholders, with no additional financial performance metrics disclosed.

• ·ATM Agreement dated January 9, 2026, under Registration Statement effective September 10, 2024 (File No 333-281813).
• ·Amendments filed: No. 1 on March 3 ($3,292,000 available), No. 2 on March 4 ($6,485,000 available), No. 3 on March 5.
• ·Trading symbol: TPET on NYSE American.

05-03-2026

Profound Medical reported record Q4 2025 revenue of $6.0 million, up 43% YoY from $4.2 million and 13% QoQ, with full-year 2025 revenue of $16.1 million, a 50% increase from $10.7 million in 2024, supported by $9.7 million in recurring revenue and growth in TULSA-PRO installed base to 78 systems. However, Q4 gross margin declined to 67% from 71% YoY due to product mix and new market pricing, operating expenses edged up to $11.4 million from $11.3 million, and net loss widened to $8.2 million ($0.27/share) from $4.9 million ($0.20/share), with full-year net loss expanding to $42.6 million ($1.41/share) from $27.8 million ($1.12/share). The company bolstered liquidity with $42.45 million in equity financings and anticipates reaching 120 TULSA-PRO installs by end-2026 amid a pipeline of 110 systems.

• ·TULSA-PRO patient mix in Q4 2025: 67% prostate cancer only, 17% hybrid cancer/BPH, 13% salvage, 3% BPH only.
• ·Strategic distribution agreements: Exclusive rights regained in Canada; new deals in Saudi Arabia with FMS/AFG and Australia/NZ with Getz Healthcare.
• ·U.S. CMS reimbursement for TULSA Procedure at Urology APC Level 7.
• ·4,000th TULSA Procedure patient treated.
• ·Kris Shah resigned from Board; Frank Baylis appointed as successor.

05-03-2026

AudioEye reported record FY 2025 revenue of $40.3M, up 15% YoY from $35.2M, with net loss narrowing 28% to $3.1M and adjusted EBITDA rising 35% to $9.1M. Q4 2025 revenue grew 8% to a record $10.5M from $9.7M, adjusted EBITDA hit $2.8M (up 22%), but gross margins slightly declined to 79% from 80% YoY while operating expenses remained flat at $9.1M. ARR reached $40M (up sequentially), customers totaled 131,000 (up 4,000 YoY), with FY 2026 guidance of $43-44.5M revenue and at least 30% adjusted EBITDA growth.

• ·Customer count increased 8,000 sequentially from Sep 30, 2025 and 4,000 YoY from Dec 31, 2024, driven by Partner and Marketplace channel.
• ·Q1 2026 guidance: revenue $10.5-10.6M, adjusted EBITDA $2.2-2.3M, adjusted EPS $0.17-0.18.
• ·FY 2025 operating expenses up 7% to $33.4M from $31.3M.
• ·Independent study: AudioEye detects 89-253% more WCAG issues than competitors.

05-03-2026

USA Rare Earth, Inc. (USAR) announced a definitive agreement to acquire all outstanding shares of Texas Mineral Resources Corp. (TMRC) for 3,823,328 shares of USAR common stock, implying a total deal value of $73M and granting USAR 100% control of the Round Top Project, including TMRC's prior 18.6% interest, 950 acres of leases, and 9,345 acres of prospecting rights. The transaction supports USAR's Accelerated Mining Plan, targeting commercial production in 2028 and 40,000 metric tons per day of rare earth and critical mineral feedstock by 2030. However, closing is expected no later than Q3 2026 subject to TMRC stockholder approval and customary conditions, amid forward-looking risks including going concern doubts for both companies.

• ·All TMRC directors and executive officers have entered voting support agreements to approve the transaction.
• ·USAR selected Fluor Corp. and WSP Global Inc. in January 2026 as EPCM partners for Round Top's Definitive Feasibility Study.
• ·Round Top operated under long-term lease with Texas General Land Office, supporting Texas Permanent School Fund.

05-03-2026

ICF International, Inc. announced its participation as a presenter at the Canaccord 2nd Annual CG Virtual Sustainability Summit on March 12, 2026, with availability via live audio webcast. Instructions for accessing the webcast are included in the attached press release (Exhibit 99.1). No financial or operational metrics were disclosed.

• ·Filing submitted under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• ·Event reported date: March 5, 2026.
• ·Webcast information furnished, not filed, per Regulation FD.

05-03-2026

RYAM's 2025 net sales declined 10% YoY to $1,466M from $1,630M, with gross margin dropping 28% to $119M (8.1% of sales) from $166M (10.2%), driven by lower volumes across most segments despite price gains in Cellulose Specialties. Operating income fell 90% to $4M from $39M, culminating in a net loss of $420M versus $39M loss in 2024, primarily due to a $323M tax expense. While Cellulose Specialties operating income remained resilient at $160M, other segments like Cellulose Commodities and Paperboard posted operating losses and sales declines.

• ·2024 Notes ($550M) and 2026 Notes ($500M) fully redeemed.
• ·2027 Term Loan ($250M) fully redeemed November 2024.
• ·Income from discontinued operations $3M in 2025.
• ·Asset impairment $0 in 2025 vs $25M in 2024.

05-03-2026

OptimizeRx reported Q4 2025 revenue of $32.2 million, flat YoY compared to $32.3 million, but achieved record GAAP net income of $5.0 million (from a $0.1 million loss) and adjusted EBITDA of $12.0 million (up from $8.8 million). Full year 2025 revenue grew 19% YoY to $109.4 million with adjusted EBITDA more than doubling to $24.3 million from $11.7 million, alongside operating cash flow of $18.7 million (up from $4.9 million). The company issued flat 2026 revenue guidance of $109-114 million, noted declining KPIs like average revenue per top 20 pharma manufacturers (down to $2.838 million from $2.976 million) and net revenue retention (116% from 121%), and authorized a $10 million share repurchase program.

• ·Total assets increased to $176.9M from $171.2M as of Dec 31, 2025.
• ·Long-term debt, net decreased to $21.4M from $30.8M as of Dec 31, 2025.
• ·Share repurchase program effective March 12, 2026, expires March 15, 2027 or upon $10M repurchased.
• ·2026 guidance: Revenue $109-114M, Adjusted EBITDA $21-25M.

05-03-2026

Wheeler Real Estate Investment Trust, Inc. (WHLRL) reported 2025 revenues of $99.4M, down 4.9% YoY from $104.6M, with net operating income declining 4.2% to $66.4M and operating cash flow dropping 18.7% to $21.1M amid a reduction in owned retail centers from 72 to 62. However, net income surged to $14.8M from $0.7M, driven by $14.4M gain on property disposals (up 158.6% YoY), while total debt decreased slightly to $482.8M and FFO available to common stockholders rose to $13.7M. Same-Property NOI grew modestly 1.6% to $60.2M, but impairment charges more than doubled to $2.9M.

• ·Series D Preferred Stock shares decreased to 107,522 in 2025 from 187,410 in 2024.
• ·Impairment charges increased 141.0% YoY to $2.9M.
• ·Interest expense rose 3.5% YoY to $33.8M.
• ·Weighted average rate increase on renewals improved to 11.7% from 9.5%.
• ·New leases sq ft increased to 252,374 from 230,953, with weighted avg change over prior rates at 26.4%.
• ·AFFO increased to $10.3M from $7.2M.

05-03-2026

Ring Energy reported FY 2025 sales volumes up 3% YoY to a record 20,253 Boe/d with oil flat at 13,263 Bo/d, record Adjusted Free Cash Flow of $50.1M (+15% YoY), and proved reserves up 14% to 153.3 MMBoe, while reducing debt by $40M since the Lime Rock acquisition and capex by 35% to $98.2M. However, revenues declined 16% YoY to $307.2M due to 18% lower realized prices, resulting in a net loss of $34.7M including $108.8M in non-cash impairments, and Q4 net loss of $12.8M with $35.9M impairment. For 2026, guidance targets flat production midpoint of 20,150 Boe/d and $115M capex.

• ·Q4 2025 LOE $10.02 per Boe, 11% below Q4 2024 and 7% below guidance low end
• ·Hedged 48% of 2026 oil sales guidance midpoint at $65.21 average downside protection
• ·Hedged 66% of 2026 natural gas sales guidance midpoint at $3.79 average downside protection
• ·Next borrowing base redetermination scheduled for May 2026

05-03-2026

PreAxia Health Care Payment Systems Inc. dismissed Sadler Gibb & Associates as its independent auditor on February 19, 2026, after a brief engagement from December 23, 2025, due to missed filing deadlines and unresolved discussions on valuation, materiality, and identified errors in prior financial statements for periods ended May 31, 2025, and August 31, 2025. The company immediately engaged M&K CPAs on February 20, 2026, marking another auditor change following Fruci & Associates II's termination on December 9, 2025, and GreenGrowth CPAs' resignation on October 25, 2024, with Sadler Gibb noting the circumstances as a reportable event. PreAxia is in communications with the SEC Office of Chief Accountant regarding these issues.

• ·Sadler Gibb served from December 23, 2025, through February 19, 2026, and issued no reports.
• ·Fruci audited year ended May 31, 2025; no disagreements.
• ·GreenGrowth audited year ended May 31, 2024; resigned October 25, 2024; no disagreements.
• ·Errors identified in Q ended August 31, 2025 (filed October 21, 2025, amended October 24, 2025) and year ended May 31, 2025 (filed September 12, 2025).

05-03-2026

CooperCompanies reported Q1 FY26 revenue of $1.024B, up 6% YoY (3% organically), driven by 8% growth in CooperVision ($695.1M) including 10% in toric/multifocal, but CooperSurgical grew only 3% ($329M) and Asia Pacific revenues declined 4%. GAAP diluted EPS rose 27% to $0.66 and non-GAAP EPS increased 20% to $1.10, with operating margins improving to 21% (27% non-GAAP); however, non-GAAP gross margin dipped 60 bps to 68%. The company raised FY26 guidance for revenue to $4.306-$4.346B (4.5-5.5% organic growth), non-GAAP EPS to $4.58-$4.66, and free cash flow to $600-$625M, while repurchasing $92.5M in shares.

• ·Interest expense $22.4M, down from $26.0M YoY.
• ·Capital expenditures $102.2M in Q1 FY26.
• ·CVI Americas up 6% organically, EMEA up 4%.
• ·CSI Office and surgical up 2% organically, Fertility up 3%.
• ·FY26 CVI guidance $2.906-$2.932B (4.5-5.5% organic), CSI $1.400-$1.413B (4.0-5.0% organic).

05-03-2026

FS KKR Capital Corp filed an 8-K on March 5, 2026, under Item 7.01 Regulation FD Disclosure, announcing that investor presentations will be made available on its website (www.fskkrcapitalcorp.com) after market close on the same day, located under the 'Events & Presentations' page in the 'For Investors' section. The filing includes standard forward-looking statements disclaimers but provides no specific financial data or performance metrics. No updates or revisions to the presentations are planned unless required by federal securities laws.

• ·Presentations accessible at www.fskkrcapitalcorp.com under 'Events & Presentations' in 'For Investors' section
• ·Company's common stock trades on New York Stock Exchange under symbol FSK

05-03-2026

One Liberty Properties reported FY2025 net income of $25.5M ($1.15/share), down 16.3% YoY due to higher impairments and interest expense, while FFO rose 3.0% to $39.2M ($1.80/share) and AFFO increased 1.0% to $41.6M ($1.91/share, flat YoY). In Q4, net income fell 77.1% to $2.4M ($0.10/share), FFO grew 8.2% to $10.8M ($0.50/share), but AFFO declined 4.3% to $10.4M ($0.48/share). The company advanced its industrial focus to 82% of ABR, acquiring 23 industrial properties for $245.5M in 2025 and post-year-end while selling non-core assets for $61.3M net proceeds, with portfolio occupancy at 98.5%.

• ·Extended or renewed leases for 888,000 sq ft in 2025.
• ·Entered contracts to sell vacant retail property for $6.0M (expected gain $2.5M) and retail property for $4.2M (expected gain $1.3M).
• ·Acquired 14 acres land for $800,000 post-year-end.
• ·New mortgage debt of $17.0M at 5.53% on six properties maturing 2033.

05-03-2026

MetLife, Inc. issued a news release on March 5, 2026, confirming its previously announced declaration of a first quarter 2026 dividend of $0.31501229 per share on its Floating Rate Non-Cumulative Preferred Stock, Series A, which carries a $25 liquidation preference per share. The release is attached as Exhibit 99.1. No other financial metrics or comparisons were provided.

• ·Filing includes Inline XBRL cover page (Exhibit 101) and Cover Page Interactive Data File (Exhibit 104)

05-03-2026

Drilling Tools International Corp. (DTI) reported FY2025 consolidated revenue of $159.6M, up 3% YoY from $154.4M, with Tool Rental revenue growing 10% to $129.6M, but Product Sales declining 18% to $30.1M; the company posted a net loss of $3.8M versus $3.0M profit in 2024. Adjusted EBITDA reached $39.3M and Adjusted Free Cash Flow was $19.2M, while Q4 2025 revenue fell 3% YoY to $38.5M but delivered net income of $1.2M versus a Q4 2024 loss. Despite a 7% global rig count decline, DTI reduced net debt to 1.1x trailing Adjusted EBITDA after $11M paydown and $0.66M share buybacks, with Eastern Hemisphere revenue doubling to 14% of total.

• ·2026 outlook: Revenue $155M-$170M, Adjusted EBITDA $35M-$45M (23-26% margin), Adjusted FCF $17M-$22M.
• ·Cash $3.6M and accounts receivable $37.7M as of Dec 31, 2025 (down from $6.2M cash in 2024).
• ·Conference call scheduled for March 6, 2026 at 10:00 a.m. ET.

05-03-2026

American Tower Corporation announced via press release that its Board of Directors declared a cash distribution of $1.79 per share on its common stock. The dividend is payable on April 28, 2026, to stockholders of record at the close of business on April 14, 2026. No comparative financial metrics or performance data were provided in the filing.

• ·Filing signed by Rodney M. Smith on March 5, 2026
• ·Common stock trades on NYSE under symbol AMT

05-03-2026

Clarus reported Q4 2025 sales of $65.4 million, down 8% YoY from $71.4 million, with Outdoor segment sales down 8% to $47.2 million (apparel up 10%) and Adventure segment down 10% to $18.2 million; adjusted EBITDA fell to $1.2 million (1.8% margin) from $4.4 million (6.1%). Full year 2025 sales declined 5% to $250.4 million from $264.3 million, with Outdoor down 3.7% and Adventure down 8.9%, while adjusted EBITDA dropped to $1.1 million (0.4% margin) from $6.9 million (2.6%), reflecting impairments, lower volumes, and margin compression to 33.1% from 35.0%. Positives include Q4 free cash flow of $11.6 million, debt-free balance sheet with $36.7 million cash, and 2026 guidance for sales of $255-265 million and adjusted EBITDA of $9-11 million.

• ·Q4 SG&A expenses down to $25.5M from $27.8M due to cost reductions.
• ·Full year SG&A down to $105.2M from $111.9M.
• ·RockyMounts acquisition contributed $1.0M incremental Q4 sales.
• ·PIEPS sold in July 2025; contributed $2.1M in 2025 vs $5.5M in 2024.
• ·2026 capex guidance $6-7M; free cash flow $3-4M.
• ·U.S. federal R&E tax credits $5.7M, expiring starting 2033.

05-03-2026

On March 2, 2026, the Board of Directors of German American Bancorp, Inc. approved the 2026 Management Incentive Plan applicable to all executive officers, including those named in upcoming proxy disclosures. The approval was made by non-interested directors upon recommendation from the Compensation/Human Resources Committee, with plan details provided in Exhibit 10.1. No specific performance metrics or financial impacts were disclosed in the filing.

05-03-2026

Littelfuse, Inc. (NASDAQ: LFUS) appointed Holly B. Paeper to its Board of Directors, effective March 4, 2026, and to the Technology Committee. Paeper, President of Commercial HVAC Americas at Trane Technologies, offers extensive leadership in thermal management, life sciences, and prior roles at Corning, Eaton, and Intel. The company employs approximately 17,000 global associates serving over 100,000 end customers.

• ·Paeper previously served as President of global Life Science Solutions at Trane Technologies (2021–2024) and held VP/General Manager roles in Commercial HVAC (2016–2021).
• ·Paeper serves on the board of Mitsubishi Trane HVAC US (METUS) and previously on LiquidStack (2023–2025).
• ·Paeper holds a BS in Electrical Engineering from University of Minnesota – Institute of Technology and MBA from University of Minnesota – Carlson School of Management.

05-03-2026

Wix.com Ltd. reported FY2025 revenues of $1.99B, up 13% YoY from $1.76B, with Creative Subscriptions growing 12% to $1.41B and Business Solutions up 18% to $583M. However, operating income declined 98% to $1.8M amid a 24% rise in operating expenses to $1.35B (R&D up 30%), leading to net income of $51M, down 63% YoY from $138M. Bookings increased 13% to $2.07B and free cash flow rose 20% to $573M, while cash from operations grew 17% to $583M.

• ·Net cash used in investing activities was $902M in FY2025, compared to $35M in FY2024.
• ·Income tax benefit of $51M in FY2025 vs expense of $14M in FY2024.
• ·Gross profit margin improved slightly to 68.1% from 67.9%.

05-03-2026

ISG reported Q4 2025 GAAP revenues of $61.2M, up 6% YoY from $57.8M, driven by 28% growth in Europe to $19.1M, though Americas grew only 1% to $38.3M and Asia Pacific declined 22% to $3.9M; adjusted EBITDA rose 24% to $8.1M. Full-year revenues fell 1% to $244.7M (up 7% excluding divested automation unit), with adjusted EBITDA up 28% to $32.2M and cash from operations up 46% to $29M, but Asia Pacific revenues down 13% to $18.3M. The company acquired the AI Maturity Index platform in January 2026 and provided Q1 2026 guidance of $60.5M-$61.5M revenues and $7.5M-$8.5M adjusted EBITDA.

• ·Q4 GAAP net income $2.6M and EPS $0.05 vs prior year $3.0M and $0.06 (prior included $2.3M gain from automation sale); adjusted EPS $0.08 vs $0.06.
• ·FY GAAP operating income $17.8M vs $5.8M prior; adjusted net income $16.5M and EPS $0.33 vs $10.0M and $0.20.
• ·Q4 dividends paid $2.2M, share repurchases $2.3M.
• ·Q1 dividend $0.045/share payable March 26, 2026 to record March 20, 2026.
• ·Q1 2026 guidance: revenues $60.5M-$61.5M, adjusted EBITDA $7.5M-$8.5M.

05-03-2026

Copper Property CTL Pass Through Trust announced a cash distribution of $0.082844 per trust certificate, payable on March 10, 2026 to certificateholders of record as of March 9, 2026, via a press release (Exhibit 99.2). The Trust also made available its monthly report for the period ending February 28, 2026 on its investor website (www.ctltrust.net), attached as Exhibit 99.1. No comparative financial performance data was disclosed in the filing.

• ·Monthly report covers period ending February 28, 2026; dated March 9, 2026.
• ·Investor website: www.ctltrust.net
• ·Filing signed on March 5, 2026.

05-03-2026

Net interest income rose $4.7M YoY to $51.2M for 2025, with net interest margin expanding to 3.12% from 2.73%, driven by favorable rates despite lower volumes. However, average loans declined to $1.35B from $1.43B, total interest income fell $2.0M to $87.6M, and nonperforming assets increased to $16.7M from $14.3M. Non-interest income grew 10.25% to $11.1M supported by gains on loan sales (+32%), while non-interest expenses edged up 1.49% to $42.9M.

• ·Capital ratios remain strong: Total capital 14.6% (2025) vs 15.6% (2024), all well above well-capitalized thresholds.
• ·CRE portfolio: $443M Non-Owner Occupied, $240M Owner-Occupied, with criticized loans at 1.4%-7.9% of segments.
• ·Net loan recoveries of $58k in 2025 vs net charge-offs of $100k in 2024; NCOs (annualized) 0.00% vs (0.01)%.

05-03-2026

Upexi, Inc. issued a press release on March 3, 2026, announcing that members of its management team will participate in the Webull Digital Asset Treasury Crypto Webinar on March 12, 2026, and the 38th Annual ROTH Conference from March 22-24, 2026. The press release includes details on participating management members and webcast information, furnished as Exhibit 99.1.

• ·Filing signed by Andrew J. Norstrud on March 5, 2026
• ·Information in Item 7.01 and Exhibit 99.1 is furnished, not filed

05-03-2026

Azitra, Inc. (NYSE American: AZTR) canceled its adjourned Special Meeting of Stockholders, originally held February 6, 2026 but lacking quorum and rescheduled for March 6, 2026, and withdrew all proposals from its January 2, 2026 definitive proxy statement. The announcement was made via a March 5, 2026 press release filed as Exhibit 99.1, signaling potential challenges in shareholder engagement with no further reconvening planned.

• ·Azitra is an emerging growth company under Rule 405/12b-2.
• ·Special Meeting convened February 6, 2026, adjourned due to insufficient quorum.
• ·Definitive proxy statement filed January 2, 2026; Annual 10-K filed February 27, 2026.

05-03-2026

Monroe Capital Corporation (MRCC) reported Q4 2025 net investment income (NII) of $2.2M ($0.10/share), up 22% QoQ from $1.8M ($0.08/share), with Adjusted NII at $2.3M ($0.11/share), but net operations loss widened to $(2.6M) ($0.12/share) from $(1.1M) amid NAV decline to $166.5M ($7.68/share, down 3.8% QoQ). Full year 2025 NII plunged 53% YoY to $11.4M ($0.53/share) from $24.5M ($1.13/share), swinging to a net operations loss of $(5.1M) ($0.24/share) versus a $9.7M gain prior year, driven by lower investment income and mark-to-market losses. MRCC anticipates closing its merger with Horizon Technology Finance (HRZN) in late Q1 or early Q2 2026 and declared a reduced Q1 dividend of $0.09/share payable March 31, 2026.

• ·Portfolio average mark improved to 89.7% of amortized cost at Dec 31, 2025 from 88.3% at Sep 30, 2025 but declined 2.5% YoY from 92.2%.
• ·Weighted average contractual yield declined to 9.4% from 9.9% QoQ; effective yield to 8.4% from 8.8%.
• ·SLF return of capital distributions totaled $28.3M in Q4 2025, including $10.2M in-kind.
• ·Revolving credit facility amended Jan 14, 2026; 2026 Notes fully redeemed Jan 15, 2026.
• ·Definitive joint proxy statement filed Jan 20, 2026 for asset sale to MCIP and merger with HRZN.

05-03-2026

Farmers National Banc Corp reported total assets of $5.16B at year-end 2025, up 1.5% from $5.09B in 2024, with average loans increasing 2% YoY to $3.29B at 5.82% yield and net interest income rising 11% to $145M with margin expanding to 2.95% from 2.69%. However, nonperforming assets rose 15% to $26.3M (0.50% of assets from 0.45%), nonperforming loans increased to $26.2M (0.79% of loans from 0.70%), and stockholders' equity grew to $441M amid merger integration risks with Middlefield. Quarterly cash dividends remained flat at $0.17 per share.

• ·Commercial real estate nonaccrual loans increased to $15.8M at Dec 31, 2025 from $10.6M in 2024.
• ·Loans delinquent 30-89 days rose to $17.0M (0.51% of loans) in 2025 from $13.0M (0.40%) in 2024.
• ·Allowance for credit losses covered 142% of nonaccrual loans at Dec 31, 2025, down from 162% in 2024.
• ·Total interest-bearing deposits averaged $3.41B in 2025, up from $3.26B in 2024.

05-03-2026

Greenidge Generation Holdings Inc. reported preliminary Q4 2025 revenue of $11.5M, down $3.7M QoQ from Q3, with net income of $1.9-2.9M also declining $9.1-10.1M QoQ, though power and capacity revenue improved $0.8M QoQ to $5.6M. For FY 2025, total revenue was $58.8M, slightly down $0.8M YoY, but net income improved $24.0-25.0M YoY to $4.2-5.2M amid debt reduction from $68.5M to $36.7M and strategic progress including 100MW power approvals and NYSDEC agreement for Dresden Title V permit renewal. Bitcoin production fell to 53 in Q4 (down 42 QoQ) and 371 for FY (down 570 YoY), reflecting mixed transition to AI/HPC datacenters.

• ·Secured 60MW non-curtailable power at Dresden via grid interconnection and 40MW at Mississippi greenfield site by Q1 2027.
• ·Initiated NYISO study for additional 200MW at Dresden.
• ·Agreement with NYSDEC ensures Title V permit renewal post-public comment, compliant with NY Climate Leadership Community Protection Act.
• ·Extended C-Pond closure deadline to Oct 2027; testing at Lockwood Landfill in Q2 2026.
• ·Senior unsecured debt reduced from $157.5M in 2023 to $39.0M as of Dec 31, 2025.

05-03-2026

Lifecore Biomedical, Inc. (LFCR) reported that its Board of Directors established June 4, 2026, as the date for the 2026 Annual Meeting of Stockholders, following a fiscal year change approved on August 1, 2025, to align with the calendar year ending December 31, effective for the period from May 26, 2025, to December 31, 2025. This shifts the meeting date more than 30 days from the 2025 Annual Meeting held on October 29, 2025. Shareholder proposals and director nominations must be received by March 16, 2026, and sent to the Secretary at 3515 Lyman Blvd., Chaska, MN 55318.

• ·Fiscal year change effective for period May 26, 2025, to December 31, 2025.
• ·Proposals must comply with Rule 14a-8, Rule 14a-18, Rule 14a-19(b), Bylaws, and Delaware law.

05-03-2026

Greystone Housing Impact Investors LP's South Carolina subsidiaries (Borrowers) entered into a First Amendment to their Loan Agreement dated December 31, 2025, effective February 27, 2026, with BankUnited, N.A. as Administrative Agent and Lender, amending key definitions including Debt Service (now based on 30-year amortization), Net Operating Income (incorporating $250/unit/year replacement reserve), and covenants such as Debt Service Coverage Ratio tests (1.00:1.00 by Feb 15, 2027; 1.05:1.00 by June 30, 2027) and Loan-to-Value ratio (max 65% at maturity). The amendment confirms full funding of the Future Advance Amount, adds post-closing pledges, and requires mold remediation at specific Vietti Property units by March 31, 2026. No performance metrics, declines, or financial amounts were disclosed.

• ·Amendment effective upon payment of Future Advance Origination Fee (amount not specified).
• ·Borrower may satisfy DSCR failures via partial prepayment, cash collateral, or letter of credit, releasable after 3 consecutive months of compliance.
• ·Original Loan Agreement dated December 31, 2025; Filing Date March 05, 2026.

05-03-2026

This DEF 14A proxy statement, filed March 5, 2026, seeks shareholder approval to elect Ms. Keefe and Mr. Keith as Class I Trustees for First Trust Intermediate Duration Preferred & Income Fund (FPF), First Trust Enhanced Equity Income Fund, and First Trust Mortgage Income Fund at their annual/special meetings. It details service providers including investment advisor First Trust Advisors L.P., sub-advisors Chartwell Investment Partners (for Enhanced Equity) and Stonebridge Advisors (for FPF), administrator/custodian The Bank of New York Mellon, and transfer agent Computershare. During the last fiscal year (Oct 31, 2025 for FPF and Mortgage Income Fund; Dec 31, 2025 for Enhanced Equity), boards held 8 meetings each with audit committees at 13, but dividend and executive committees held 0; minor late Section 16(a) Form 3 filings were reported for certain sub-advisor officers and Independent Trustee Thomas J. Driscoll.

• ·By-Laws require 66-2/3% Trustee approval for matters to be proper for shareholder action at meetings.
• ·Fiscal year end: October 31 for FPF and Mortgage Income Fund; December 31 for Enhanced Equity Income Fund.
• ·Shareholder proposals for next annual meeting must be received by June 23, 2026.

05-03-2026

Methode Electronics reported fiscal Q3 2026 net sales of $233.7M, down 2.6% YoY from $239.9M, driven by Automotive segment declines of 8.2% to $106.2M and a sharp drop in Interface to $5.0M from $12.3M, partially offset by 9.5% growth in Industrial to $122.5M. Net loss widened to $15.9M from $14.4M, with adjusted EBITDA falling to $7.3M from $12.3M amid transformation costs and market disruptions. FY26 guidance was narrowed to $950M-$1B in sales and lowered to $58-62M adjusted EBITDA; post-quarter, the company closed the $16M sale of dataMate business and finalized sale of Harwood Heights facility.

• ·Net cash provided by operating activities Q3 FY26: $15.4M (down from $28.1M YoY)
• ·Free cash flow Q3 FY26: $10.1M (down from $19.6M YoY)
• ·9M FY26 free cash flow: $16.5M
• ·FY26 guidance: Interest expense $21-23M, Tax expense $17-21M, D&A $58-63M, Capex $24-29M
• ·Conference call scheduled for March 6, 2026 at 11:00 a.m. ET

05-03-2026

NIKE, Inc. approved organizational changes on February 27, 2026, to improve efficiency and reignite growth, expecting approximately $300 million in pre-tax charges for the nine months ended February 28, 2026, primarily for employee severance costs, with substantially all recognized in Q3 FY2026. The company noted these are estimates subject to assumptions and local laws, and actual charges may differ materially; additional actions could lead to further charges.

• ·Plan approved by management on February 27, 2026
• ·Charges for nine months ended February 28, 2026
• ·Substantially all charges recognized in third quarter of fiscal year 2026
• ·Company may incur additional charges in future quarters

05-03-2026

On February 27, 2026, the Tennessee Valley Authority (TVA) Board of Directors approved Mitch Graves as Chair, effective immediately with his term ending on April 1, 2027. The Board also selected Jeff Hagood as Chair Elect, who will assume the Chair role on the earlier of April 1, 2027, or when Mr. Graves is unable to serve, with his term ending on May 18, 2029.

05-03-2026

Interactive Strength Inc. (TRNR) announced the full recovery of a $5.0M loan principal plus $1.4M in interest and expenses from Sportstech Brands Holding GmbH, totaling $6.4M received and generating a net financial return after costs; however, the Sportstech acquisition did not complete as hoped. The settlement resolves all disputes, including lawsuits and a canceled share auction, allowing focus on the pending Ergatta acquisition (>$10M annual revenue, ~30% EBITDA margins), Wattbike scaling (700+ Air-Pro bikes, $2.5M UK commercial revenue since July 2025), and 2026 pro forma revenue guidance of >$30M, nearly sixfold from 2024's $5.4M.

• ·Settlement received in full as of announcement; TRNR retains no ownership in Sportstech
• ·Resolves January 2025 and May 2025 loan agreements and 100% share pledge
• ·Berlin court win preceding settlement; lawsuits to be withdrawn and March 11, 2026 share auction canceled

05-03-2026

Equinix subsidiaries issued $700M aggregate principal amount of 4.400% Senior Notes due 2031 (Singapore Finco) and $800M aggregate principal amount of 4.700% Senior Notes due 2033 (Europe 2 Finco), both fully guaranteed by Equinix, Inc., for a total of $1.5B. Post-issuance currency swaps reduced effective rates to approximately 2.6% for the 2031 Notes and 3.6% for the swapped portion of the 2033 Notes. The notes feature semi-annual interest payments starting September 15, 2026, standard redemption options after par call dates, and covenants limiting liens, asset sales, and sale-leasebacks.

• ·2031 Notes mature March 15, 2031; par call date February 15, 2031
• ·2033 Notes mature March 15, 2033; par call date January 15, 2033
• ·Underwriting agreements dated February 19, 2026; Indentures supplemented March 5, 2026
• ·Notes rank equally with other unsecured senior debt; structurally subordinated to subsidiary liabilities
• ·Events of default allow acceleration by Trustee or 25% holders

05-03-2026

FreeCast, Inc. disclosed updates on its revolving convertible promissory note with Nextelligence, Inc., controlled by CEO William A. Mobley, Jr., with the outstanding principal increasing from an initial $1.3M on November 21, 2025, to $2.7M as of January 19, 2026, and further to $4.4M as of March 5, 2026, approaching the $5M cap. The note carries 12% annual interest, is due June 30, 2026, and is convertible into Class A common stock at $8.00 per share at Nextelligence's option. This related-party debt accumulation highlights ongoing funding needs but raises concerns over repayment obligations and potential dilution.

• ·Note prepayment allowed with 5 days prior notice.
• ·Default triggered by non-compliance or bankruptcy events.
• ·Conversion price adjusts proportionately for stock splits or combinations.
• ·Note due no later than June 30, 2026.

05-03-2026

Nomadar Corp. (NOMA) entered into a subscription agreement on February 27, 2026, for a private placement offering of up to $5.4M in class A common stock at $3.65 per share, representing up to 1,480,937 shares across three tranches. The first tranche closed on March 3, 2026, issuing 584,969 shares. The second and third tranches are scheduled for March 31, 2026, and April 30, 2026, respectively, under Regulation D exemption.

• ·Securities sold under Section 4(a)(2) or Regulation D exemption from registration.
• ·Common stock par value $0.00001 per share.
• ·Emerging growth company status confirmed.

05-03-2026

T Stamp Inc. completed the acquisition of 100% of Lexverify Ltd., a UK-based private company, on February 27, 2026, through a share purchase agreement payable entirely in Class A Common Stock structured as 25% upfront (Completion Consideration) and 75% deferred in three equal tranches over 90, 180, and 270 days. The deal, described as limited in size, aims to add expertise in training and using large language models while providing UK market access. No specific purchase price dollar amount was disclosed, and deferred payments are subject to potential withholdings for warranties or set-offs.

• ·Certain Lexverify sellers agreed to 12-month non-compete and non-solicit restrictions post-Closing.
• ·Company committed to approving continuing employment of Lexverify employees on substantially similar compensation, benefits, and equity terms.
• ·Deferred Consideration accelerates upon change of control of T Stamp Inc.

05-03-2026

O-I Glass, Inc. announced an organizational change where Arnaud Aujouannet will cease serving as Senior Vice President and Chief Sales and Marketing Officer effective March 4, 2026. He will transition to a non-executive employee on garden leave, receiving continued salary and benefits until his employment terminates on June 30, 2026, and will be eligible for severance under the company's Amended and Restated Executive Severance Policy.

• ·Event reported on March 3, 2026; filing dated March 5, 2026
• ·Company headquartered at One Michael Owens Way, Perrysburg, Ohio 43551-2999

05-03-2026

Dominari Holdings Inc. held a special stockholder meeting on March 4, 2026, achieving a quorum of 7,019,711 voting shares (43.27% turnout). Shareholders approved amendments to the 2022 Equity Incentive Plan, increasing the common share reserve by 10,000,000 from 11,720,750 to 21,720,750 and adding an annual evergreen provision (lesser of 20% of outstanding shares or board-determined amount) starting January 1, 2027 through 2032, with votes of 6,380,149 FOR, 631,857 AGAINST (9% opposition), and 7,705 ABSTAIN. The adjournment proposal also passed with 6,395,283 FOR and 603,973 AGAINST.

• ·Record date for meeting: January 22, 2026
• ·Proxy statement filed with SEC: February 6, 2026
• ·Common stock par value: $0.0001 per share

05-03-2026

ClearOne, Inc. entered into a Securities Purchase Agreement with First Finance Ltd., its affiliate and single largest stockholder, to sell 437,500 shares of common stock at $4.00 per share and a warrant for up to 437,500 shares at $5.00 exercise price, generating gross proceeds of $1.75M in a private placement. Of the proceeds, $0.5M is immediately available, while $1.25M is contingent on the Company's reincorporation from Delaware to Nevada. The agreement imposes restrictions on incurring indebtedness over $10,000 or entering material transactions without Purchaser consent, with closing expected on or about March 6, 2026.

• ·Warrant term: 2 years, exercisable six months from issuance date.
• ·Securities offered pursuant to Section 4(a)(2) and Rule 506(b) exemption.
• ·Registration rights: Form S-3 for resale effective within 90 days after filing full Form 10-K for year ended December 31, 2025.
• ·Proceeds held in segregated bank account pending disbursement.
• ·Date of earliest event: March 2, 2026; Filing date: March 5, 2026.

05-03-2026

The GEO Group, Inc. (NYSE: GEO) announced that its Chief Financial Officer, Mark Suchinski, will depart effective March 31, 2026, to relocate out-of-state and join another industry. Shayn March, Executive Vice President, Finance and Treasurer with 17 years at GEO, has been appointed as the new CFO effective April 1, 2026. Chairman and CEO George C. Zoley highlighted March's experience and expressed optimism for growth opportunities.

• ·GEO provides services in the United States, Australia, South Africa, and the United Kingdom.
• ·Announcement dated March 5, 2026.

05-03-2026

On March 5, 2026, the Board of Directors of Paycom Software, Inc. authorized an additional $200M for repurchases of the company's common stock under its existing stock repurchase plan, following the completion of approximately $1.45B in aggregate repurchases since the plan's authorization in July 2024. Repurchases may occur through open market transactions, privately negotiated deals, or Rule 10b5-1 programs, subject to market conditions, and the plan expires on August 15, 2026. No declines or flat performance metrics were reported in this filing.

• ·Stock repurchase plan may be suspended or discontinued at any time at the Board's discretion.
• ·Repurchase timing, number, and value depend on market price, general market conditions, and other corporate considerations.

05-03-2026

The Goldman Sachs Group, Inc. issued CAD 1.75 billion principal amount of 3.641% Fixed/Floating Rate Notes due 2032 and CAD 1 billion principal amount of 4.340% Fixed/Floating Rate Notes due 2037 on March 5, 2026, under its shelf registration statement on Form S-3 (File No. 333-284538). This issuance provides additional funding through unsecured debt securities traded on NYSE under various symbols. No period-over-period financial performance data or comparisons are included in the filing.

• ·Securities registered pursuant to Section 12(b) of the Act include Common stock (GS), Depositary Shares Series A (GS PrA), Series C (GS PrC), Series D (GS PrD), GS/43PE, GS/43PF, GS/31B, GS/31X on NYSE.
• ·Exhibits include Forms of Notes (4.1, 4.2), Opinion of Sullivan & Cromwell LLP (5.1), and Consent (23.1).

05-03-2026

ABVC BioPharma, Inc. has issued a proxy statement for its 2026 Annual Meeting of Shareholders, to be held virtually on March 26, 2026 at 10:00 a.m. EST, with a record date of January 26, 2026 and 25,423,654 shares of Common Stock outstanding. Shareholders will vote on re-electing current director nominees for one-year terms, ratifying S&E as the independent registered public accounting firm for the year ending December 31, 2026, and approving an amendment to the Amended and Restated 2016 Equity Incentive Plan to increase authorized shares to a maximum of 15% of issued and outstanding shares inclusive of the evergreen provision. The Board unanimously recommends voting 'FOR' all proposals, with no financial performance metrics or period comparisons disclosed.

• ·Proxy submission deadline: 11:59 p.m. EST on March 25, 2026
• ·Meeting held virtually via Zoom (Meeting ID: 271 131 5701, Passcode: f3w3a6)
• ·Voting methods: Internet (www.proxyvote.com), telephone (1-800-690-6903), or mail

05-03-2026

On February 27, 2026, Lunai Bioworks Inc. (LNAI) implemented a temporary furlough of its employees in the United States and Canada to preserve liquidity while pursuing additional financing, with affected employees not receiving compensation during this period. The company's Chief Executive Officer and Chief Financial Officer voluntarily deferred their salaries, though the company maintains limited operations and has begun recalling certain employees for platform development. No timeline for full recall was provided, highlighting ongoing financial pressures.

• ·Furlough affects employees in United States and Canada only.
• ·Salary deferrals by CEO and CFO do not modify employment terms.
• ·Company address: 3400 Cottage Way, Suite G2, #3256, Sacramento, California 95825.
• ·Registrant telephone: +1 (424) 222-9301.

05-03-2026

Sunrise Realty Trust, Inc. (SUNS) expanded its senior secured revolving credit facility to $165M with a $25M commitment from Customers Bank, bringing total commitments from the prior amount implied at $140M. The facility, originally established with East West Bancorp in November 2024, remains expandable to $200M to support CRE lending and liquidity needs. No declines or flat metrics were reported in this positive liquidity enhancement announcement.

• ·Facility originally established with East West Bancorp in November 2024
• ·Customers Bancorp accolades: Top 10 Performing Bank by American Banker (2021-2025), #1 in 2024 among midsize banks, No. 45 in 2026 Forbes Best Banks list, Net Promoter Score of 81
• ·Investor Relations: Robyn Tannenbaum, 561-510-2293, ir@thetcg.com
• ·Media Contact: Doug Allen, 646-722-6530, TCG@DLPR.com

05-03-2026

RPM International Inc. entered into a Seventh Amendment to its revolving credit facility on February 27, 2026, extending the maturity by five years to February 27, 2031. Interest spreads are set initially at 0.0% for base rate loans and 1.00% for SOFR and RFR-based loans (with ranges of 0.0%-0.30% and 0.785%-1.30%, respectively), alongside a 0.125% facility fee (range 0.09%-0.20%), all adjustable by debt rating. The amendment retains a maximum leverage ratio covenant of 3.75:1.0 but eliminates the prior interest coverage ratio requirement.

• ·Original Credit Agreement dated October 31, 2018.
• ·Full Credit Agreement Amendment to be filed as exhibit to Form 10-Q for quarter ending February 28, 2026.
• ·Covenants include limitations on liens and asset sales/transfers.
• ·Events of default include payment defaults, covenant breaches, change of control, and ERISA events.

05-03-2026

South Plains Financial, Inc. reported net income of $58.5M for the year ended December 31, 2025, up 17.6% YoY from $49.7M in 2024, supported by net interest income growth of 13.6% to $167.0M and total assets expansion of 5.9% to $4.48B. However, noninterest income declined 6.6% to $44.9M, primarily due to a $3.5M drop in mortgage banking activities, while noninterest expense rose 4.0% to $132.6M. Credit quality strengthened with nonperforming assets falling to 0.26% of total assets from 0.58%, and efficiency ratio improved to 62.32%.

• ·Provision for credit losses increased 20.8% YoY to $5.2M in 2025.
• ·Net interest margin expanded to 3.98% from 3.65% YoY.
• ·Common equity tier 1 capital ratio strengthened to 14.45% from 13.53%.
• ·Total risk-based capital ratio slightly declined to 17.26% from 17.86%.
• ·Allowance for credit losses on loans stable at 1.44% of total loans (up from 1.42%).

05-03-2026

Genco Shipping & Trading Limited executed a Sixth Amendment to its August 2021 Credit Agreement on February 27, 2026, establishing $80M in Incremental Revolving Commitments (2026 Upsize Revolving Commitments) to finance the acquisition of two 5-8 year old vessels: Genco Stars and Stripes and Genco Valkyrie (2026 Accordion Vessels). Consenting Lenders approved increasing the appraisal value threshold from 50% to 53.7% solely for these vessels, accepting pre-delivered appraisals from Fearnleys (Jan 20, 2026) and Clarksons (Jan 28, 2026). No declines or flat metrics reported in this financing update.

• ·Credit Agreement originally dated August 3, 2021; prior amendments on November 8, 2022; May 30, 2023; October 16, 2023; November 29, 2023; July 10, 2025
• ·Vessel appraisals dated January 20, 2026 (Fearnleys) and January 28, 2026 (Clarksons)

05-03-2026

Bowman Consulting Group Ltd. reported gross contract revenue of $490M for FY2025, up 14.9% YoY from $427M, with strong segment growth in Natural Resources (+27.2%), Power/Utilities & Energy (+22.7%), and Transportation (+18.2%), though Building Infrastructure grew modestly at 7.4%. Net income rose sharply to $12.8M (2.6% margin) from $3M (0.7% margin), and Adjusted EBITDA increased 22.4% to $72.9M (16.8% margin). However, acquired revenue plunged 79.4% to $8.7M, operating expenses grew to $242M, and revolving credit facility debt more than doubled to $95M from $37M.

• ·Operating income swung to $19.7M profit from $2M loss YoY.
• ·Cash and equivalents increased to $11.1M from $6.7M.
• ·Goodwill rose to $174M from $135M, reflecting acquisitions.
• ·Diluted EPS improved to $0.73 from $0.17.
• ·Total liabilities increased to $319M from $260M.

05-03-2026

Visa Inc. filed an S-4 registration statement on March 5, 2026, for an Exchange Offer to convert any and all outstanding Class B-1 and Class B-2 common stock into a combination of newly issued Class B-3 common stock and Class C common stock, plus cash for fractions, building on a 2024 Class B-1 Exchange where 98% participated. Participants must enter a Makewhole Agreement with uncapped cash reimbursement liability for future U.S. covered litigation costs that would otherwise adjust conversion rates downward. The offer introduces Class B-3 stock with accelerated (4x vs. Class B-1, 2x vs. Class B-2) future conversion rate adjustments, but includes multiple conditions and risks that may prevent closing.

• ·Applicable Conversion Rates as of filing: Class B-1 (1.5475 shares of Class A), Class B-2 (1.5075 shares of Class A), Class C (4 shares of Class A)
• ·Approximate Class C issuance: 0.2877 shares per Class B-1 share; 0.1884 shares per Class B-2 share
• ·Class B-3 conversion downward adjustments accelerated 4x vs. Class B-1 and 2x vs. Class B-2
• ·Prior events: IPO March 2008; Eighth Restated Certificate effective January 2024
• ·Exchange ratio details: 1 Class B-1 -> 0.25 Class B-3 + Class C equiv. to 0.5 B-1 + 0.25 B-2; 1 Class B-2 -> 0.5 Class B-3 + Class C equiv. to 0.5 B-2
• ·Withdrawal possible prior to Expiration Date or within 40 business days if not accepted

05-03-2026

Simon Property Group, L.P. entered into a Fourth Amended and Restated $5,000,000,000 Revolving Credit Agreement on March 5, 2026, fully amending and restating the prior Third Amended and Restated Credit Agreement dated March 14, 2023 (as amended October 3, 2024 and May 12, 2025). The facility is administered by JPMorgan Chase Bank, N.A., with joint lead arrangers including BOFA Securities, Inc., Mizuho Bank, Ltd., PNC Capital Markets LLC, and Wells Fargo Securities LLC, providing enhanced liquidity access in USD and alternative currencies up to the full facility amount.

• ·Alternative Currency Sublimit equals 100% of the $5B Maximum Revolving Credit Amount.
• ·Prior Existing Credit Agreement dated March 14, 2023, with amendments on October 3, 2024 and May 12, 2025.

05-03-2026

PACS Group, Inc. (NYSE: PACS) appointed Dr. Patrick H. Conway, MD, MSc, CEO of Optum, to its Board of Directors on March 5, 2026, bringing extensive expertise in clinical care, CMS regulatory leadership, and value-based payment models. The company operates over 320 post-acute care facilities across 17 states, serving more than 31,700 patients daily, with 73.4% of its skilled nursing portfolio rated 4-5 stars on CMS ratings and occupancy rates 17 percentage points above industry average. PACS reported full-year 2025 revenue of $5.29B, up 29.3% YoY.

• ·PACS founded in 2013 and headquartered in Salt Lake City, Utah
• ·Dr. Conway elected to National Academy of Medicine in 2014 and recipient of President’s Senior Executive Distinguished Service Award

05-03-2026

On March 1, 2026, Invitation Homes Inc.'s Compensation Committee approved increased target long-term incentive awards for key executives based on 2025 performance, including $11.3M for CEO Dallas Tanner, $2.7M for CFO Jonathan Olsen, $2.2M for COO Timothy Lobner, and $3.6M for CIO Scott Eisen. The committee also granted time-vesting RSUs (e.g., $2.8M to Tanner), performance-vesting RSUs at target (e.g., $8.5M to Tanner), and substantial retention RSUs amid competitive talent market risks (e.g., $10M to Tanner, $5M to Olsen). No declines or flat metrics reported, with awards designed to retain leadership driving operational momentum.

• ·Time-vesting LTIP RSUs vest in equal annual installments over three years starting March 1, 2026.
• ·Performance-vesting LTIP RSUs based on NOI CAGR and relative TSR vs. Nareit Residential Index over Jan 1, 2026 to Dec 31, 2028; subject to TSR Modifier and Value Cap (300% of target RSUs × $55/share).
• ·Retention RSUs vest 65% on third anniversary, 35% on fourth anniversary of March 1, 2026.

05-03-2026

Sealed Air Corporation filed an 8-K under Item 8.01 to provide Rule 135c notice on expected debt financing for its acquisition by CD&R affiliates, approved by stockholders on February 25, 2026, pursuant to the November 16, 2025 merger agreement. The financing includes a $4.3B USD senior secured term loan, $600M euro term loan, $1.15B senior secured notes, $600M euro senior secured notes, $500M senior unsecured notes, and up to $1.4B revolving credit facility, to be used for the transaction and related redemptions. Final terms remain subject to market conditions, with plans to redeem outstanding senior notes due 2027-2032 while leaving $450M of 6.875% notes due 2033 outstanding.

• ·Existing notes to be redeemed: 4.000% senior notes due 2027, 6.125% senior notes due 2028, 5.000% senior notes due 2029, 7.250% senior notes due 2031, and 6.500% senior notes due 2032.

05-03-2026

Gaming and Leisure Properties, Inc. (GLPI) closed a $800M offering of 5.625% senior notes due 2036 on March 4, 2026, co-issued by GLP Capital, L.P. and GLP Financing II, Inc., generating net proceeds of approximately $791.1M after discounts and expenses. The proceeds were primarily used to repay outstanding borrowings under the Operating Partnership’s term loan credit facility, with remaining funds allocated to working capital, general corporate purposes, potential acquisitions, and development projects. No declines or underperformance noted in this debt refinancing event.

• ·Notes issued pursuant to Base Indenture (Oct 30, 2013), First Supplemental Indenture (Mar 28, 2016), and Seventeenth Supplemental Indenture (Mar 4, 2026).
• ·Interest payable semi-annually on March 1 and September 1, commencing September 1, 2026.
• ·Maturity date: March 1, 2036; Par Call Date: 90 days prior to maturity.
• ·Senior unsecured obligations ranking pari passu with existing senior indebtedness; guaranteed by GLPI.

05-03-2026

Cryoport, Inc. reported total revenue of $176.2M for the year ended December 31, 2025, up 12.4% YoY from $156.8M, with Life Sciences Services growing 17.6% to $96.5M (including BioLogistics up 16.6% and BioStorage/BioServices up 22.2%) while Life Sciences Products increased only 6.6% to $79.7M. Gross margin rose 19.2% to $83.1M, and the company achieved net income of $78.3M versus a $114.8M loss in 2024, driven by $112.3M income from discontinued operations; however, loss from continuing operations narrowed but remained at $34.0M, and Adjusted EBITDA from continuing operations was a $5.8M loss.

• ·Cost of products revenue increased 0.3% YoY to $43.7M.
• ·Selling, general and administrative expenses decreased 6.4% YoY to $102.8M.
• ·No impairment loss in 2025 versus $63.8M in 2024.
• ·Net cash increase of $205.2M in 2025 versus decrease of $1.1M in 2024, driven by $250.3M investing activities.

05-03-2026

Inuvo reported full-year 2025 net revenue of $86.2M, up 3% YoY from $83.8M driven by growth in the first nine months, but Q4 revenue declined sharply 45% to $14.3M from $26.2M due to a strategic platform reset reducing lower-quality activity. Gross margins fell to 74.5% FY (from 85.6%) and 66.4% Q4 (from 83.1%) reflecting revenue mix changes, while operating expenses decreased 8% FY to $70.9M and 50% Q4 to $10.7M; net loss improved to $5.1M FY from $5.8M, with adjusted EBITDA worsening slightly to -$1.2M from -$0.8M. The company outlined 2026 growth pillars including IntentKey expansion and high-margin focus amid recent liquidity boosts from a $3.3M convertible note and $6.2M settlement.

• ·Added 83 new clients in 2025.
• ·Availability under working capital facility: $6.7M as of Dec 31, 2025.
• ·Total assets as of Dec 31, 2025: $24.9M, down from $32.2M at end of 2024.
• ·Conference call held March 5, 2026 at 4:15 PM ET.

05-03-2026

ClearThink 1 Acquisition Corp. filed an 8-K/A amendment on March 5, 2026, to refile an updated audited balance sheet as of February 25, 2026, correcting disclosures in the notes regarding offering costs and fair value measurements from the original 8-K filed March 3, 2026. The original filing reported the closing of the IPO of 12,500,000 units and a simultaneous private placement with sponsor ClearThink 1 Sponsor LLC. No other information from the original 8-K is modified.

• ·Securities registered on Nasdaq Stock Market LLC
• ·Emerging Growth Company status confirmed
• ·Auditors' report on Updated Balance Sheet dated March 5, 2026

05-03-2026

SentinelOne, Inc. appointed Sonalee Parekh as Chief Financial Officer and principal financial officer, effective March 24, 2026, replacing interim CFO Barry Padgett who will return to his role as Chief Growth Officer, with no disagreements noted. Ms. Parekh brings extensive experience from Asana (CFO since Sep 2024), RingCentral (CFO 2022-2024), HPE (Divisional CFO 2019-2022), and investment banks. Her compensation includes a $600K base salary, 70% target bonus, $300K sign-on bonus, and $18M aggregate equity award (75% RSUs, 25% PSUs).

• ·RSUs vest starting with 10% on first vesting date (month following 3-month anniversary), with tiered quarterly vesting thereafter.
• ·PSUs vest based on performance metrics for fiscal years ending Jan 31, 2027-2030, certified by Compensation Committee.
• ·CIC severance: 12 months base + bonus + equity acceleration on change of control termination; 6 months base on non-CIC termination.
• ·Ms. Parekh, age 52, holds Bachelor of Commerce from McGill University and is a Chartered Accountant; serves on board of indie Semiconductor since June 2021.

05-03-2026

Ares Capital Corporation (ARCC) filed definitive additional proxy materials (DEFA14A) on March 05, 2026, for its Annual Meeting of Stockholders scheduled for May 7, 2026. The materials urge stockholders to vote in favor of the proposals via phone (1-800-690-6903), online at www.proxyvote.com, or mail, emphasizing that votes are crucial regardless of share count to avoid adjournment. Notice of Internet Availability is used to reduce costs and environmental impact.

05-03-2026

AA Mission Acquisition Corp. II, a SPAC, reported its first financials for the period from inception (May 20, 2025) through December 31, 2025, with total assets of $117.2M primarily in a Trust Account of $116.4M from its IPO proceeds. The company generated net income of $585K, driven by $1.1M in Trust Account dividends offsetting a $497K operating loss from general and administrative expenses. No initial business combination has been completed, with shareholders' deficit at $2.4M.

• ·IPO closed with $115M gross proceeds and $3.6M private placement units to Sponsor.
• ·Trust Account shares redemption value at $10.12 per share.
• ·Basic and diluted EPS of $0.08 for both redeemable and non-redeemable shares.
• ·Net cash used in operating activities: $344K; investing: $115.3M; financing provided $116.3M.

05-03-2026

Fortress Value Acquisition Corp. V consummated its IPO on February 27, 2026, issuing 25,000,000 Class A ordinary shares at $10.00 per share for gross proceeds of $250M, alongside a private placement of 200,000 shares to sponsor Fortress Value Acquisition Sponsor V LLC for $2M, with $250M placed in trust. The balance sheet as of that date reflects total assets of $251.6M, including $250M in trust and $1.6M cash outside trust. However, it shows total liabilities of $14.8M and a shareholders' deficit of $13.2M driven by accumulated deficit.

• ·Underwriter granted 45-day option to purchase up to 3,750,000 additional Class A ordinary shares for over-allotments.
• ·Over-allotment option liability of $359,250 recorded.
• ·7,187,500 Class B ordinary shares issued, including 937,500 subject to forfeiture if over-allotment not exercised.
• ·IPO registration statement effective February 25, 2026.

05-03-2026

Apple iSports Group, Inc. (AAPI) signed a Joint Venture Agreement with AiC Enterprises LLC (AiC) on February 28, 2026, to jointly supply a gaming products platform and technical services to B2B and B2C clients, while licensing the 'apple-i' brand for promotion in the gaming ecosystem. The agreement, approved by both boards, positions the companies to expand in online gambling services, led by AiC's CEO Michael Cho and supported by Apple iSports' management expertise under CEO Joe Martinez. No financial terms or performance metrics were disclosed.

• ·Agreement executed with legal effect on February 28, 2026 (Asia-Pacific time)
• ·AiC's infrastructure includes UX & Conversion Engineering, Secure Payment Rails, and Aggregator Ecosystem
• ·Websites: https://appleicasino.com, https://appleisports.com, https://corporate.appleisports.com

05-03-2026

Thomson Reuters Corp filed its Form 40-F annual report for the fiscal year ended December 31, 2025, covering IFRS financial statements, operating segments including Legal Professionals, Tax & Accounting Professionals, Reuters News, Corporates, and Global Print across regions like Americas, EMEA, and Asia Pacific. The filing discloses details on debt instruments such as 3.35% Notes due 2026, 4.50% Notes due 2043, and 5.50% Debentures due 2035; pension plans including Thomson Reuters Group Pension Plan; acquisitions like Pagero Group AB, Credere Technologies Inc (Materia), and Additive AI Inc; and ongoing Normal Course Issuer Bid share repurchases in February 2026. No specific financial metrics or period-over-period changes are detailed in the provided XBRL tags.

• ·Acquisitions completed in 2025: Pagero Group AB, Credere Technologies Inc (doing business as Materia), Additive AI Inc.
• ·Debt instruments referenced: 3.35% Notes due 2026, 4.50% Notes due 2043, 5.50% Debentures due 2035, 5.65% Notes due 2043, 5.85% Notes due 2040.
• ·Pension plans: Thomson Reuters Group Pension Plan, The Thomson Corporation Plc Pension Scheme.
• ·Share repurchases under Normal Course Issuer Bid: transactions from 2026-02-01 to 2026-02-28.
• ·Dividends declared post year-end: 2026-02-01 to 2026-02-28.

05-03-2026

Cherry Hill Mortgage Investment Corp (CHMI) reported net income of $6.9M for the year ended December 31, 2025, down 43% YoY from $12.2M in 2024, with net income applicable to common stockholders swinging to a $3.0M loss from a $2.1M profit amid unrealized losses on derivatives and servicing assets. However, earnings available for distribution (EAD) attributable to common stockholders increased 30% YoY to $15.8M ($0.46 per diluted share from $0.40), supported by net interest income surging to $11.3M from near-zero levels due to lower interest expense. Segment results were mixed, with RMBS comprehensive income rising sharply to $16.9M from $2.1M while Servicing Related Assets declined to $8.8M from $18.6M, and net servicing income fell 6% YoY to $34.0M.

• ·Total expenses decreased 22% YoY to $14.2M from $18.3M.
• ·Accumulated other comprehensive income improved to $3.7M as of Dec 31, 2025 from a $7.3M loss.
• ·Dividends on preferred stock were $9.8M in 2025, slightly down from $10.0M in 2024.
• ·All Other segment showed comprehensive loss of $7.9M in 2025, improved from $13.2M loss in 2024.

05-03-2026

Smith Micro Software reported improved gross margins of 74.1% for FY 2025 (up from 70.2% in 2024) and reduced total operating expenses to 241.1% of revenue (from 310.5%), narrowing the operating loss to 167.1% of revenue and net loss to 168.9% of revenue. However, the company recorded a $63.7% goodwill impairment (down from 116.7% but eliminating all goodwill), resulting in total assets declining to $25.0M from $48.0M and stockholders' equity dropping to $18.4M from $40.8M. Cash burn from operations improved to $7.2M used (from $14.3M), with net cash decrease of $1.3M versus $4.3M prior year.

• ·Accounts receivable declined to $1.8M from $5.7M at Dec 31, 2025 vs 2024.
• ·Selling and marketing expenses improved to 34.4% of revenue from 43.2%.
• ·Research and development expenses decreased to 61.7% of revenue from 68.5%.
• ·General and administrative expenses increased to 57.6% of revenue from 51.5%.
• ·Intangible assets net $18.5M at Dec 31, 2025 vs $24.0M at Dec 31, 2024.

05-03-2026

TRG Latin America Acquisitions Corp., a blank check company, consummated its initial public offering (IPO) on February 27, 2026, selling 20,000,000 units at $10.00 per unit, generating gross proceeds of $200 million. Simultaneously, the company completed a private placement of 225,000 units to its sponsor, TRG Latin America Acquisitions LLC, for $2.25 million. A total of $200 million from the IPO and private placement net proceeds was deposited into a trust account.

• ·Company incorporated November 7, 2025, as Cayman Islands exempted company targeting business combination in Latin America.
• ·IPO registration statement effective February 25, 2026.
• ·Transaction costs totaled $6,768,470, including $250,000 cash underwriting fee.
• ·5,750,000 Class B ordinary shares issued and outstanding, with up to 750,000 subject to forfeiture if over-allotment option not exercised.
• ·Trust account invested in U.S. government treasury obligations or money market funds.

05-03-2026

Adial Pharmaceuticals reported a reduced net loss of $7.98M for the year ended December 31, 2025, compared to $13.20M in 2024, primarily due to lower R&D expenses ($2.62M, down 19% YoY) and absence of $4.46M inducement expense. However, G&A expenses rose slightly by 2% to $5.18M, total operating expenses declined modestly to $7.80M, and significant share dilution occurred with common shares outstanding increasing over 4x to 1.11M. Cash and equivalents grew 57% to $5.88M, bolstered by $8.47M in financing activities, though operating cash use remained high at $6.49M.

• ·Total assets increased to $6.67M as of Dec 31 2025 from $5.04M as of Dec 31 2024.
• ·Equity method investment declined to $0.49M from $0.98M.
• ·Net cash used in operating activities improved slightly to $6.49M from $6.92M.
• ·Weighted average shares outstanding increased to 668,630 from 194,059; loss per share improved to $(11.93) from $(68.01).

05-03-2026

Outlook Therapeutics, Inc. issued a press release on March 5, 2026, announcing it conducted a requested Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated December 30, 2025, regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab for wet AMD. The press release is attached as Exhibit 99.1.

• ·Filing includes Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).

05-03-2026

Relativity Acquisition Corp, a SPAC, has filed a DEFM14A proxy statement for a special stockholder meeting to approve a business combination merger forming Pubco, along with a Redemption Limitation Amendment and Adjournment Proposal. Initial Stockholders control 98.5% of the 4,309,988 outstanding Common Shares, ensuring quorum and ability to approve all proposals without public stockholder support. Directors and officers have differing interests, including $6.56M at risk from Founder Shares and Private Placement Units.

• ·Proxy revocation deadline: 5:00 p.m. Eastern time on December 5, 2025
• ·IPO closing date: February 15, 2022
• ·Company address: 3753 Howard Hughes Pkwy, Suite 200, Las Vegas, Nevada 89169

05-03-2026

Liberty Energy Inc. filed additional definitive proxy materials (DEFA14A) on March 5, 2026, for its 2026 Annual Stockholder Meeting to be held virtually on April 14, 2026, at 9:00 AM Mountain Time. Key proposals include the election of four director nominees (Simon Ayat, Arjun Murti, Gale Norton, Cary Steinbeck), an advisory vote to approve named executive officer compensation, and ratification of the independent registered public accounting firm appointment. The Board of Directors recommends voting 'FOR' all proposals, with voting available online, by phone, mail (by April 13, 2026), or virtually at the meeting.

• ·Virtual meeting link: edge.media-server.com/mmc/p/azh3pr84 (password: liberty2026)
• ·Proxy materials available at www.astproxyportal.com/ast/21952
• ·Request paper/email copies by March 31, 2026 via 1-888-Proxy-NA, help@equiniti.com, or us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials
• ·Online/phone voting until 11:59 PM ET on April 13, 2026; mailed proxies by April 13, 2026